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Chapter 1
GENERAL INTRODUCTION
 The studies described in this thesis give insights into the mechanism by which the 
3A protein of the coxsackievirus, a member of the genus enterovirus, inhibits protein transport 
through the secretory pathway. In addition, the structure-function relationship of the 3A protein was 
analyzed and described. In this chapter, an overview will be given of the enterovirus classification, 
pathogenesis, genome organization, genome replication, and the enterovirus-induced modifications 
of the host cell. Furthermore, the (entero)viral evasion of the immune system, the early secretory 
pathway, and the enterovirus 3A protein will be introduced.
Enteroviruses
Classification.
	 Enteroviruses belong to the family of the Picornaviridae. The picornaviruses are among 
the most diverse and oldest known viruses and they are the cause of a number of serious human 
and animal diseases and major economical damage. This large family of small RNA viruses consists 
of nine genera and several unassigned viruses (Fig. 1). The genera that belong to this family are: 
enterovirus (described below), rhinovirus (cause of the common cold), cardiovirus, aphthovirus, 
hepatovirus, parechovirus, erbovirus, kobuvirus, and teschovirus.
 The enteroviruses are divided into several species, namely poliovirus (PV), human 
enterovirus A (HEV-A), human enterovirus B (HEV-B), human enterovirus C (HEV-C), human 
enterovirus D (HEV-D), bovine enterovirus, porcine enterovirus A, porcine enterovirus B, and simian 
enterovirus. Several serotypes have not been assigned to specific species.
Pathogenesis.
 The major route of enterovirus infection is the faecal-oral route, but intranasal, aerosol, 
and ocular routes of enterovirus infection have been described as well. Enteroviruses are spread 
throughout the body via the blood stream from where they can affect other tissues and organs. 
Enterovirus infections are highly prevalent, with epidemics peaking between June and October in 
temperate climates and epidemics occuring year-round in tropical climates. They are often mild or 
asymptomatic, especially in young children, and are therefore frequently undiagnosed. However, 
acute or chronic diseases like meningo-encephalitis, paralysis, myocarditis, pancreatitis, and type 
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Fig. 1. Classification of the Picornaviridae. The nine genera of the Picornavirus family and their containing species are depicted. 
The coxsackievirus B3 belongs to the Enterovirus species Human enterovirus B.
1 diabetes have been described as a result of enterovirus infection (Rotbart, 2002). Poliomyelitis 
(polio) is probably the best known disease that is caused by an enterovirus (PV). Coxsackievirus 
B3 (CVB3), the model virus in this study, is the most common human pathogen for viral myocarditis 
and CVB and ECHO viruses are implicated in the onset of type 1 diabetes (Vreugenhil et al., 
2000). 
 Besides causing acute infections, enteroviruses have been discussed to cause persistent 
infections. Persistent enterovirus infections in humans with humoral immunodeficiency have been 
well described and several studies report detection of enteroviruses or the enterovirus genome in 
immunocompetent humans or animals several months after infection, although these findings are 
still debated (Zoll et al., 1993; Melchers et al., 1994; Kandolf et al., 2002). 
 
Genome organization.
 Enteroviruses contain an infectious, single stranded RNA genome of positive polarity. All 
enteroviruses share one common genome organization, which is depicted in Fig. 2. An important 
characteristic of their genome is the presence of the covalently linked VPg (virion protein, genome 
linked) to the 5’ end of the genome. The genome of approximately 7,500 nucleotides contains 
a single large open reading frame (ORF) that encodes the viral polyprotein of approximately 
2,200 amino acids. The polyprotein is divided into the P1, P2, and P3 region and is proteolytically 
processed by virally encoded proteases into the capsid proteins (1A [VP4], 1B [VP2], 1C [VP3], 
and 1D [VP1]) and the nonstructural replication proteins (2Apro, 2B, 2C, 3A, 3B, 3Cpro, and 3Dpol). 
In addition, the relatively stable precursor proteins 2BC, 3AB, and 3CDpro are formed, which are 
suggested to have different functions than the individual proteins. 
 The ORF is preceded by a quite long and highly structured 5’ untranslated region (UTR) 
that harbors the internal ribosomal entry site (IRES) required for translation and a cloverleaf-like 
RNA element required for positive- and negative-strand replication (Ehrenfeld and Teterina, 2002; 
Paul, 2002). The ORF is followed by a much shorter 3’ UTR and a genetically encoded poly(A) 
tail. The 3’ UTR and poly(A) tail are both needed for the efficient initiation of negative-strand RNA 
synthesis (Pilipenko et al., 1996; Melchers et al., 1997; Herold and Andino, 2001). Recently, it was 
proposed that the 3’ UTR of PV is involved in site selection for initiation of negative-strand RNA 
synthesis (Brown et al., 2005). In addition to the RNA elements in the UTRs, enteroviruses contain 
a cis-acting replication element (CRE) in the coding region of the 2C protein (Goodfellow et al., 
2000; van Ooij et al., 2006a). This CRE is thought to be involved in the uridylylation of VPg and 
thereby in positive-strand and negative-strand RNA synthesis. 
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Fig. 2. Schematic representation of the enterovirus genome. The genome consists of a 7.5 kb single-stranded RNA molecule 
with the viral VPg protein bound at the 5’ end. The boxes represent the protein coding region, which is preceded by a quite long 
5’ untranslated region (UTR) and followed by a much shorter 3’ UTR and a genetically encoded poly(A) tail. The protein coding 
region encodes a single polyprotein that is proteolytically processed by the virus-encoded proteases to yield the P1 capsid 
proteins and the P2 and P3 replication proteins. Besides the individual proteins, several relatively stable cleavage intermediates 
are formed.
Virus replication.
 Enteroviruses have a lytic infection cycle, which is summarized in Fig. 3. To be able to 
replicate, the virus must first enter the cell. A primary requirement for enterovirus cell entry is binding 
to a specific cell surface receptor, which is known for many enteroviruses. All known serotypes 
of CVB specifically interact with the coxsackievirus-adenovirus receptor (CAR) (Bergelson et al., 
1997). In addition, CVB serotypes 1, 3, and 5 bind the decay-accelerating factor (DAF or CD55) as 
a coreceptor (Shafren et al., 1995). Coxsackievirus A9 (CVA9) uses the integrin αvβ3, also known 
as the vitronectin receptor, as a receptor (Roivainen et al., 1994). CVA21 has been shown to bind to 
the intercellular adhesion molecule 1 (ICAM-1) and the DAF (Shafren et al., 1997a+b). All three PV 
serotypes use the PV receptor (CD155), which is an immunoglobulin like molecule (Mendelsohn et 
al., 1989). ECHO serotypes 1 and 8 use the very late antigen (VLA-2) (α2β1) integrin as their cellular 
receptor (Bergelson et al., 1992; Bergelson et al., 1993), whereas many other ECHO serotypes 
bind to the DAF (Bergelson et al., 1994). Upon receptor binding, enteroviruses are invaginated into 
the cytoplasm by endocytosis. For enteroviruses, not much is known about how this internalization 
takes place. Echovirus 1 has been reported to enter the cell via caveolar endocytosis (Marjomäki 
et al., 2002). Recently, it has been proposed that CVB3 uses a clathrin-dependent endocytosis 
(Chung et al., 2005). 
 After uncoating, the viral RNA (vRNA) is released into the cytoplasm and the VPg protein 
is removed. Subsequently, the vRNA is translated into a large polyprotein. Translation requires the 
IRES and cellular proteins, including some nuclear proteins. The polyprotein is cleaved by virally 
encoded proteases to yield the capsid proteins and the non-structural replication proteins. The viral 
proteins that are most directly involved in vRNA synthesis are the template- and primer-dependent 
RNA polymerase 3Dpol, the viral peptide primer VPg, and the protease and RNA-binding protein 
3CDpro. Once a critical concentration of viral proteins is reached, viral translation is shut down 
and replication is initiated by binding of 3CD to the cloverleaf RNA (Gamarnik and Andino, 1998). 
vRNA replication takes place on replication complexes on the cytoplasmic surface of membranous 
vesicles (Fig. 4) (Bienz et al., 1994). The origin of these membranes is not completely clear. During 
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Fig. 3. Schematic representation of the enterovirus life cycle. Infection starts with binding of the virus to a specific cell surface 
receptor. After uptake of the virus, the viral RNA is released into the cytoplasm and translated into a large polyprotein. Processing 
of the polyprotein yields the structural capsid proteins and the nonstructural replication proteins. The genomic RNA is used as a 
template for the production of a complementary negative strand RNA molecule, which, in turn, is used as a template to generate 
large numbers of new positive strand RNA molecules. The newly formed positive strand RNA molecules are encapsidated by 
the capsid proteins to produce new viruses. Cell lysis is induced to release virus progeny. 
early PV infection, the membranes are thought to be accumulated anterograde transport carriers 
that are derived from the secretory pathway (Rust et al., 2001). At late timepoints in infection, 
several organelles of the host-cell seem to contribute to the virus-induced membranes (Schlegel et 
al., 1996). In addition, a role for autophagy has been suggested in the origin of the membranes that 
accumulate upon PV infection (Suhy et al., 2000; Jackson et al., 2005). Despite the cytoplasmic 
location of the viral replication complexes, several nuclear proteins have been shown to be involved 
in vRNA replication. At the replication complexes, complementary negative-stranded RNA molecules 
are transcribed from the positive-stranded genome. This occurs at the replication intermediate, a 
dynamic structure that contains the viral polymerase, a number of partially synthesized RNA strands, 
and the template strand. The negative-stranded RNA serves as a template for the production of 
a large amount of positive-stranded progeny genomes. On one negative-stranded RNA molecule 
multiple rounds of positive-strand synthesis can occur. Uridylylated VPg serves as the primer 
used by the 3Dpol for both positive and negative strand RNA synthesis. The newly formed positive-
stranded genomes are also translated and the process repeats many times untill sufficient capsid 
protein precursors are formed to allow assembly of the procapsid. Encapsidation of enteroviruses 
is still a largely unknown proces. It has been suggested that only newly formed RNAs are packaged 
(Nugent et al., 1999). Entry of viral genomes into procapsids results in capsid maturation. These 
newly formed virions accumulate in the cytoplasm until the host cell loses its integrity by the action 
of viral proteins and the viruses are released via cell lysis. 
Effects on the host cell.
 Several functions of enteroviral proteins have been described that convert the host cell 
into an environment that is suitable for efficient vRNA replication. Some of the enterovirus induced 
effects are described below.
Shutoff of host cell transcription.
 Eukaryotes have three RNA polymerases (RNA Pol). The RNA Pol I transcribes the 
ribosomal RNA (rRNA) genes, the RNA Pol II transcribes the protein-encoding genes into messenger 
RNA (mRNA) and the small nuclear RNA (snRNA) genes, and RNA Pol III transcribes one of 
the rRNA genes and all the transfer RNA (tRNA) genes. Enterovirus infection causes a severe 
decrease in cellular transcription catalyzed by all three polymerases (Weidman et al., 2003). At 1 to 
2 h postinfection, transcription mediated by RNA Pol I is inhibited, followed by inhibition of RNA Pol 
II at approximately 3 h postinfection and RNA Pol III at approximately 4 h postinfection. This is not 
due to direct inhibition of the RNA Pols, but rather to inactivation of transcriptional components. The 
viral protease 3Cpro is responsible for the shutoff of RNA Pol II mediated transcription by cleaving 
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Fig. 4. Membrane rearrangements in enterovirus-infected cells. (A) Electron microscopy picture of a Hela cell infected with 
poliovirus showing the virus-induced accumulation of vesicles. (B) Rosette of virus-induced vesicles (V) surrounding a granular 
structure containing the replicating viral RNA, thus representing the actual replication complex (RC). Such rosettes are isolated 
from infected cells by sucrose gradient centrifugation. Both images were kindly provided by Dr. K. Bienz, University of Basel, 
Schwitzerland.    
the TATA-binding protein (TBP) (Clark et al., 1993). Recently, it was shown that PV infection of a cell 
line expressing a noncleavable form of TBP resulted in reduced viral yields in single cycle infection 
and a small plaque phenotype, suggesting that shutoff of transcription is required for efficient PV 
replication (Kundu et al., 2005). In addition, the 3Cpro was also shown to induce cleavage of the 
activator proteins cAMP-responsive element binding protein (CREB), octamer binding protein (Oct-
1), and the tumor suppressor p53, either directly (CREB and Oct-1) or in combination with a cellular 
activity (p53) (Yalamanchili et al., 1997a; Yalamanchili et al., 1997b; Weidman et al., 2001). Besides 
a role in replication, shutoff of host cell transcription may help in the evasion of antiviral host cell 
responses by inhibiting the production of cytokines.
Shutoff of host cell translation.
 Enteroviruses use IRES-driven translation, which is a cap- independent mode of initiation 
of translation. Therefore, they can inhibit the normal, cap-dependent mode of translation of cellular 
genes, without affecting their own translation. Enterovirus infection causes a rapid and drastic 
inhibition of host cell protein synthesis (Ehrenfeld, 1982). Enteroviruses induce cleavage of 
eukaryotic initiation factors (eIF) 4GI and 4GII (Etchison et al., 1982; Gradi et al., 1998a). eIF4GI 
is a subunit of the eIF4F, a three-subunit complex that binds to the cap structure, and eIF4GI 
plays an important role in the assembly of the mRNA-ribosome initiation complex. eIF4GII is a 
human homolog of eIF4GI (Gradi et al., 1998b). Cleavage of eIF4GII, but not eIF4GI, was shown 
to correlate with the kinetics of inhibition of host mRNA translation in PV (Gradi et al., 1998a). In 
addition, cleavage of the poly(A)-binding protein (PABP), a regulating factor in mRNA function 
reviewed in Mangus et al., 2003, was shown to correlate with the kinetics of inhibition of host 
mRNA translation in PV (Joachims et al., 1999). Therefore, it has been suggested that cleavage of 
eIF4GII and PABP plays a key role in the inhibition of mRNA translation in PV-infected cells. The 
viral proteins 2Apro and 3Cpro are responsible for the shutoff of host cell translation by cleaving eIF4G 
and PABP, respectively (Gradi et al., 1998b; Joachims et al., 1999; Kuyumcu-Martinez et al., 2002). 
Like the shutoff of host cell transcription, the shutoff of host cell translation is suggested to help in 
the evasion of antiviral host cell responses by inhibiting the production of cytokines. In addition, 
the shutoff of host cell translation makes the proteins of the translation machinery available for the 
virus. 
Disruption of nucleo-cytoplasmic trafficking.
 Enterovirus infection results in a nuclear-cytoplasmic redistribution (Gustin and Sarnow, 
2001). This is mediated by efflux of nuclear proteins into the cytoplasm and inhibition of several 
nuclear import pathways (Belov et al., 2004; Gustin and Sarnow, 2001; Gustin, 2003). The 2A 
protein alone has been shown to induce efflux of nuclear proteins (Belov et al., 2004), but the 
viral factor responsible for the inhibition of nuclear import is yet unknown. Both the induced efflux 
and the inhibited import are thought to result from disorders in the nuclear pore complex and the 
nuclear envelope. It has been suggested that the affected nucleo-cytoplasmic trafficking results in 
provision of viral proteins to the nucleus and nuclear proteins to the cytoplasm, where they can help 
the viral translation and replication (Gustin and Sarnow, 2001). Furthermore, the inhibited nuclear 
import has been suggested to be involved in the evasion of antiviral host cell responses, since 
transcription factors that are triggered upon viral infection to enter the nucleus and activate cytokine 
genes are sequestered in the cytoplasm (Gustin and Sarnow, 2001).
 
Induction of membrane vesicles.
 As discussed in the section “virus replication”, enterovirus RNA replication takes place on 
accumulated membrane structures of which the origin is not completely clear. The 2BC precursor 
Chapter 1
14
protein seems to be responsible for the membrane accumulation, since expression of the 2BC 
protein induces vesicles that are quite similar as those formed during PV infection (Cho et al., 
1994). In addition, it has been proposed that the combined actions of 2BC and 3A mimic the PV 
induced vesicles even more (Suhy et al., 2000).
Membrane permeabilization.
 Enterovirus infection results in an increased permeability of the plasma membrane (Munoz 
and Carrasco, 1983; Lopez Rivas et al., 1987). Initial studies in Escherichia coli suggested that the 
viral proteins 2B, 3A and 3AB are involved in this permeabilization (Lama and Carrasco, 1992), but 
studies in mammalian cells showed that the viral proteins 2B or 2BC, and not 3A or 3AB, are each 
sufficient to induce membrane permeabilization (Doedens and Kirkegaard, 1995; Van Kuppeveld 
et al., 1997). It has been suggested that the 2B protein induces membrane permeabilization by 
(homo)multimerization to form pores that allow the passage of ions and small solutes across 
host cell membranes (de Jong et al., 2002; Agirre el al., 2002). Although it has been suggested 
that 2B induces plasma membrane permeability by introducing pores in the plasmamembrane, 
recent studies show that 2B is localized at intracellular membranes of the ER and the Golgi (de 
Jong et al., 2003). It has been suggested that plasma membrane permeability is a downstream 
consequence of the increased Golgi membrane permeability and the subsequent alterations in 
Golgi ion homeostasis (de Jong et al., 2004; Campanella et al., 2004).
Inhibition of protein transport.
 Enterovirus infection causes an inhibition of protein transport (Doedens and Kirkegaard, 
1995). This occurs also upon individual expression of 2B and 3A, as well as the precursor protein 
2BC (Doedens and Kirkegaard, 1995). Since the 2C protein did not affect the protein transport, it 
was suggested that the 2B is the active part of 2BC for its inhibition of protein transport (Doedens 
and Kirkegaard, 1995). It has been suggested that the inhibition of protein transport by 2B is a 
downstream consequence of the increased permeability of ER and Golgi membranes, but the exact 
mechanism by which 2B inhibits protein transport is as yet unknown (de Jong et al., 2006). The 
mechanism by which 3A inhibits protein transport is unknown and the 3A-mediated inhibition of 
protein transport is the main topic of the studies described in this thesis. It has been suggested that 
the inhibition of protein transport by 3A is necessary for the accumulation of replication vesicles. 
However, the observation that a PV carrying a 3A protein defective in inhibition of protein transport 
is viable and grows with wild-type characteristics at temperatures above 32.5ºC, shows that 
inhibition of protein transport is not essential for vRNA replication (Doedens et al., 1997; Bernstein 
and Baltimore, 1988). The possible purpose of the inhibition of protein transport by 3A is discussed 
below in “(entero)viral evasion of the immune system”.
Cleavage of the cytoskeleton.
 The cytoskeleton is a system of protein filaments in the cytoplasm of eukaryotic cells that 
is involved in the movement and shape of a cell. Actin filaments, microtubules, and intermediate 
filaments are the most abundant components of the cytoskeleton. Already long time ago it has been 
described that intermediate filaments are remodeled in PV-infected cells (Lenk and Penman, 1979). 
Enteroviruses do not need an intact cytoskeleton for their replication, since several drugs that 
disrupt the cytoskeleton did not block vRNA replication (Doedens et al., 1994). The first example 
of a specific alteration in a cytoskeletal protein upon PV infection was the cleavage of microtubule-
associated protein 4 (MAP4) by the PV protease 3C (Joachims and Etchison, 1992; Joachims et al, 
1995). CVB3 infection results in cleavage of the cytoskeletal protein dystrophin by the action of the 
2A protease (Badorff et al., 1999). Mutations in dystrophin cause dilated cardiomyopathy, a disease 
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in which enterovirus infection is thought to play a role. Enteroviruses showed greater replication 
in dystrophin-deficient mice and caused more severe cardiomyopathy as compared with wild-type 
mice, indicating that the absence of functional dystrophin is of benefit for the virus (Xiong et al., 
2002).
(Entero)viral evasion of the immune system.
 Nucleated cells can communicate their status to neighbouring cells and to effector cells 
of the immune system. Upon viral infection, cells respond by an innate immune response that 
involves secretion of cytokines (e.g. interferons [IFNs] and chemokines). IFNα and IFNβ inhibit 
virus replication in infected cells and chemokines attract leukocytes to infection sites. Moreover, 
infected cells can present viral antigens in the context of MHC class I (MHC-I) molecules to stimulate 
an acquired immune response by activating cytotoxic T lymphocytes (CTLs). Most viruses have 
evolved specifically tailored mechanisms to evade these antiviral host cell responses (reviewed in 
Lorenzo et al., 2001 and Alcami and Koszinowski, 2000). The large genome size of DNA viruses 
allows a large number of genes to be committed to host control. However, the genome size of RNA 
viruses is limited due to the low fidelity of RNA polymerase, resulting in little or no space for genes 
involved in immune defenses. RNA viruses encode therefore often multifunctional proteins. 
 Enteroviruses can evade the immune system at several levels. They cause a shutoff host 
cell transcription and translation, thereby interfering with the production of cytokines (discussed in 
“effects on the host cell” above). Furthermore, they inhibit the activation of IFN effector pathways, 
thereby preventing the anti-viral state in the cell (discussed in “Interfering with nucleo-cytoplasmic 
trafficking” above). Another stategy is the inhibition of protein transport. Enterovirus infection, as 
well as expression of the proteins 2B and 3A inhibit protein transport through the secretory pathway 
(Doedens and Kirkegaard, 1995). This has been suggested to have a function in evasion of the 
extrinsic apoptotic pathway and the cellular immune response (Neznanov et al., 2001; Dodd et 
al., 2001; Deitz et al., 2000). The expression of 2B or 3A reduced the amount of tumor necrosis 
factor (TNF) receptors on the plasma membrane, thereby confering resistance to TNF-induced 
apoptosis (Neznanov et al., 2001). In addition, 2B is proposed to suppress several intrinsic apoptotic 
pathways via interference with intracellular calcium homeostasis (Campanella et al., 2004). The 
role of 3A-mediated inhibition of protein transport in evasion of antiviral immune responses was 
investigated in two studies of the Kirkegaard lab. Deitz et al. tested the effects of 3A expression 
and PV infection on the presentation of hepatitis C virus (HCV) antigens in cultured chimpanzee 
target cells (Deitz et al., 2000). They derived CD8+ CTLs from an HCV-infected chimpanzee and 
showed that 3A expression protected the cells from CTL-mediated lysis by reducing the transport 
of newly synthesized MHC-I molecules to the cell surface. They also showed that PV infection of 
target cells reduced the secretion of granzyme A from CTLs, which is an indication for reduced 
antigen presentation to CTLs. This reduction was not observed upon infection with a mutant PV 
carrying a 3A protein defective in inhibition of protein transport, indicating that PV inhibits antigen 
presentation by 3A-dependent inhibition of protein transport. Dodd et al. used the same mutant PV 
to study the effect of 3A on the secretion of cytokines from human cells that are highly inducible 
for IFNβ synthesis (Dodd et al., 2001). They showed a significant increase in the secretion of the 
cytokines IFNβ, interleukine (IL)-8, and IL-6 from cells upon single-cycle infections with the mutant 
PV compared to the wild-type PV. These data suggest that the secretion of cytokines is reduced 
as a result of the inhibition of protein transport by 3A. Both studies favour a role of 3A-mediated 
transport inhibition in evasion of both the innate immune response (secretion of cytokines) and the 
acquired immune response (antigen presentation via MHC-I molecules). However, both studies 
investigated the effect of transport inhibition by 3A in tissue culture systems, and data are lacking 
showing the biological relevance of transport inhibition by 3A in vivo. 
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The early secretory pathway.
 The 3A protein inhibits protein trafficking through the secretory pathway. An overview of 
the early secretory pathway is depicted in Fig. 5. Newly synthesized proteins enter the secretory 
pathway in the endoplasmic reticulum (ER). These proteins can be transmembrane proteins, which 
become embedded in the ER membrane, or water-soluble proteins, which are released into the ER 
lumen. The import of proteins is a co-translational process, meaning that the import begins before 
the polypeptide chain is completely synthesized. In the ER lumen, the proteins fold, oligomerize 
and several modifications take place. Correctly folded proteins that are destined for the Golgi 
complex, the lysosomes, the endosomes, the plasma membrane and for secretion are selectively 
separated from ER resident proteins at the ER exit sites (ERES) by the action of the COP-II coat 
complex (Mancias and Goldberg, 2005). The COP-II coat consists of Sec23-Sec24 and Sec13-
Sec31 heteromultimers, which are recruited to the membranes by the Sar1 GTPase (Barlowe et al., 
1994; Matsuoka et al., 1998). Sar1 cycles between an inactive, GDP-bound state, and an active, 
GTP-bound state and this cycling is catalyzed by guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs). In yeast, the Sec12 protein was shown to function as a GEF 
for Sar1 and recently the mammalian homologue of Sec12 (mSec12) was identified (Barlowe and 
Schekman, 1993; Weissman et al., 2001). Sec23 is a GAP for Sar1 and also the outer layer of the 
COP-II coat, Sec13-Sec31 multimers, accelerate the rate of GTP hydrolysis by Sar1 (Yoshihisa et 
al., 1993; Antonny et al., 2001). The action of the COP-II coat complex results in the formation of 
a transport carrier by a mechanism that is not completely understood yet. These transport carriers 
are transported along microtubules to form vesicular tubular clusters (VTC), also called the ER-
Golgi-intermediate compartment (ERGIC). Recently, it was shown that the COP-II subunit Sec23 
interacts with the dynactin complex, providing a direct link between the ER export machinery and 
microtubules (Watson et al., 2005). VTCs are transported along microtubules to the cis side of the 
Golgi complex, where they fuse with Golgi membranes (Lippincott-Schwartz et al., 1998).
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Fig. 5. Schematic representation of the early secretory pathway. Cargo molecules are concentrated in COP-II coated ER exit 
sites, specialized domains at the ER. Following budding from the ER exit site, transport carriers fuse to form vesicular tubular 
clusters (VTCs), also called the ER-Golgi-intermediate compartment (ERGIC). VTCs are transported along microtubules to the 
cis side of the Golgi complex, where they fuse with Golgi membranes. The COP-I coat acts in retrograde transport within the 
Golgi and from the Golgi and VTCs to the ER. COP-I function is also required for ongoing anterograde transport.
 Another type of coated vesicles are the COP-I coated vesicles. Like the COP-II coated 
vesicles, COP-I coated vesicles mediate transport between the ER and Golgi. However, the exact 
role of COP-I in ER-to-Golgi transport is debated (reviewed in Rabouille and Klumperman, 2005). 
The vesicular transport model suggests that COP-I is involved in the anterograde movement of 
cargo, whereas the cisternal maturation model suggests that COP-I is involved in the retrograde 
movement of Golgi enzymes. The COP-I coat contains seven subunits (α, β’, ε, δ, β, γ, and ξ). 
Recruitment of the COP-I coat to membranes is regulated by the ADP-ribosylation factor 1 (Arf1) 
(Donaldson et al., 1991). This small GTPase cycles between an inactive, GDP-bound state, and an 
active, GTP-bound state (reviewed in [Moss and Vaughan, 1998] and [Shin and Nakayama, 2004]). 
The cycling is catalyzed by GEFs, like GBF1, and GAPs, like ArfGAP1. In mammalian cells, five 
different Arf isotypes exist. They are grouped in three classes: Class I, containing Arf1 and Arf3, 
Class II, containing Arf4 and Arf5, and Class III, containing Arf6. Different Arf isotypes are thought 
to have different functions and different ArfGEFs and ArfGAPs. In the Golgi complex the proteins 
are further modified, sorted and dispatched. 
 Transport within in the secretory pathway is thought to depend on vesicles. Vesicle 
formation requires coat proteins (e.g. COP-I and COP-II, which are described above). They have 
two major functions: selection of cargo and induction of membrane curvature. Besides the coat 
proteins, proteins are needed that target the transport vesicle with high coordination and specificity. 
Two classes of proteins play a role in this recognition step: soluble NSF (N-ethylmaleimide-
sensitive factor) attachment protein receptors (SNAREs) and Rab-GTPases. SNARE proteins 
are transmembrane proteins that provide specificity and catalize the fusion of vesicles with the 
target membrane (reviewed in Ungermann and Langosch, 2005). A vesicle membrane SNARE 
(v-SNARE) has a complementary target membrane SNARE (t-SNARE). Vesicle docking and the 
matching of v-SNAREs and t-SNAREs are regulated by the Rab proteins. 
 Most proteins travel from the ER to the Golgi. However, ER-resident proteins must be 
retained within the ER. This retrieval pathway for returning proteins back to the ER depends on ER 
retrieval signals. Soluble ER resident proteins contain a KDEL sequence at their C-terminus. By 
binding to specialized receptor proteins such as the KDEL receptor these proteins are packaged 
into COP-I coated retrograde transport vesicles. Resident ER membrane proteins contain a KKXX 
signal (two lysines, followed by any two other amino acids). This signal binds directly to COP-I 
coats and leads to packaging of these proteins into COP-I coated retrograde transport vesicles. 
Both of these signals do not prevent proteins from being transported to the Golgi. Instead, they 
cause resident ER proteins to be selectively retrieved from the Golgi and returned to the ER.  
The enterovirus 3A protein.
 The main topic of this study is the enterovirus protein 3A. The properties and functions 
that were known when this study was started, are summarized below. 3A is a small, multifunctional 
protein of 87-89 amino acids, containing a hydrophobic domain in its C-terminal portion. This 
C-terminal hydrophobic anchor is responsible for its membrane association (Towner et al., 1996). 
The 3A protein, mostly in its 3AB precursor form, has been suggested to be involved in multiple 
steps in the process of vRNA replication (Fig. 6). Only membrane-bound 3AB can be cleaved to 
3A and VPg (3B), suggesting that the precursor 3AB delivers VPg to the membranous replication 
complex (Lama et al., 1994; Paul et al., 1998). It was shown that 3AB and 3CDpro form a complex, 
which interacts with the 5’ cloverleaf and the 3’ UTR of the enteroviral genome (Harris et al., 1994). 
The stimulation of specific complex formation with 3CDpro on the 5’ cloverleaf by 3AB might be 
essential for RNA replication (Xiang et al., 1995). Furthermore, 3AB stimulates the self-cleavage 
of 3CDpro to 3Cpro and 3Dpol (Molla et al., 1994). Once cleaved, the newly generated 3Dpol is likely 
to remain bound to 3AB, which fits well the observed stimulation of the polymerase activity of 3Dpol 
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by 3AB and the role of 3AB in binding of 3Dpol to membranes (Lama et al., 1994; Paul et al., 1994; 
Lyle et al., 2002). It seems that the above-mentioned functions in vRNA replication are performed 
by 3AB, but it is unknown whether 3A alone also plays a role in these or other steps in vRNA 
replication. This is difficult to investigate, since introduction of mutations in the 3A coding sequence 
of the virus results in both mutated 3A and 3AB. In addition to a function in replication, the PV 3A 
protein has been shown to inhibit protein transport at an unknown step somewhere between the ER 
and the Golgi (Doedens and Kirkegaard, 1995; Doedens et al., 1997).
 
Aim and outline of this thesis.
 The PV 3A protein has been shown to inhibit protein transport. The aim of this thesis is 
(i) to study whether this function is conserved in the 3A protein of CVB3, (ii) to elucidate the 
underlying molecular mechanism, (iii) to gain more insight into the structure-function relationship of 
3A, and (iv) to determine the physiological relevance of this function for the viral life cycle. 
 In Chapter 2, we provide evidence that the ability to inhibit ER-to-Golgi transport is 
conserved in the 3A protein of CVB3. In Chapters 2 and 3, we combined in silico and in vivo 
approaches to obtain insight into the structure-function relationship of 3A. We generated a 
molecular model of CVB3 3A using the NMR structure of PV 3A as a template. On basis of this 
model, a variety of mutants was constructed to determine residues in 3A that are important for 
its transport inhibiting function. Following this approach, several important determinants for the 
transport inhibiting function of 3A were identified. By introducing these mutations into an infectious 
CVB3 cDNA clone, several mutant viruses carrying a 3A protein that was defective in inhibiting 
transport were obtained. Some of these viruses replicated with wild-type characteristics in tissue 
culture cells, indicating that the 3A-mediated transport inhibition is not essential for the process of 
viral RNA replication.  
 In Chapter 4, we used a mouse model of CVB3-induced acute myocarditis to show the 
biological significance of 3A-mediated inhibition of protein transport in vivo. Moreover, experiments 
were undertaken to elucidate the mechanism by which the 3A protein inhibits transport. The Arf1 
GTPase plays an important role in ER-to-Golgi transport by recruiting COP-I coats to transport 
carriers. We show that 3A inhibits GBF1, one of the GEFs of Arf1, by interacting with it, thereby 
blocking the Arf1 activation and COP-I assembly. In Chapter 5, the molecular interaction between 
3A and GBF1 is further characterized by testing various mutants of both proteins. 
 The naming of the picornavirus proteins is based on their place in the genome. All 
picornaviruses have a similar genome organization, and therefore they all contain a 3A protein. It is 
not known whether the 3A proteins of picornaviruses have similar funtions. Therefore, in Chapter 6 
we studied whether the ability of the CVB3 3A protein to interfere with GBF1- and Arf1-dependent 
COP-I assembly is conserved among other picornavirus 3A proteins. 
 The results that are describd in this thesis are summarized and discussed in Chapter 7.
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Fig. 6. Schematic representation of the role of 3A in viral RNA replication. The positive strand RNA genome is depicted in 
a circular organization, allowing initiation of negative strand RNA synthesis. The following putative roles of 3A (or 3AB) are 
depicted: (i) 3A delivers the viral peptide primer 3B (VPg) to the membrane-bound replication complex; (ii) 3AB stimulates 
autocleavage of 3CD to produce 3Cpro, which is bound to the cloverleaf structure in the 5’ untranslated region, and 3Dpol, which 
is bound to the 3’ untranslated region; (iii) 3AB stimulates the polymerase activity of 3Dpol.
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The ability of the 3A protein of coxsackievirus B (CVB) to inhibit protein secretion was investigated for this study. Here we show that the ectopic expression of CVB 3A blocked the transport of both the glycoprotein of vesicular stomatitis virus, a membrane-
bound secretory marker, and alpha-1 protease inhibitor, a lumenal secretory protein, at a 
step between the endoplasmic reticulum (ER) and the Golgi complex. CVB 3A contains a 
conserved proline-rich region in its N terminus. The importance of this proline-rich region 
was investigated by introducing Pro-to-Ala substitutions. The mutation of Pro19 completely 
abolished the ability of 3A to inhibit ER-to-Golgi transport. The mutation of Pro14, Pro17, or 
Pro20 also impaired this ability, but to a lesser extent. The mutation of Pro18 had no effect. 
We also investigated the possible importance of this proline-rich region for the function 
of 3A in viral RNA replication. To this end, we introduced the Pro-to-Ala mutations into an 
infectious cDNA clone of CVB3. The transfection of cells with in vitro-transcribed RNAs of 
these clones gave rise to mutant viruses that replicated with wild-type characteristics. We 
concluded that the proline-rich region in CVB 3A is required for its ability to inhibit ER-to-
Golgi transport, but not for its function in viral RNA replication. The functional relevance of 
the proline-rich region is discussed in light of the proposed structural model of 3A.
Introduction 
 Enteroviruses (poliovirus, coxsackievirus, echovirus, and several unnamed enteroviruses) 
are small viruses that contain a 7.5-kb single-stranded RNA genome with positive polarity. The 
genomic RNA harbors one large open reading frame that encodes the viral polyprotein. This 
polyprotein is proteolytically processed by virally encoded proteases into the individual capsid 
proteins and the nonstructural replication proteins (2Apro, 2B, 2C, 3A, 3B, 3Cpro, and 3Dpol), as well 
as the relatively stable precursor proteins 2BC, 3AB, and 3CDpro (Porter et al., 1993; Wimmer et al., 
1993). Replication of the viral RNA (vRNA) takes place in replication complexes in conjunction with 
secretory pathway-derived membrane vesicles that accumulate in the cytoplasm of the infected 
cell (Bienz et al., 1994; Rust et al., 2001). Enteroviruses are nonenveloped, cytolytic viruses that 
do not rely on an intact secretory pathway to release their virus progeny. Instead, poliovirus (PV) 
has been shown to induce a general blockage of protein secretion (Doedens and Kirkegaard, 
1995). Through the individual expression of the different nonstructural proteins of PV, Doedens and 
Kirkegaard have shown that proteins 2B and 3A are each sufficient to inhibit transport through the 
secretory pathway (Doedens and Kirkegaard, 1995). The step blocked by the 2B protein is presently 
unknown. The expression of the PV 3A protein resulted in the accumulation in the ER of both the 
G protein of vesicular stomatitis virus (VSVG) and the alpha-1 protease inhibitor (A1PI) (Doedens 
and Kirkegaard, 1995; Doedens et al., 1997). Moreover, the inhibition of ER-to-Golgi transport 
by PV 3A was shown to result in a reduced secretion of cytokines and interleukins (Dodd et al., 
2001), a downregulation of major histocompatibility complex class I (MHC I)-dependent antigen 
presentation (Deitz et al., 2000), and resistance to tumor necrosis factor alpha (TNF-α)-induced 
apoptosis (by elimination of the TNF receptor from the cell surface) (Neznanov et al., 2001). These 
findings represent unique examples of the evasion of both innate and acquired immune responses 
as well as the extrinsic apoptotic pathway by viral interference with secretory pathway trafficking. 
The mechanism by which the 3A protein inhibits secretory transport is as yet unknown. 
 In addition to its function in manipulating intracellular protein transport, the enterovirus 3A 
protein is involved in multiple steps in the process of vRNA replication. The 3A protein is a small 
hydrophobic protein (87 to 89 amino acids [aa]) that contains a C-terminal hydrophobic anchor 
which is responsible for its membrane association (Towner et al., 1996). Several studies have 
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shown that mutations in 3A give rise to defects in vRNA synthesis (Bernstein et al., 1986; Giachetti 
et al., 1992; Hope et al., 1997; Xiang et al., 1995). The membrane-bound precursor 3AB is most 
likely the donor for VPg (i.e., 3B), the peptide that serves as the primer for vRNA synthesis, to the 
membranous replication complex (Paul et al., 1998). Moreover 3AB serves as a cofactor for the 
binding of 3CD to the 5’ and 3’ termini of the RNA genome (Harris et al., 1994), the polymerase 
activity of 3Dpol (Lama et al., 1994; Paul et al., 1994) and the autocatalytic processing of 3CDpro to 
3Cpro and 3Dpol (Molla et al., 1994). 
 For this study, we investigated whether the function of the 3A protein in interfering with 
endoplasmic reticulum (ER)-to-Golgi transport is conserved in the closely related coxsackievirus B 
(CVB). Expression of the CVB3 3A protein was indeed sufficient to inhibit ER-to-Golgi transport. All 
enterovirus 3A proteins contain a proline-rich region in their N termini. The biological significance 
of this proline-rich region, which may be involved in protein-protein interactions, was investigated 
by the individual expression of CVB3 3A mutants and the introduction of these mutations in an 
infectious cDNA clone of CVB3. Our results indicate that the integrity of this proline-rich region is 
required for the inhibition of ER-to-Golgi transport by the CVB3 3A protein, but not for its functions 
in vRNA replication. 
Results
Inhibition of ER-to-Golgi transport by CVB3 and 3A expression.
 To monitor secretory pathway trafficking, we made use of a GFP fusion of the temperature-
sensitive ts045 mutant of VSVG, a well-known membrane-bound secretory marker (VSVG-GFP). 
Figure 1A shows that at the nonpermissive temperature (40°C), VSVG-GFP was improperly folded 
and, as a consequence, retained in the ER (as indicated by its colocalization with calreticulin, an 
ER protein). Upon shifting the temperature to the permissive temperature (32°C), the protein was 
correctly folded and transported out of the ER. After 45 min, the majority of the protein was found at 
the Golgi complex (as indicated by colocalization with GM130, a cis-Golgi protein) (Fig. 1B). After 
120 min, the protein was localized mostly at the plasma membrane (Fig. 1C).
 To investigate whether CVB3 inhibits vesicular trafficking, we transfected BGM cells with 
the VSVG-GFP expression plasmid, incubated them at 40°C, and then infected them with CVB3 at 
an MOI of 50. The infected cells were further incubated at 40°C and then shifted to 32°C (for 120 
min) at 1-h time intervals between 0 and 5 h postinfection (p.i.). The cells were fixed and stained, 
and VSVG-GFP localization was analyzed by CLSM. In infected cells that were kept at 40°C, 
VSVG-GFP was retained in the ER (Fig. 1D). In infected cells that were shifted to 32°C at 0, 1, 2, 
or 3 h p.i., VSVG-GFP was mainly localized at the plasma membrane (similar as the case shown in 
Fig. 1C). In cells that were shifted to 32°C at 4 or 5 h p.i., VSVG-GFP was found to accumulate both 
in the ER (Fig. 1E) and a dispersed post-ER compartment that also contained the cis-Golgi marker 
(Fig. 1F). Together, these results suggest that in CVB3-infected cells, protein transport is blocked 
from about 4 h p.i. at a step between the ER and the Golgi. 
 Next, we tested whether expression of the CVB3 3A protein alone was sufficient to inhibit 
ER-to-Golgi transport. BGM cells were cotransfected with VSVG-GFP and a 3A expression plasmid 
(in a 1:3 ratio to optimize the cotransfection efficiency). The cells were incubated at 40°C for 20 h 
(Fig. 1G) and then shifted to 32°C for 120 min. Figs. 1H and I show that in cells cotransfected with 
VSVG-GFP and 3A, VSVG was mainly retained in the ER (Fig. 1H) and in a dispersed post-ER 
compartment that also contained the cis-Golgi marker (Fig. 1I), which was more or less similar to 
the case for infected cells. 
 In order to quantify the inhibitory effects of CVB3 infection and 3A expression on protein 
secretion, we made use of the reporter protein A1PI, a secreted soluble glycoprotein. In pulse-
Proline-rich region in CVB3 protein 3A
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Fig. 1. CVB3 infection and expression of the 3A protein inhibit VSVG-GFP trafficking. BGM cells were transfected with a 
construct coding for the GFP-tagged ts045 temperature-sensitive mutant of the VSVG protein, either alone or together with 3A, 
and grown at 40ºC for 20 h. (A to C) Control cells. In control cells, VSVG was improperly folded at 40ºC, and as a consequence, 
was retained in the ER, as shown by its colocalization with calreticulin (merged picture on the right in panel A). Upon shifting 
to the permissive temperature (32ºC), the VSVG-GFP protein was correctly folded and transported out of the ER. VSVG could 
be observed in the Golgi complex after 45 min, as shown by its colocalization with GM130, a cis-Golgi marker (B), and at the 
plasma membrane after 120 min (C). (D to F) Cells infected with CVB3 (MOI of 50) for 5 h at 40ºC. At 40ºC, VSVG was retained 
in the ER (D). Upon shifting to 32ºC for 120 min, VSVG could be found in the ER (E) and a post-ER compartment that also 
contained the cis-Golgi marker (F). (G to I) 3A-expressing cells. VSVG was retained in the ER at 40ºC (G), whereas it was 
observed in the ER (H) and a post-ER compartment that also contained the cis-Golgi marker (I) when shifted to 32ºC for 120 
min.  Bar = 10 µm. For full colour figure, see page 130.
chase experiments, the level of A1PI secretion can be determined by measuring the percentages of 
reporter protein in the cell and medium fractions. For this study, a fusion protein of A1PI and EYFP 
was used because the A1PI protein was found to migrate to the same position as an nonspecific 
protein band in the BGM cell lysates (data not shown). Figure 2A shows that the A1PI-EYFP fusion 
protein, which was labeled for a 30-min pulse period and immunoprecipitated with anti-EGFP, was 
efficiently secreted into the medium during a 2-h chase period. 
 The inhibitory effect of CVB3 infection on protein secretion was determined at various 
times p.i. Because enterovirus infection shuts off cap-dependent translation (Ehrenfeld, 1982), a 
plasmid was used that contained the A1PI coding sequence behind the PV 5’ non-coding region. 
Cells transfected with this construct were infected with CVB3 (MOI = 50), pulse labeled for 30 min 
with [35S]methionine at 2, 4, or 6 h p.i., and subsequently chased for 2 h in the presence of unlabeled 
methionine. In cells labeled at 2 h p.i. (i.e., chased between 2.5 and 4.5 h p.i.), the majority of A1PI 
was secreted into the medium (Fig. 2A). In cells labeled at 4 h or 6 h p.i. (i.e., chased between 
4.5 and 6.5 h p.i. and between 6.5 and 8.5 h p.i., respectively), however, only a small amount of 
A1PI was observed in the medium fraction, whereas a large amount of A1PI was retained in the 
cell. The amount of A1PI in the medium fraction was determined as the percentage of the total 
amount of A1PI and compared to that of control cells (for which the value was normalized to 100% 
A1PI secretion). The average results of three independent experiments are shown in Fig. 2B. The 
results demonstrate that CVB3 infection inhibited reporter protein secretion to approximately 30% 
compared to control cells from about 4 h p.i. 
 To quantify the inhibitory effect of 3A on protein secretion, we coexpressed the 3A protein 
(behind an SV40 promoter) and the A1PI secretion marker (behind a CMV promoter) from a single 
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Fig. 2. CVB3 infection (MOI 50) and expression of the 3A protein inhibit A1PI secretion. BGM cells were transfected with A1PI 
expression constructs. Twenty hours after transfection, the cells were starved of methionine for 30 min, labeled with [35S]-
methionine for 30 min, and then chased for 2 h. Cell (C) and medium (M) fractions were collected and analyzed for the amount 
of labeled reporter protein by immunoprecipitation with an anti-EGFP antiserum, SDS-PAGE, and phosphorimaging. (A) Cells 
transfected with a plasmid containing A1PI behind the PV noncoding region were infected and subjected to pulse-chase analysis 
at 2, 4, and 6 h p.i. The differences in the migration between A1PI in the medium and cell fractions were due to differences in 
the glycosylation state (endoglycosidase F treatment resulted in faster migration of A1PI in both the medium and cell fraction 
[data not shown]). (B) Average secretion (means ± standard errors of the means [SEM]) of three independent experiments. 
A1PI secretion was calculated as the percentage of A1PI secretion in uninfected control cells, which was normalized to 100%. 
(C to E) BGM cells were transfected with constructs expressing either EGFP (-3A) or EGFP-3A (+3A) from an SV40 promoter 
and the A1PI-EYFP protein from a cytomegalovirus promoter. (C) Western blot analysis of EGFP and EGFP-3A expression. 
(D) Analysis of A1PI secretion. (E) Average secretion (means ± SEM) of three independent experiments. A1PI secretion was 
calculated as the percentage of A1PI secretion in EGFP-expressing control cells, which was normalized to 100%.  
plasmid. The 3A protein was expressed as an EGFP-3A fusion protein (the fusion of EGFP to the 
N terminus of 3A did not affect its protein secretion inhibiting function  [data not shown]). As a control, 
a plasmid was constructed that contained the EGFP sequence behind the SV40 promoter. Western 
blot analysis showed that both proteins were efficiently expressed (Fig. 2C). Figure 2D shows that 
the expression of the 3A protein resulted in a severely reduced amount of labeled reporter protein 
in the medium fraction. A quantitative analysis of A1PI secretion in three independent experiments 
showed that 3A expression inhibited reporter protein secretion to approximately 25% of that of 
control cells (Fig. 2E)  (the percentage of A1PI secretion was calculated as described above). 
Importance of proline-rich region in 3A for inhibition of ER-to-Golgi transport.
 The enterovirus and rhinovirus 3A proteins are characterized by the presence of a proline-
rich region in the N terminus (Fig. 3). This proline-rich region is located at aa 17 to 19 (numbering 
refers to the CVB3 3A protein). Pro17 and Pro19 are present in all 63 enterovirus and rhinovirus 
3A proteins sequenced to date (except for enterovirus [EV] type 71). Pro18 is present in nearly all 
enteroviruses and rhinoviruses (except for coxsackievirus A16 [CVA16], CVA24, EV70 and EV71). 
All human enterovirus group B (HEV-B) members (which include all CVB types, all echoviruses, 
some CVA types, and several unassigned EVs) contain additional Pro residues at positions 14 and 
20.
 Proline-rich regions are often involved in protein-protein interactions (reviewed in Kay 
et al., 2000). To investigate the functional importance of the proline-rich region in the CVB3 3A 
protein, we constructed mutant 3A expression plasmids. Since Pro17, Pro18, and Pro19 are the most 
conserved proline residues, we first replaced these three residues simultaneously with Ala residues 
(P17A/P18A/P19A). Figures 4A and B show that this 3A mutant was no longer able to inhibit protein 
secretion. This was not due to reduced expression of the mutant protein, as it was expressed at a 
similar level as wild-type 3A (Fig. 4E). Moreover, in cells that coexpressed this mutant 3A protein 
and VSVG-GFP we observed that VSVG accumulated at the plasma membrane (data not shown). 
Thus, the proline-rich region is required for the ability of 3A to inhibit protein secretion. 
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Fig. 3. Alignment of aa 14 to 20 of the enterovirus and rhinoviruses 3A proteins. The genome organization of CVB3 is depicted. 
CVB3 contains a single open reading frame flanked by a 5’ and 3’ nontranslated region (NTR) and a poly(A) tail. The four capsid 
proteins (VP1 to VP4) and seven nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C, 3D) are shown. The 3A protein of CVB3 is an 
89-aa protein which contains a C-terminal hydrophobic domain (aa 61 to 82). 3A contains several Pro residues (at positions 14 
and 17 to 20) in its N terminus. An alignment of these residues for all enteroviruses and rhinoviruses that have been sequenced 
to date is shown. The species names are shown in bold. HEV-B, human enterovirus B; HEV-A, human enterovirus A; HEV-C, 
human enterovirus C; HEV-D, human enterovirus D; PV, poliovirus; HRV-A, human rhinovirus A; HRV-B, human rhinovirus B; 
CVB, coxsackievirus B; ECHO(*), all echoviruses sequenced to date (i.e., echoviruses 1 to 7, 9, 11 to 21, 24 to 27, and 29 to 
33); CVA, coxsackievirus A; EV, enterovirus.
 To investigate the importance of the Pro residues individually, we constructed mutant 
3A proteins in which single Pro residues at position 14, 17, 18, 19 and 20 were replaced with 
Ala residues (mutations P14A, P17A, P18A, P19A, and P20A, respectively). The P19A mutation 
completely abolished the ability of 3A to inhibit A1PI secretion (to a similar extent as the 
P17A/P18/A/P19A mutant) (Figs. 4C and D). The P14A, P17A, and P20A mutations also impaired 
the ability of 3A to inhibit protein secretion, although to a lesser extent. The P18A mutation had no 
effect on the secretion inhibiting activity of 3A. Western blot analysis showed that all mutant 3A 
proteins were efficiently expressed (Fig. 4E). Thus, the Pro residues at position 14, 17, 19, and 20, 
but not that at position 18, are important for the ability of 3A to inhibit protein secretion.  
Importance of a proline-rich region in 3A for its function in viral replication.
 To study the effect of the 3A mutations on viral RNA replication and virus growth, we 
introduced mutations into an infectious cDNA clone of CVB3. For each mutation, two p53CB3/T7 
clones were tested, derived from two independently generated site-directed mutagenesis clones. 
The effects of the P17A/P18A/P19A, P14A, P17A, P18A, P19A, and P20A mutations on virus 
viability were studied by the transfection of BGM cells with RNA transcripts. The results obtained for 
the P17A/P18A/P19A mutant are described below. Cells transfected with RNA transcripts carrying 
the single Pro mutations exhibited complete CPE in all transfections (Fig. 5A). vRNAs were isolated 
from these cell cultures, and the 3A-coding region was amplified by reverse transcription-PCR 
and then sequenced. In all cases, the original mutations were retained in the vRNAs, and no 
secondary amino acid replacements had occurred. The mutant viruses were further characterized 
by single-cycle growth analysis (Fig. 5B). Viruses carrying mutations exhibited wild-type growth 
characteristics. This indicated that the mutant 3A proteins were correctly folded. In conclusion, 
mutation of the individual Pro residues had no effect on viral replication. 
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Fig. 4. Proline-rich region is required for secretion inhibition by CVB3 3A. Cells were transfected with plasmids expressing the 
indicated 3A mutant proteins from an SV40 promoter and the A1PI reporter protein from a cytomegalovirus promoter. Twenty 
hours after transfection, the cells were labeled with [35S]-methionine for 30 min and chased in the presence of unlabeled 
methionine for 2 h. Cell (C) and medium (M) fractions were collected, immunoprecipitated with an anti-EGPF serum, analyzed 
by SDS-PAGE (A and C) and quantified by phosphoimaging (B and D). The amount of secreted A1PI in the absence of 3A was 
normalized to 100%, and the ability of 3A and 3A mutants to secrete A1PI was calculated as a percentage of the A1PI secretion 
in control cells without 3A. Values represent means ± SEM of three independent experiments. a, significantly different from A1PI 
secretion in control cells without 3A; b, significantly different from A1PI secretion in the presence of wild-type 3A (calculated by 
analysis of variance with LSD; p<0.05). (E) Western blot of  EGFP-3A wild-type and mutant proteins.
Identification of a second site suppressor mutation.
 Cells transfected with RNA transcripts containing the P17A/P18A/P19A mutations exhibited 
no CPE up to 5 days posttransfection. After passage to fresh BGM cells, CPE was observed in 
only one of eight transfected cell cultures (Fig. 6A). A sequence analysis of the 3A coding region 
showed that the introduced mutations were retained in the obtained virus but that a second site 
suppressor mutation, A→T, had occurred at nt 5119. This nucleotide mutation resulted in a Ser-to-
Cys substitution at aa 31 of the 3A protein. To demonstrate that this amino acid change in 3A was 
indeed responsible for the growth of this mutant virus, we introduced the P17A/P18A/P19A/S31C 
mutations into the infectious cDNA clone. BGM cells transfected with RNA transcripts of this mutant 
showed CPE on all occasions. A sequence analysis of the 3A coding region of the resulting viruses 
showed that the introduced mutations were retained in the vRNAs. Thus, a S31C mutation can 
indeed rescue the defect in virus growth caused by the P17A/P18A/P19A mutations. Single-cycle 
growth analysis showed that the mutant virus exhibited a severe delay in virus growth (Fig. 6B). 
 To investigate whether the quasi-infectious phenotype [a definition that indicates that the 
mutation disrupts vRNA replication to such an extent that (pseudo)reversion mutations or second 
site suppressor mutations can arise but that no virus progeny can be observed harboring the 
original mutation] of the P17A/P18A/P19A mutant was due to a defect in polyprotein processing, 
we performed in vitro translation reactions with RNA transcripts generated from the wild type and 
the mutant cDNA clone. An analysis of the [35S]methionine-labeled translation products by SDS-
PAGE showed no differences between the wild type and the mutant, arguing that it is unlikely 
that the growth defect of the mutant was due to aberrant processing of the viral polyprotein (data 
not shown). To investigate whether the primary defect occurred at the level of vRNA replication, 
we introduced the P17A/P18A/P19A mutations into p53CB3/T7-LUC, a subgenomic replicon that 
contains the luciferase gene in place of the P1 coding region. BGM cells were transfected with RNA 
transcripts of this clone, and at 10 h posttransfection, the cells were lysed and luciferase expression 
was analyzed. Transfected cells were grown in the absence or presence of guanidine hydrochloride 
(GuHCl), an inhibitor of enterovirus replication that is used to determine the luciferase levels in the 
absence of replication (under this condition, luciferase production only reflects translation of the 
transfected replicon RNA). Figure 6C shows that luciferase production by replicons carrying the 
P17A/P18A/P19A mutant was the same in the absence or presence of GuHCl and also the same 
as that observed for the wild-type replicons when replication was inhibited by GuHCl. However, 
replicons carrying the P17A/P18A/P19A/S31C mutant showed an increase in luciferase production. 
These findings provide evidence that the quasi-infectious phenotype of the P17A/P18A/P19A 
mutant was due to a primary defect in vRNA replication. 
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Fig. 5. Proline-rich region is not important 
for CVB3 growth. (A) Effect of the 
indicated 3A mutations on virus growth. 
Mutations were introduced into the 
infectious cDNA clone p53CB3/T7. Copy 
RNA transcripts were transfected into 
BGM cells and examined for the ability 
to yield viruses. All mutations resulted 
in viable viruses except the P17A/P18A/
P19A mutations, which caused a quasi-
infectious (q.i.) phenotype. (B) Single-
cycle growth analysis of the mutant 
viruses. BGM cells were infected with 
an MOI of 1 and incubated at 37°C. At 
2, 4, 6, or 8 h postinfection, viruses were 
released from the infected cells by three 
cycles of freezing and thawing. Virus titers 
were determined by titration on BGM cells 
and expressed in TCID50 values.
 We also investigated whether the second site suppressor mutation could rescue 
the effect of the P17A/P18A/P19A mutant on protein secretion. To this end, we introduced the 
P17A/P18A/P19A and S31C mutations into the 3A protein and tested their effect on A1PI secretion 
as described above. The P17A/P18A/P19A/S31C mutant caused a similar disruptive effect on the 
ability of 3A to inhibit A1PI secretion as the P17A/P18A/P19A mutant (Fig. 6D). Thus, the second 
site suppressor mutation S31C did not rescue the defect in protein secretion inhibition caused by the 
P17A/P18A/P19A mutations.  
 It has been suggested that the enterovirus 3A protein forms a homodimer. Cross-linking 
and analytical ultracentrifugation studies showed that the first 60 aa of the PV 3A protein form of 
a homodimer (Strauss et al., 2003). Evidence for PV 3A homomultimerization was also obtained 
by yeast two-hybrid analysis (Xiang et al., 1998). The possibility was considered that the second 
site suppressor mutation S31C might restore 3A-3A interactions that were disrupted by the 
P17A/P18A/P19A mutations. We investigated homomultimerization reactions of CVB3 wild-type 3A 
and 3A proteins carrying the P17A/P18A/P19A or P17A/P18A/P19A/S31C mutations by use of a 
mammalian two-hybrid system (de Jong et al., 2002). To this end, we cloned the 3A sequences in 
the correct reading frame into the expression plasmids pACT (which provides the activation domain 
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Fig. 6. A second-site suppressor mutation in 3A rescues the effect of the P17A/P18A/P19A mutations. (A) Effect of the indicated 
3A mutations on virus growth. The P17A/P18A/P19A mutations resulted in a quasi-infectious (q.i.) phenotype and yielded virus 
in only one of eight transfected cultures. A sequence analysis showed the presence of the second-site suppressor mutation 
S31C. The P17A/P18A/P19A/S31C mutant yielded viruses upon all transfections. (B) Effect of the P17A/P18A/P19A/S31C 
mutations on virus growth. Single-cycle growth analysis was performed as described in the legend to Fig. 5. (C) Effect of P17A/
P18A/P19A and P17A/P18A/P19A/S31C mutations on viral RNA replication. The mutations were introduced into p53CB3-LUC, 
and transcripts from these replicons were transfected into BGM cells. The cells were grown for 10 h in the presence (+) or 
absence (-) of 2 mM GuHCl, an inhibitor of enterovirus replication. Luciferase activities are depicted in light units (LU). (D) Effect 
of P17A/P18A/P19A and P17A/P18A/P19A/S31C mutations on A1PI secretion. The analysis was performed as described in 
the legend to Fig. 4. (E) Homomultimerization reactions of wild-type 3A, and the 3A-P17A/P18A/P19A and 3A-P17A/P18A/
P19A/S31C mutants expressed as fusion proteins to the HSV VP16 activation domain or the yeast GAL4 DNA binding domain. 
COS cells were transfected with the indicated constructs and assayed for firefly luciferase production at 48 h posttransfection. 
Dashes indicate the expression of unfused VP16 or GAL4 protein. LU, light units. 
of herpes simplex virus type 1 VP16) and pBIND (which provides the yeast Gal4 DNA binding 
domain). COS cells were cotransfected with these two plasmids and with the plasmid pG5luc, 
a reporter plasmid that contains five GAL4 binding sites upstream of a minimal TATA box that 
precedes the firely luciferase gene. An analysis of the luciferase activity showed that the wild-type 
CVB3 3A protein did indeed form homomultimers (Fig. 6E). No multimerization was observed with 
3A carrying the P17A/P18A/P19A mutations. No obvious increase in multimerization was observed 
with 3A carrying mutation P17A/P18A/P19A/S31C.
Discussion
 In this study, we showed that CVB3 infection and expression of the 3A protein alone 
interfere with protein secretion by blocking ER-to-Golgi transport. Moreover, we demonstrated that 
the proline-rich region in the N terminus of 3A is required for this ability. Pro17, Pro18, and Pro19 are 
evolutionary conserved in nearly all enteroviruses and rhinoviruses. Of these residues, Pro19 was 
found to be the most important for 3A to inhibit protein secretion. Mutation of this residue almost 
completely abolished this activity. The mutation of Pro17, on the other hand, was far less disruptive 
for the inhibitory activity of 3A. Mutation of this residue was even less disruptive than mutation of the 
less-conserved Pro14 and Pro20 residues, which are conserved in all HEV-B members (i.e., all CVBs 
and echoviruses, some CVAs and some unnamed enteroviruses), but not in other enteroviruses 
and rhinoviruses. Remarkably, the mutation of Pro18 had no notable effect. 
 The mechanism by which 3A inhibits protein secretion is still unknown. Therefore, we can 
only speculate about a role of the proline-rich region in inhibition of protein secretion. Pro residues 
can play an important role in protein-protein interactions (reviewed in Williamson, 1994). We 
propose that the 3A protein exerts its activity by tethering a cellular protein through an interaction 
with its proline-rich region. 
 Two well-known protein interaction domains that interact with Pro residues are Src 
homology 3 (SH3) and WW domains. SH3 domains recognize proline-rich sequences containing 
the core PXXP, where “X” denotes any amino acid. WW domains bind ligands containing PPXY or 
PPLP core motifs, usually flanked by additional Pro residues (Kay et al., 2000; Maclas et al., 2002). 
It seems unlikely, however, that 3A interacts with proteins containing an SH3 or a WW domain. 
When considering putative interaction domains, one should take into account the fact that the Pro14 
and Pro20 residues are not conserved among all enteroviruses and rhinoviruses. The 3A proteins 
of CVB3 and PV (which lacks Pro14 and Pro20) most likely use identical mechanisms to inhibit 
protein secretion. Given the observation that a mutation of Pro18 had little effect on this ability, these 
proteins most likely only share Pro17 and Pro19 for their secretion inhibiting function. Therefore, 
alternative interaction domains or mechanisms should be considered.
 Recently, the structure of the first 60 aa of the PV 3A protein was determined by nuclear 
magnetic resonance spectroscopy (Strauss et al., 2003). The PV 3A protein was found to form 
a classical homodimer. Dimerization occurs through ionic interactions, hydrogen bonds, and 
hydrophobic interactions between two helices formed by aa 23 to 29 and aa 32 to 41. Figure 7 
shows the putative structure of the first 60 aa of CVB3, obtained by molecular modeling of the 
published PV 3A structure. The structure suggests that the proline-rich regions of two interacting 
3A proteins are oriented in such a way that they are contiguous and thereby form a Pro platform. 
We suggest that this Pro platform, rather than specific SH3 or WW binding domains, may be the 
interaction domain responsible for the binding of a (still unknown) cellular protein.   
 The CVB3 3A protein inhibited protein secretion to an extent similar as previously described 
for the 3A protein of the closely related PV (Doedens et al., 1997). A PV mutant (mutant 3A-2) 
containing a Ser insertion between 3A residues 14 and 15 (corresponding to aa 15 and 16 in CVB3) 
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was strongly impaired in inhibiting A1PI secretion (Doedens et al., 1997). The PV carrying this 
insertion mutation showed a reduced ability to inhibit the presentation of MHC-I-antigen complexes 
(Deitz et al., 2000) and to block the secretion of cytokines and interleukins (Dodd et al., 2001). 
The introduction of this mutation in CVB 3A (i.e., a Ser insertion between residues 15 and 16) also 
interfered with the ability of 3A to inhibit A1PI secretion (data not shown). The mutation disrupted 
this 3A function to a similar extent as mutation P19A. It is therefore reasonable to assume that 
CVB3 carrying Pro-to-Ala mutations (in particular P19A) is also impaired in the ability to suppress 
MHC I-antigen presentation and to block the secretion of cytokines and interleukines. 
 Enterovirus genome replication takes place at secretory pathway-derived membrane 
vesicles that accumulate in the cytosol of the infected cell. The 2BC protein has been identified 
as playing a major role in the accumulation of these vesicles (Bienz et al., 1994; Rust et al., 2001; 
Schlegel et al., 1996). It has been speculated that the 3A-induced inhibition of ER-to-Golgi transport 
might also contribute to the accumulation of the vesicles with which the viral replication complexes 
are associated (Suhy et al., 2000). However, in the present study, we showed that viruses carrying 
mutations in 3A that interfered with its ability to inhibit ER-to-Golgi transport replicated with 
wild-type growth characteristics, arguing against a possible role of 3A in the accumulation of 
replication vesicles. It cannot be excluded that the 3A protein contributes to an accumulation of 
vesicles, but this activity seems not to be essential for viral RNA replication, at least not in vitro.
 In contrast to the wild-type phenotype of viruses carrying the single Pro-to-Ala mutations, the 
P17A/P18A/P19A mutant yielded a quasi-infectious phenotype. Upon  multiple RNA transfections, 
only on one occasion was virus obtained. A sequence analysis of the viral RNA showed that a second 
site suppressor mutation at position 31 of 3A (S31C) had occurred. This second site suppressor 
mutation rescued a defect in 3A in viral RNA replication, but not its ability to inhibit protein secretion. 
Since the single Pro-to-Ala mutations did not affect viral RNA replication, it can be hypothesized 
that the P17A/P18A/P19A mutations interfere with the conformation of 3A or its precursor 3AB 
and thereby with its function in vRNA replication. Indeed, we found that the P17A/P18A/P19A 
mutant interfered with 3A homomultimerization in a mammalian two-hybrid system. This finding is 
remarkable because the structural model predicts no important role for the proline-rich region in 
dimerization. Together, these data are consistent with the idea that the P17A/P18A/P19A mutation 
causes a general disruption of the 3A structure. How the S31C suppressor mutation, which is 
present in the loop between the two α-helices implicated in dimerization (Fig. 7), can (partially) 
rescue the defect in vRNA replication imposed by the P17A/P18A/P19A mutation remains to be 
established. Further research is needed to establish the requirement of 3A dimerization for its 
function in vRNA replication and its ability to inhibit ER-to-Golgi trafficking. 
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Fig. 7. Putative model of CVB3 3A protein. The structural model shows a homodimer of the N-terminal 60 aa of CVB3 3A. 
Molecular modeling (using WHAT_IF [Vriend, 1990] and YASARA NOVA [Krieger et al., 2002] software) was used to predict the 
CVB3 3A structure on the basis of the published nuclear magnetic resonance structure of the N-terminal 60 aa of PV 3A. Pro14,	
Pro17, Pro18, Pro19, and Pro20 in the bottom of the 3A dimer and Ser31 in the loop connecting the two α-helices are indicated. For 
full colour figure, see page 131.
Acknowledgements
 We thank Jeroen van Kilsdonk, Vladimir van Hoek, and Sander Jannink for technical 
assistance, Henri Dijkman for assistance with CLSM, and Patrick Keller and Kai Simons (Max 
Planck Institute of Molecular Biology and Genetics, Dresden, Germany) for the kind gift of the 
VSVG-GFP plasmid.
 This work was partly supported by grants from The Netherlands Organization for Scientific 
Research (NWO-VIDI-917.46.305), the M.W. Beijerink Virology Fund from the Royal Netherlands 
Academy of Sciences, and the European Communities (INTAS 2012).
Materials and Methods
 Cells and viruses.	 Buffalo green monkey (BGM) kidney cells were grown in minimal essential 
medium (MEM) (Gibco) supplemented with 10% fetal bovine serum. COS-1 cells were grown in Dulbecco’s 
modified Eagle’s medium (Gibco) supplemented with 10% fetal bovine serum. Cells were grown at 37°C in a 
5% CO2 incubator. All viruses used for this study were recombinant CVB3 viruses obtained by the transfection of 
T7 RNA polymerase-generated runoff RNA transcripts from the infectious cDNA clones (see below). Virus yields 
were determined by end-point titration as described previously (van Kuppeveld et al., 1995). Virus titers were 
calculated and expressed as 50% tissue culture infective dose (TCID50) values (Reed and Muench, 1938).
 
 Plasmids. (i) p53CB3/T7. The CVB3 infectious cDNA clone used in this study was p53CB3/T7, which 
contains a full-length cDNA of CVB3 (strain Nancy) behind a T7 RNA polymerase promoter. This cDNA clone 
was constructed by removing the nonviral nucleotides between the T7 promoter and the 5’ end of the CVB3 
genome in plasmid pCB3/T7 (Klump et al., 1990). Furthermore, an MluI site was introduced downstream of the 
3’ end of the CVB3 genome to ensure that in vitro transcribed RNAs do not contain nonviral nucleotides at their 
3’ end, resulting in an increased infectivity of the RNA transcripts (data not shown). 
 (ii) p53CB3-LUC. Plasmid p53CB3-LUC, which contains the firefly luciferase gene in place of the P1 
capsid coding region, was derived from pCB3-LUC (van Kuppeveld et al., 1995) and contains the same deletion 
of nonviral nucleotides at the 5’ and 3’ termini as p53CB3/T7. 
 (iii) pVSVG-GFP. The plasmid pVSVG-GFP (Toomre et al., 1999), which encodes the ts045 VSVG 
protein fused to enhanced green fluorescent protein (EGFP) at its C terminus, was kindly provided by P. Keller 
and K. Simons (Max Planck Institute of Molecular Biology and Genetics, Dresden, Germany).  
 (iv) p3A. For construction of the p3A plasmid, the 3A coding sequence was amplified by use of a 
forward primer that introduced a SalI restriction site and a start codon preceded by a Kozak sequence (p120-
4, 5’-GGG GGG TCG ACC ATG GGA CCA CCA GTA TAC AGA-3’ [the SalI site is underlined]) and a reverse 
primer that introduced a stop codon followed by a BamHI restriction site (p120-5, 5’-GGG GGG GGA TCC CTA 
TTG AAA ACC CGC AAA GAG-3’ [the BamHI site is underlined]). The PCR product was cloned into pEGFP-C3 
(Clontech) from which the EGFP coding region had been deleted. 
 (v) pC-A1PI-EYFP-S-EGFP-3A. The plasmid pCMS-EGFP (Clontech) was used to express A1PI 
and 3A from a single plasmid. The pCMS-EGFP plasmid contains two promoters, namely, a cytomegalovirus 
(CMV) promoter followed by a multiple cloning site and a simian virus 40 (SV40) promoter followed by the 
EGFP coding sequence. The secretory marker A1PI, with enhanced yellow fluorescent protein (EYFP) at its 
C-terminus, was cloned into the multiple cloning site behind the CMV promoter by the use of EcoRI and NotI. 
The EGFP coding sequence behind the SV40 promoter was replaced with 3A (wild-type or mutant) N-terminally 
fused to EGFP by the use of AgeI and BclI. The fusion of EGFP to the N terminus of 3A did not affect its protein 
secretion inhibiting function (data not shown). 
 (vi) pPV5’NC-A1PI-EYFP. To construction of the pPV5’NC-A1PI-EYFP plasmid, the 5’ noncoding 
region of PV fused to the coding sequence for the secretory marker A1PI was removed from pLink-2B (Doedens 
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and Kirkegaard, 1995) by the use of SmaI and EcoRI and then cloned in pEGFP-C1 (Clontech) by the use of 
Ecl136III and EcoRI. The A1PI coding sequence was replaced with the coding sequence for A1PI-EYFP by 
removing A1PI by the use of EcoRV and SmaI and then cloning in the A1PI-EYFP fragment cut with EcoRV and 
HpaI. 
 Mammalian-two hybrid plasmids. The pACT, pBIND and pG5luc plasmids were obtained from the 
Checkmate mammalian Two-Hybrid System (Promega). For the construction of pACT-3A and pBIND-3A, the 
3A coding sequence was cloned into the BamHI and EcoRV sites of the pACT and pBIND plasmids. To obtain 
pACT and pBIND-3A mutant plasmids, we replaced the wild-type 3A sequence with mutant 3A sequences by 
using the enzymes Bst1107I and BamHI.
 DNA Transfections. BGM cell monolayers were grown in six-well plates (for A1PI  secretion assays 
or Western blot analysis) or on coverslips in 24-well plates (for microscopic purposes) to subconfluence and 
then transfected with 2 µg of plasmid DNA per well of a 6-well plate or with 0.5 µg of plasmid DNA per well of 
a 24-well plate. COS cell monolayers were grown in 24-well plates to subconfluence and then transfected with 
0.75 µg of plasmid DNA. Transfections were performed by use of the FuGENE 6 reagent (Roche) according to 
the manufacturer’s instructions. Cells were grown at 37°C until further analysis, unless otherwise stated. 
 VSVG trafficking. The subcellular localization of VSVG-GFP was determined as described previously 
(de Jong et al., 2003). Briefly, BGM cells expressing either VSVG-GFP alone or VSVG-GFP together with 
3A were incubated at 40°C. After a temperature shift to 32°C, the cells were fixed, stained, and analyzed 
by confocal laser scanning microscopy (CLSM) under a TCS NT microscope (Leica Lasertechnik GmbH, 
Heidelberg, Germany). Rabbit polyclonal anti-calreticulin was obtained from Sigma-Aldrich. Mouse monoclonal 
anti-GM130 was obtained from BD. Alexa fluor 594 goat anti-rabbit immunoglobulin G and Alexa fluor 594 goat 
anti-mouse immunoglobulin G were obtained from Molecular Probes. Primary antibodies were diluted 1:200, 
and conjugates were diluted 1:500. 
 A1PI secretion assay. BGM cells grown in six-well plates were transfected with plasmid DNA, and 
at 20 h after transfection, were washed with phosphate-buffered saline (PBS) and incubated in MEM lacking 
methionine (Sigma) for 30 min at 37°C. Proteins were pulse labeled with [35S]methionine (50 µCi/well) for 30 
min at 37°C and then washed twice with PBS, after which 800 µl fresh serum-free MEM was added. After a 2 h 
chase, the medium was collected and adjusted to 1x lysis buffer by adding 200 µl 5x lysis buffer (250 mM Tris 
[pH7.4], 750 mM NaCl, 5 mM EDTA, 5% Nonidet P-40, 0.25% sodium dodecyl sulfate [SDS]). The cells were 
washed twice with PBS and then lysed in 1 ml of lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 
1% Nonidet P-40, 0.05% SDS). An anti-EGFP rabbit polyclonal antiserum (1:1,000) was added to the cell 
lysate and culture medium, and the mixtures were incubated at 4°C for 16 h. Antibody-protein complexes were 
collected with protein A-Sepharose (Amersham Biosciences) for 1.5 h, washed twice with dilution buffer (0.01 
M Tris [pH 8.0], 0.14 M NaCl, 0.1% bovine serum albumine, 0.1% Triton X-100), once with TSA (0.01 M Tris [pH 
8.0], 0.14 M NaCl), once with 0.05 M Tris (pH 6.8) and then precipitated. The samples were resuspended in 25 
µl of Laemmli sample buffer, boiled for 5 min, and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). The amounts of radiolabeled A1PI-EYFP in the cell fraction and the medium fraction were quantified by 
use of a phosphorimaging device (Bio-Rad Multi-Analyst version 1.0.1). 
 Site-directed mutagenesis. In vitro mutagenesis was performed with single-stranded DNAs 
generated from a subgenomic pALTER phagemid construct containing the XhoI (nucleotide [nt] 2014) to SalI (nt 
7438) fragment of CVB3, by use of the Altered Sites in vitro mutagenesis system according to the manufacturer’s 
recommendations (Promega). The following synthetic oligonucleotides were used to introduce site-specific 
mutations (as well as restriction sites, which are underlined, to allow a rapid identification of mutants): primer 
p388-1, 5’-GAG CAG GTC CGC AAT GGC GGG CGC TGC AGC TGT CTC TGG TGC AAC GCT AAT-3’ (P17A/
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P18A/P19A mutations, PvuII site), primer p388-12, 5’-CGG TGG TGG TGT CTC AGC TGC AAC GCT AAT TTT-
3’ (P14A mutation, PvuII site), primer p388-7, 5’-CAG GTC CGC AAT GGC GGG CGG TGG CGC CGT CTC 
TGG TGC AAC GCT AAT TTT-3’ (P17A mutation, NarI site), primer p388-8, 5’-GAG CAG GTC CGC AAT GGC 
GGG CGG CGC CGG TGT CTC TGG TGC AAC GCT AAT -3’ (P18A mutation, NarI site), primer p388-9, 5’-TTT 
GAG CAG GTC CGC AAT GGC GGG CGC CGG TGG TGT CTC TGG TGC AAC GCT-3’ (P19A mutation, NarI 
site), primer p388-10, 5’-CGA TTT GAG CAG GTC CGC AAT GGC CGC GGG TGG TGG TGT CTC TGG TGC 
AAC-3’ (P20A mutation, SacII site), primer p388-11, 5’-CAC AGC CTC ACA GTC TAC CGA TTT GAG CAG 
GTC CGC AAT GGC GGG CGC TGC AGC TGT CTC TGG TGC AAC GCT AAT-3’ (P17A/P18A/P19A/S31C 
mutations, PvuII site). The nucleotide sequences of the mutant pALTER clones were verified by sequence 
analysis. The 3A mutations were introduced into the p53CB3/T7 plasmid by the use of unique BssHII (nt 4242) 
and BstEII (nt 6263) sites. The mutant cDNAs were used as template to amplify mutant 3A sequences by use 
of a forward primer introducing a BamHI site (p120-3, 5’-GAG GCA CGG ATC CAG GGA CCA CCA GTA TAC-3’ 
[the BamHI site is underlined]) and a reverse primer (p388-6, 5’-GAG GGT GGA GTT GGT CTC CGG AAC CAA 
CCA TCC-3’) that anneals downstream the internal ScaI site in the 3A-coding sequence. The PCR products 
were cut with the restriction enzymes BamHI and ScaI and cloned into pEGFP-3A cut with BglII and ScaI to yield 
the pEGFP-3A mutant plasmids.
 Transfection of cells with RNA transcripts. Plasmids were linearized with MluI, purified, and 
transcribed in vitro by T7 RNA polymerase as described previously (van Kuppeveld et al., 1995). The RNA 
transcripts were checked by agarose gel electrophoresis. BGM monolayer cells grown in 25-cm2 flasks to 
subconfluency were transfected with 2.5 µg of RNA transcripts using the DEAE-dextran method as described 
previously (van Kuppeveld et al., 1995). After transfection, cells were grown at 37°C. When virus growth was 
observed, the cultures were incubated until cytopathic effect (CPE) was complete. In cases in which no CPE 
was observed after 5 days, the cultures were subjected to three successive cycles of freezing and thawing, and 
200 µl was passaged onto fresh BGM monolayer cells, which were grown at 37°C for another 5 days. 
 Sequence analysis of viral RNA. RNAs were isolated from virus suspensions and reverse 
transcribed as described previously (van Kuppeveld et al., 1995). The 3A coding region was amplified by PCRs 
using SuperTaq DNA polymerase (HT Biotechnology), and the sequences were analyzed. 
 Single-cycle growth analysis. Confluent BGM monolayer cells were infected with virus at a 
multiplicity of infection (MOI) of 1 TCID50 for 30 min at room temperature. The cells were washed three times 
with PBS, supplied with MEM, and grown at 37°C. At the indicated times, the cells were disrupted by three 
cycles of freezing and thawing, and the virus titers were determined by end-point titration.  
 Analysis of viral RNA synthesis. BGM cell monolayers were transfected with 1 µg of T7 RNA 
polymerase-generated RNA transcripts from MluI-linearized p53CB3/T7-LUC plasmids as described above. At 
the indicated times posttransfection, the cells were lysed and luciferase activities was assayed as described 
previously (van Kuppeveld et al., 1995).  
 Calculations. Data are presented as mean values ± standard error of the means (SEM). Differences 
were tested for significance by analysis of variance (least significant difference [LSD]).
 Western blot analysis. BGM cells grown in six-well plates were transfected with pC-A1PI-EYFP-
S-EGFP-3A plasmids (wild-type or mutant). At 24 h posttransfection, the cells were lysed in 1x lysis buffer (50 
mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.05% SDS). Samples were run in an SDS-
12.5% polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad). EGFP fusion proteins were 
stained with an anti-EGFP polyclonal antiserum (diluted 1:10,000) and peroxidase-conjugated goat anti-rabbit 
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immunoglobulins (diluted 1:5,000) and visualized with the Lumi-Lightplus Western blotting substrate (Roche 
Molecular Biochemicals) according to the manufacturer’s instructions.   
 Mammalian two-hybrid analysis. COS cells grown in 24-wells plates were transfected with a total 
of 0.75 µg plasmid DNA (1:1:1 mix of the pACT, pBIND, and pG5luc plasmids). At 48 h posttransfection, the 
cells were lysed, and both the firefly luciferase and Renilla luciferase enzyme activities were measured from 
the same cell lysate by use of a dual-luciferase reporter assay system (Promega), as described previously (de 
Jong et al., 2002). An analysis of the Renilla luciferase activities, encoded by the pBIND plasmid and allowing 
monitoring of the transfection efficiency, revealed no gross differences in efficiencies of transfection among the 
different samples.  
Proline-rich region in CVB3 protein 3A
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The coxsackievirus B3 3A protein forms homodimers and plays important roles in both viral RNA (vRNA) replication and the viral inhibition of intracellular protein transport. The molecular determinants that are required for each of these functions 
are yet poorly understood. Based on the NMR structure of the closely related poliovirus 3A 
protein, a molecular model of the CVB3 3A protein was constructed. Using this structural 
model, specific mutants were designed to study the structure-function relationship of 3A. 
The mutants were tested for their capacity to dimerize, support vRNA replication, and block 
protein transport. A hydrophobic interaction between the monomers and an intermolecular 
salt bridge were identified as major determinants required for dimerization. We show 
that dimerization is important for both efficient vRNA replication and inhibition of protein 
transport. In addition, determinants were identified that were not required for dimerization 
but that were essential for either one of the biological functions of 3A. The combination of 
the in silico and in vivo results obtained in this study provides important insights in both the 
structural and functional aspects of 3A.
Introduction
	 Enteroviruses are small RNA viruses that belong to the family of the Picornaviridae. The 
enteroviruses are divided into several species, e.g. poliovirus (PV), human enterovirus A (HEV-A), 
human enterovirus B (HEV-B, which include the coxsackieviruses B [CVB]), human enterovirus C 
(HEV-C), and human enterovirus D (HEV-D). The enterovirus genome encodes a large polyprotein 
that is divided into a P1, P2, and P3 region and is processed by virally encoded proteases to yield the 
capsid proteins and the nonstructural proteins, as well as some relatively stable precursor proteins 
(Porter, 1993; Wimmer et al., 1993). The nonstructural proteins are involved in viral RNA (vRNA) 
replication and account for the virus-induced alterations in host cell metabolism and structure. 
These alterations serve to create an environment that is suitable for efficient vRNA replication and/
or to suppress anti-viral host cell responses. 
 Enteroviruses are nonenveloped, cytolytic viruses that replicate on secretory pathway-
derived membrane vesicles. These viruses do not need an intact secretory pathway to release their 
virus progeny. Instead, the viral nonstructural proteins 2B and 3A have been shown to inhibit protein 
transport through the secretory pathway (Doedens and Kirkegaard, 1995). 3A inhibits protein 
transport between the endoplasmic reticulum and Golgi (Doedens et al., 1997; Wessels et al., 
2005), whereas the step inhibited by the 2B protein is presently unknown. The inhibition of protein 
transport by 3A is not essential for viral replication in cell culture (Doedens et al., 1997; Wessels 
et al., 2005), but has been proposed to have a function in evasion of innate and acquired immune 
responses and the extrinsic apoptotic pathway (Deitz et al., 2000; Dodd et al., 2001; Neznanov et 
al., 2001). 
 Besides inhibiting protein transport, the 3A protein is involved in multiple steps in the 
process of vRNA replication. Several mutations in 3A were shown to cause defects in vRNA synthesis 
(Bernstein et al., 1986; Giachetti et al., 1992; Hope et al., 1997; Xiang et al., 1995). However, the 
exact role of 3A, or its precursor 3AB, is not completely understood. 3AB is thought to deliver VPg 
(3B), the protein primer for RNA synthesis, to the replication complex where vRNA synthesis takes 
place (Paul et al., 1998). In addition, several other activities have been suggested for 3AB: (i) 
stimulation of autoprocessing of the 3CDpro precursor protein to produce the 3Cpro protease and the 
3Dpol polymerase (Molla et al., 1994), (ii) stimulation of the polymerase activity of 3Dpol (Lama et al., 
1994; Paul et al., 1994), (iii) stimulation of the binding of 3CDpro to the vRNA (Harris et al., 1994), 
and (iv) mediating binding of 3Dpol to membranes (Lyle et al., 2002).
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 3A is a small protein (87-89 aa) that is associated to membranes via its C-terminal 
hydrophobic domain (Towner et al., 1996). The structure of the soluble N terminus (aa 1-59) of PV 
3A has been resolved by NMR (Strauss et al., 2003). PV 3A was shown to form a homodimer. Each 
monomer consists of two amphipathic α-helices (aa 23-29 and aa 32-41), which are bended 180° 
to form a helical hairpin, flanked by unstructured N  and C termini. To gain insight into the structure-
function relationship of the CVB3 3A protein, we generated a molecular model of this protein using 
the PV 3A structure as template. We used this model to design mutants and tested them for their 
ability to dimerize, inhibit protein transport and support vRNA replication. Our data show that 
dimerization is important for efficient functioning of 3A. In addition, we identified determinants in 3A 
that do not affect dimerization, but that do affect the ability to inhibit protein transport or to support 
vRNA replication.
Results
Molecular model of the 3A protein.
 We constructed a molecular model of the N-terminal 60 aa of CVB3 3A using the WHAT_
IF software (Fig. 1A) (Wessels et al., 2005; Vriend, 1990). In this program, the backbone of the 
protein model is derived from a structurally similar protein (that serves as a template) and side 
chains are replaced according to differences in sequence alignment (Vriend, 1990). As a template, 
we used sequence and structure information from the soluble N terminus of the PV 3A protein (aa 
1-59), which has been resolved by NMR spectrometry (Strauss et al., 2003). The conformation 
of replaced side chains was determined using the position-specific rotamer method, which is a 
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Fig. 1. Putative model of the CVB3 3A protein and an alignment of several residues of the enterovirus 3A proteins. (A) Model 
of the homodimer formed by the N-terminal 60 aa of CVB3 3A. N, N terminus; C, C terminus; α1, first α-helix (aa 20-27); α2, 
second α-helix (aa 31-42). (B) Genome organization of CVB3. CVB3 contains a single open reading frame, flanked by a 5’ and 
3’ non-translated region (NTR) and a poly A tail. The four capsid proteins (1A, 1B, 1C, 1D) and seven nonstructural proteins 
(2A, 2B, 2C, 3A, 3B, 3C, 3D) are shown. The 3A protein of CVB3 is an 89-aa protein which contains a C-terminal hydrophobic 
domain (aa 61 to 82). An alignment of the aa 6 to 10, 24 to 28, 37, and 41 of all enteroviruses sequenced to date is shown. The 
species names are shown in bold. HEV-A, human enterovirus A; HEV-B, human enterovirus B; HEV-C, human enterovirus C; 
HEV-D, human enterovirus D; PV, poliovirus; cons., consensus. Letter size indicates the prevalence of a specific residue in the 
species. +, positively charged aa; -, negatively charged aa; Φ, hydrophobic aa.
component of the WHAT_IF software (Chinea et al., 1995). Having 47% identity and an almost 
gapless alignment between the PV and CVB3 3A sequences, the two proteins were predicted to 
share a common fold. Subsequently, the CVB3 3A model was optimized using the YASARA NOVA 
force field package (Krieger et al., 2002) and finally validated by WHAT_CHECK (Hooft et al., 1996) 
(Fig. 1A). CVB3 3A was predicted to form a homodimer. Each monomer consists of two α-helices 
(aa 20-27 and aa 31-42) connected by a relatively large loop. For PV 3A, it was described that a 
conserved hydrophobic surface, which is mainly made up from residues in the central amphipathic 
α-helices, could form a dimer interface with the hydrophobic surface of the other molecule (Strauss 
et al., 2003). For CVB3 3A, modeling identified various amino acids that could play a role in 3A 
homodimerization. These include (i) Ile22, Leu25, Leu26, Val29, and Val34, which were predicted to be 
involved in the hydrophobic packing of the homodimer; (ii) Asp24 and Lys41, which were predicted 
to form an intermolecular salt bridge; and (iii) Ser28 and Tyr37, which were predicted to form an 
intermolecular hydrogen bond. Based on this model, we substituted individual residues, most 
of which were predicted to be involved in dimerization, for Ala residues to study their role in (i) 
homodimerization, (ii) inhibition of protein transport and (iii) support of vRNA replication. 
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Fig. 2. Leu25 and Leu26 are important for dimerization, inhibition of protein transport and vRNA replication. (A) Structural 
model of the predicted hydrophobic packing in which Leu25 and Leu26 are depicted. (B) Homodimerization reactions of 	
wild-type (wt) 3A and the L25A/L26A mutant expressed as fusion proteins to the HSV VP16 activation domain (pACT) or the 
yeast GAL4 DNA binding domain (pBIND). At 48 h posttransfection the firefly luciferase production was assayed. Dimerization 
efficiency was expressed as the ratio between the firefly luciferase activity measured in cells coexpressing pACT and pBIND 
fusion proteins versus that measured in cells coexpressing pACT fusion proteins and unfused pBIND. This ratio was set at 
100% for 3A wt and the ratio of the mutant was compared to that of 3A wt of the same experiment (for details, see materials 
and methods). Insets show the protein expression levels of the pACT-3A and pBIND-3A fusion proteins as detected by Western 
analysis with a polyclonal antibody against 3A. (C) BGM cells were transfected with constructs expressing either EGFP, 	
EGFP-3A wt or EGFP-3A-L25A/L26A from an SV40 promoter and the A1PI-EYFP protein from a cytomegalovirus promoter. 
The amount of A1PI in the medium fraction was determined as the percentage of the total amount of A1PI and compared 
to that of control cells (for which the value was normalized to 100% A1PI secretion). (D) Effect of mutations L25A/L26A on	
vRNA replication. Mutations L25A/L26A were introduced in pRib-CB3/T7-LUC, and transcripts from these replicons were 
transfected into BGM cells. After 8 h incubation in the presence or absence of 2mM GuHCl, cells were lysed and the luciferase 
activity was measured. The luciferase activity measured in the presence of GuHCl represents the amount of protein translated 
from the input RNA, whereas the luciferase activity in the absence of GuHCl represents the amount of protein translated from 
input RNA plus replicated RNA. The level of vRNA replication is represented by the ratio of luciferase activities with or without 
GuHCl. The values depicted in the graphs of panels B, C, and D represent the means ± standard error of the mean (SEM) of at 
least three independent experiments. a, significantly different from 3A wt (p < 0.05); b, significantly different from A1PI secretion 
in control cells without 3A (p < 0.05).
Leu25 and Leu26 are important for dimerization, inhibition of protein transport, and vRNA 
replication.
 Firstly, we studied the role of Leu25 and Leu26, which are identical in all enteroviruses 
sequenced to data (Fig. 1B) and are predicted to be part of the hydrophobic packing (Fig. 2A). 
Mutations resulting in alanine substitutions of both residues were introduced into the 3A coding 
sequence. The resulting L25A/L26A mutant was tested in a mammalian two-hybrid assay for the 
effect of these substitutions on dimerization (Fig. 2B). The firefly luciferase activity, which represents 
the ability to form homodimers in this system (for a detailed description, see material and methods 
and legends to Fig. 2), was significantly reduced to ~25% of wt levels (p < 0.05). Thus, Leu25 and 
Leu26 are important for dimerization.
 Secondly, we studied whether the L25A/L26A mutant was able to inhibit protein secretion. 
To test for this ability, we expressed 3A from a plasmid that contains a second expression cassette 
encoding the alpha 1 protease inhibitor (A1PI) reporter protein. After expression, cell and medium 
fractions were analyzed for the amount of reporter protein present. The ratio of A1PI in medium 
versus cell fractions was used as a measure to represent the ability of 3A to inhibit protein secretion. 
The ratio in control cells (expressing EGFP and A1PI) was set at 100%. Whereas expression of wt 
3A reduced secretion levels to ~30% of control cells, the L25A/L26A mutant was no longer able to 
inhibit secretion (Fig. 2C).  
 Thirdly, we investigated whether Leu25 and Leu26 were important for the ability to support 
vRNA replication. To this end, the L25A/L26A mutations were introduced into an infectious cDNA 
clone of CVB3. RNA transcripts of this clone were transfected into BGM cells, but no viruses were 
obtained. In vitro translation reactions showed that the introduced substitutions did not induce 
obvious alterations in the processing pattern of viral proteins, suggesting that it is unlikely that the 
lack of virus growth is caused by disrupted polyprotein processing (data not shown).
 To investigate whether the lack of virus growth is due to a primary defect in vRNA replication, 
the mutations L25A/L26A were introduced into a pRib-CB3/T7-LUC subgenomic replicon. This 
replicon contains the luciferase gene in place of the P1 coding region. BGM cells were transfected 
with RNA transcripts of this clone and incubated in either the presence or absence of an inhibitor 
of enterovirus replication (guanidine hydrochloride [GuHCl]). At 8 h posttransfection, the cells were 
lysed and luciferase expression was measured. The level of vRNA replication is represented by 
the ratio of luciferase activities with or without GuHCl. No detectable replication was observed with 
the L25A/L26A mutant (Fig. 2D). Together, our data show that the residues Leu25 and Leu26 are 
important for dimerization, inhibition of protein transport and vRNA replication. 
Asp24 is important for dimerization, inhibition of protein transport, and vRNA replication.
 Asp24 is identical in all enteroviruses sequenced to date (Fig. 1B), and was predicted in the 
model to be important for dimerization of 3A by forming an intermolecular salt bridge with Lys41 (Fig. 
3A). In addition to this intermolecular salt bridge, Asp24 was also predicted to form an intramolecular 
salt bridge with Lys27. Alanine substitution of Asp24 abolished dimerization (Fig. 3B) and significantly 
reduced the ability of 3A to inhibit protein transport (p < 0.05) (Fig. 3C). To test whether this mutant 
could support virus growth, a total of ten RNA transfections was performed. Virus growth was 
observed in nine cases (Fig. 4). Sequence analysis of the 3A coding regions of the obtained 
virus populations showed that mutation D24A caused a quasi-infectious phenotype (a definition 
that indicates that a mutation disrupts vRNA replication to such an extent that (pseudo)reversion 
mutations or second site suppressor mutations can arise, but no virus progeny can be observed 
harboring only the original mutation). In four of the nine cases, the virus had reverted back to 
wt. In three cases, the introduced mutation was retained in the virus, but second site suppressor 
mutations had occurred at position 41 (resulting in the genotypes D24A/K41N, D24A/K41Q, and 
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D24A/K41E). In one case, a virus mixture was obtained in which a minor part of the population 
contained the introduced Asp-to-Ala substitution together with an additional Lys-to-Ile substitution 
at aa 27 (D24A/K27I), whereas the major part of the population contained the same Lys-to-Ile 
substitution, but the introduced Asp-to-Ala substitution at position 24 had reverted back to Asp 
(K27I) (Fig. 4). In the last case, the introduced Asp-to-Ala substitution had reverted back to Asp and 
was accompanied by a Lys-to-Ile substitution at position 27 (K27I). Together, these data show that 
Asp24 is important for dimerization, inhibition of protein transport and virus growth.
 The quasi-infectious phenotype of mutation D24A is probably due to a primary defect 
in replication, since in vitro translation reactions showed no obvious defects in the polyprotein 
processing pattern (data not shown). Indeed, the replicon containing this mutation showed 
no detectable replication (Fig. 3D). The second site suppressor mutations K41N, K41Q, K41E, 
and K27I all significantly increased the level of vRNA replication compared to D24A (p < 0.05) 
(Fig. 3D), indicating that these mutations rescued virus growth by improving the function of 3A in 
vRNA replication. The observation that all second site suppressor mutations occured at aa 27 or 41 
suggests that a functional relationship exists between Asp24, Lys27 and Lys41. 
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Fig. 3. Asp24 is important for dimerization, inhibition of protein transport and virus growth and several second-site suppressor 
mutations rescue the effect of mutation 3A-D24A on virus growth. (A) Structural model of the predicted intermolecular salt 
bridge between Asp24 and Lys41 and the intramolecular salt bridge between Asp24 and Lys27. (B) Effect of mutation D24A and its 
second-site suppressor mutations on 3A dimerization. (C) Effect of mutation D24A and its second-site suppressor mutations on 
the ability of 3A to inhibit protein transport. (D) Effect of D24A and its second-site suppressor mutations on vRNA replication. 
(E) Effect of the second-site suppressor mutations of the second-site suppressor mutants found for mutation D24A (depicted 
in shaded bars) on vRNA replication. All experiments and analysis were performed as described in the legends to Fig. 2. 	
The values depicted in the graphs represent the means ± SEM of at least three independent experiments (B, D and E) or at least 
four independent experiments (C). c, significantly different from 3A-D24A (p < 0.05); d, significantly different from 3A-D24A/K41N	
(p < 0.05); e, significantly different from 3A-D24A/K41Q (p < 0.05).
 We reasoned that the second site suppressor mutations for D24A might improve vRNA 
replication by improving dimerization of 3A. Therefore, dimerization levels of these mutants were 
tested (Fig. 3B). Mutations D24A/K41E and K27I, which restored replication to the highest levels, 
significantly improved dimerization compared to the D24A mutant (p < 0.05). However, no significant 
increases in dimerization were observed for mutations D24A/K41N, D24A/K41Q, and D24A/K27I, 
which restored replication to only low levels.
 We also investigated whether these second site suppressor mutations restored the 
inhibition of protein transport (Fig. 3C). Mutations D24A/K41E and K27I, which showed a strongly 
improved dimerization, were also more potent in inhibiting protein transport than the D24A mutant. 
The activities of these two second site suppressor mutants did not significantly differ from that of 3A 
wt. In contrast, the transport inhibiting activities of mutants D24A/K41N, D24A/K41Q, and D24A/
K27I were only slightly increased compared with that of the D24A mutant and significantly differed 
from that of 3A wt. Together, these data point to a correlation between the level of 3A dimerization 
on the one hand and its activity in vRNA replication and ability to inhibit protein transport on the 
other hand. 
 To demonstrate that the observed growth of mutant viruses is caused by aa changes at 
position 41 of 3A and not by possible other mutations in a part of the virus that was not sequenced, 
mutations D24A/K41N, D24A/K41Q, and D24A/K41E were introduced into the infectious cDNA 
clone. BGM cells were transfected with copy RNA transcripts of these mutants in duplicate and 
showed virus growth on both occasions for all mutants (Fig. 4). Sequence analysis of the obtained 
virus populations showed that upon transfection of RNA carrying mutations D24A/K41N the 
mutations were retained in one case, whereas in the other case the residue at position 24 was 
substituted for a Thr (D24T/K41N). Upon transfection of RNA carrying mutations D24A/K41Q, 
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Fig. 4. Identification of second-site suppressor mutations for mutation D24A. Ten transfections were performed with RNA 
transcribed from the cDNA clone containing mutation D24A. The 3A sequence of the obtained viruses is shown. The mutations 
D24A/K41N, D24A/K41Q, and D24A/K41E were introduced into the cDNA clone and the result of transfections with RNA 
transcribed from these clones is depicted. The nucleotide (nt) changes leading to the amino acid substitutions are indicated. 
The sequence plot of the virus mixture containing D24A/K27I and K27I is shown. The asterisk indicates the nt change resulting 
in the K27I substitution. The arrow indicates the nt that differs between the two populations of which the virus mixture is 
comprised (the major population contains an adenine residue resulting in Asp24, whereas the minor part contains a cytosine 
residue resulting in Ala24). For full colour figure, see page 131.
the K41Q mutation was retained but a Ala-to-Val substitution at aa 24 had occured in one case 
(D24V/K41Q), whereas in the other case both mutations had reverted back to wt. Upon transfection 
of RNA carrying mutations D24A/K41E, both mutations were retained in both cases. We reasoned 
that the newly found second site suppressor mutations might further improve replication as 
compared to their ancestors. Hence, we introduced the newly found mutations into the subgenomic 
replicon. Indeed, mutation D24T/K41N significantly improved replication as compared to its ancestor 
D24A/K41N (p < 0.05) (Fig. 3E). Similarly, mutation D24V/K41Q significantly improved replication 
as compared to D24A/K41Q (p < 0.05) (Fig. 3E). Thus, the second site suppressor mutations 
K41N, K41Q and K41E indeed rescued the defect in virus growth caused by mutation D24A.
 
Investigation of the biological significance of Ser28 and Tyr37.
 The molecular model of CVB3 3A predicts an intermolecular hydrogen bond between 
Ser28 and Tyr37 (Fig. 5A). All of the enteroviruses sequenced to date contain a Tyr at position 37 
(Fig. 1B). Ser28 is conserved among the HEV-B and HEV-D members, but not among PV and some 
HEV-C members, which contain an Ala at the corresponding position (Fig. 1C). Mutants S28A and 
Y37A were both capable of dimerization (Fig. 5B), and were not affected in their ability to inhibit 
protein secretion (Fig. 5C). Cells transfected with RNA transcripts of the infectious cDNA clone 
containing mutation S28A exhibited virus growth in all cases and sequence analysis showed that 
the mutation was retained. As expected, mutation S28A had no effect on the level of replication 
(Fig. 5D). Cells transfected with transcripts containing mutation Y37A exhibited virus growth in one 
out of four cases. Sequence analysis showed that the introduced mutation was retained in the 
obtained virus but that a Ser-to-Cys substitution at aa 31 (nucleotide 5119, A→T) had occurred. 
The Y37A mutant showed no detectable replication, but the second site suppressor mutation S31C 
partially restored the replication. These data suggest that residues Ser28 and Tyr37 are not required 
for efficient dimerization. Ser28 is not essential for any of the functions of 3A tested in this study, 
whereas Tyr37 is essential for vRNA replication, but not for inhibition of protein transport.
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Fig. 5.	Ser28 and Tyr37 are not important for dimerization of 3A. (A) Structural model of the predicted intermolecular hydrogen 
bond between Ser28 and Tyr37. (B) Effect of mutations S28A and Y37A on 3A dimerization. (C) Effect of mutations S28A and 
Y37A on the ability of 3A to inhibit protein transport. (D) Effect of mutations S28A and Y37A on vRNA replication. All experiments 
and analysis were performed as described in the legend to Fig. 2. The values depicted in the graphs of panels B, C, and D 
represent the means ± SEM of at least three independent experiments. f, significantly different from 3A-Y37A (p < 0.05).
A Conserved N-terminal domain is important for the ability of 3A to inhibit protein 
transport.
  Almost all enteroviruses (excluding HEV-A viruses and one HEV-C member) contain 
at positions 6-10 a positive charged, negative charged, hydrophobic, positive charged, and Ile 
residue, respectively (Fig. 1B and 6A). We called these residues the Conserved N-terminal Domain 
(CND). The N-terminal 19 aa of the 3A protein, in which this CND resides, were predicted to form 
an unstructured region and this region was not implicated in dimer formation of the 3A protein. 
Indeed, mutation of the CND did not disturb the ability of 3A to form homodimers (Fig. 6B). Thus, 
conservation of these residues points to their importance for another function of the 3A protein.
 We also studied whether the CND mutant could inhibit protein transport and support vRNA 
replication. A mutant in which the five residues of the CND were substituted for Ala residues was 
not able to inhibit protein secretion (Fig. 6C). To study the role of the CND in inhibition of protein 
transport in further detail, mutant proteins were generated in which single residues of the CND 
were substituted for Ala residues. Except mutation E7A, all single amino substitutions significantly 
decreased the ability of 3A to inhibit protein transport (p < 0.05) (Fig. 6C).
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Fig. 6. A Conserved N-terminal Domain (CND), which is not important for 3A dimerization, is required for inhibition of protein 
transport by 3A. (A) Structural model of the N-terminal 60 aa of CVB3 3A, in which aa 6-10 (Arg, Glu, Ile, Lys, and Ile) are 
indicated. (B) Effect of CND mutation on 3A dimerization. (C) Effect of CND mutation on the ability of 3A to inhibit protein 
transport. All experiments and analysis were performed as described in the legend to Fig. 2. The values depicted in the graphs 
of panels B and C represent the means ± SEM of at least three independent experiments. (D and E) Effect of CND mutations 
on virus growth, depicted by single-cycle growth analysis (D) and plaque assays (E). For the single-cycle growth analysis, BGM 
cells were infected at an MOI of 5, incubated at 37°C and harvested at 2, 4, 6, 8, or 24h post infection. Viruses were released 
by three cycles of freezing and thawing, and virus titers were determined by end-point titration on BGM cells and expressed 
in TCID50/ml values. For the plaque assays, BGM cells were infected with serial dilutions of CVB3 wt or mutants. At 30 min 
post infection, the virus was replaced for M199 medium containing 0.5% agarose. Cells were incubated at 37°C for 2 days and 
stained with crystal violet. 
 No virus growth was observed upon transfection of RNA transcripts in which all five 
residues of the CND were mutated. In vitro translation reactions showed no obvious defects in the 
polyprotein processing pattern, making this an unlikely cause for the lack of virus growth (data not 
shown). We also studied the effect of single alanine substitutions within the CND on virus viability. 
Transfection of RNA transcripts carrying these single mutations resulted in virus growth in all cases. 
Sequence analysis of the obtained viruses showed that the introduced mutations were retained in 
the vRNA in all cases with mutations R6A, E7A, I8A, and K9A and in one case with mutation I10A. 
In the other three cases of mutation I10A, an Ala-to-Val substitution at aa 10 (nucleotide 5060, 
C→T) had occurred. All viruses containing mutations R6A, E7A, I8A, K9A, I10A or I10V showed 
efficient replication, but were slightly impaired in growth compared to the wt virus, as indicated by a 
delay in replication in a single cycle growth analysis (Fig. 6D) and a smaller plaque phenotype (Fig. 
6E). Together, our data show that single residues in the CND are essential for inhibition of protein 
transport, but not for dimerization or virus growth. 
Discussion
 In this paper, we described a structure-function analysis of the CVB3 3A protein. Using the 
NMR structure of the related PV 3A as a template (Strauss et al., 2003), we derived a molecular 
model for the N-terminal 60 aa of CVB3 3A. The model shows that 3A contains two α-helices (aa 
20-27 and aa 31-42) that form a helical hairpin, whereas the remaining N- and C-terminal tails 
seem to be unstructured. Like PV 3A, CVB 3A is able to form homodimers. Based on the model and 
on sequence conservation amongst the enteroviruses, we identified several possible determinants 
for the formation of these homodimers: (i) a hydrophobic interaction between the helical hairpins of 
both monomers, (ii) an intermolecular salt bridge between Asp24 and Lys41, and (iii) an intermolecular 
hydrogen bond between Ser28 and Tyr37. We substituted individual residues that were conserved 
or were predicted to play a role in dimerization by Ala residues to investigate their importance for 
the function of the 3A protein. Using this approach, we showed that dimerization is important for 
efficient virus replication and inhibition of protein transport. When dimerization is disturbed, e.g. by 
substituting residues that participate in the predicted hydrophobic interaction (Leu25 and Leu26) or in 
the predicted salt bridge (Asp24), replication is reduced to background levels and the ability of 3A to 
inhibit protein transport is lost. 
 Upon mutation of Asp24 to Ala (D24A), a number of viruses were isolated carrying second 
site suppressor mutations that (partially) restored the function of 3A. All of the second site suppressor 
mutations occurred at residues Lys27 and Lys41, suggesting that residues at positions 24, 27 and 
41 are functionally linked. When the negatively charged Asp24 is substituted by an apolar Ala, both 
the intermolecular (Asp24-Lys41) and intramolecular (Asp24-Lys27) salt bridges are lost. Second site 
suppressor mutations in which the positively charged Lys41 is replaced for a polar residue (Asn, 
Gln) or a negatively charged residue (Glu) can compensate for this. The positive charges of Lys27 
and Lys41 are located close to each other in the 3A dimer and the repulsion between these positive 
charges is diminished by their interaction with the negatively charged Asp24. When the negative 
charge of Asp24 is lost, repulsion between Lys27 and Lys41 can no longer be compensated. It might 
be that the second site suppressors compensate the positive charges of Lys27 and Lys41, and 
thereby diminish their electrostatic repulsion. Alternatively or in addition, the negatively charged or 
polar residues may form an intermolecular salt bridge or hydrogen bond with Lys27, respectively. 
 Our experimental data show a higher level of dimerization for the D24A/K41E mutant 
as compared to the D24A/K41N and D24A/K41Q mutants. This might reflect the strength of the 
chemical bond between residues 27 and 41 (the Lys27-Glu41 salt bridge is a stronger chemical bond 
than the Lys27-Asn41 or Lys27-Gln41 hydrogen bond) or the extent in which the electrostatic repulsion 
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between Lys27 and Lys41 is compensated. In a second series of suppressor mutations that were 
found after RNA transfection of mutants D24A/K41N and D24A/K41Q, the introduced Ala24 was 
substituted by Thr or Val residues (D24T/K41N and D24V/K41Q, respectively). These Thr or Val 
residues at position 24 may further contribute to dimerization by strengthening the hydrophobic 
interaction between the helical hairpins. 
 Besides second site suppressor mutations at position 41, a suppressor mutation at 
position 27 was identified (K27I). In one occasion, transfection of RNA carrying mutation D24A 
gave rise to a K27I containing virus mixture in which the introduced D24A mutation was still present 
in a minor part of the population, whereas in the major part of the population the introduced D24A 
mutation had reverted to wt. It is tempting to speculate that the K27I virus had a growth advantage 
over the D24A/K27I virus and thereby became the dominant species within this mixture. This idea 
is supported by the higher vRNA replication level of K27I compared to D24A/K27I. How can a 
Lys-to-Ile substitution at position 27 rescue the adverse effect of the D24A mutation? The electrostatic 
repulsion that arises between Lys27 and Lys41 upon loss of the compensating negative charge of 
Asp24 may be counteracted by substitution of Lys27 for a residue lacking this positive charge. In 
addition, Ile has a large hydrophobic side chain that may further contribute to the hydrophobic 
interaction between the helical hairpins. Taken together, our results support a model in which an 
intermolecular salt bridge contributes to dimerization. 
 A correlation was observed between the efficiency of dimerization on the one hand 
and the activity of 3A in vRNA replication and transport inhibition on the other hand. Mutations 
D24A/K41N, D24A/K41Q, and D24A/K27I, for which little, if any, increase in dimerization could be 
observed (which may be due to the limited sensitivity of the assay used), rescued vRNA replication 
and transport inhibition to only low levels. Mutations D24A/K41E and K27I (without D24A), which 
significantly improved dimerization, rendered 3A much more active in transport inhibition. Mutation 
K27I also restored vRNA replication to wild-type level. The finding that mutation D24A/K41E, which 
improved dimerization and transport inhibition to similar levels as K27I, restored vRNA replication to 
only ~25% of wild-type level shows that, in addition to dimerization, sequence-specific determinants 
influence the efficiency of vRNA replication. 
 Mutations targeted to the conserved N-terminal domain (CND), which is of major 
importance for the inhibition of protein transport, did not decrease dimerization. Instead, an increased 
dimerization efficiency was observed. The reason for this is unknown. Dimerization efficiency may 
be affected by primary sequence features of the CND or, alternatively, by proteins that may bind to 
this conserved motif. Alanine substitutions of individual residues in this region resulted in viruses 
that showed slightly impaired growth characteristics. However, the ability to inhibit protein transport 
was completely lost upon substitution of Arg6, Ile8, Lys9 or Ile10 of the CND. An important role for Lys9 
in inhibition of protein transport was also described for the 3A proteins of PV and the closely related 
human rhinovirus 14 (Choe et al., 2005). In contrast to the residues at positions 6, 8, 9, and 10, 
the residue at position 7 is not conserved and is a Pro in HEV-A viruses, while it is an acid residue 
in the other enterovirus species. Indeed, we found that Glu7 was not essential for ability of 3A to 
inhibit protein transport. Thus, besides dimerization, sequence conservation and residue identity in 
the CND is also essential for inhibition of secretion. For this function, it is very likely that a cellular 
protein involved in secretory pathway transport interacts with the 3A dimer. We propose a model 
in which dimerization creates a binding pocket for this cellular counterpart, which is defined by the 
CNDs of both 3A monomers. 
 Upon substitution of individual residues of the CND, viruses were obtained that grew 
efficiently, though with slightly impaired growth characteristics. Alanine substitutions of most of 
these residues drastically disturbed the ability to inhibit protein transport. These results confirm that 
the inhibition of protein transport is not essential for vRNA replication, as has been demonstrated 
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earlier (Doedens et al., 1997; Wessels et al., 2005). However, the finding that growth of viruses 
carrying single mutations in the CND is slightly affected leaves open the possibility that the 
3A-mediated inhibition of protein transport may contribute to some extent to vRNA replication.  
 Using mutational analysis, we confirmed that residues involved in the predicted hydrophobic 
interaction and salt bridge are important for dimerization, replication and inhibition of transport. In 
contrast, substitution of Ser28 and Tyr37, which were predicted to form an intermolecular hydrogen 
bond, did not influence dimerization or inhibition of secretion. Therefore, it is very likely that the 
predicted hydrogen bond, if formed at all, does not contribute to dimerization. Ser28 is not conserved 
among enteroviruses: it is not present in PV 3A, nor can an equivalent hydrogen bond be formed in 
the PV dimer. In contrast to Ser28, Tyr37 is conserved among enteroviruses. In the PV structure, the 
corresponding Tyr was assigned as part of the hydrophobic surface of the helical hairpin (Strauss 
et al., 2003), and thus would contribute to dimerization. However, when we mutated this residue 
in CVB3 3A, dimerization still occurred with wt efficiency, and protein transport was inhibited to 
the same levels as seen for wt 3A. In sharp contrast, viral replication was reduced to background 
levels. These observations indicate that Tyr37 plays an important role in vRNA replication, possibly 
by forming a contact site for a viral or cellular protein. 
 The defect in vRNA replication induced by the Y37A mutation was found to be rescued 
by the second site suppressor mutation S31C. Remarkably, this same second site suppressor 
mutation was previously identified to rescue the defect in vRNA replication caused by mutations 
P17A/P18A/P19A in 3A (Wessels et al., 2005). Introduction of the S31C mutation in wt 3A reduced 
vRNA replication (data not shown), whereas it increased vRNA replication in the Y37A and 
P17A/P18A/P19A mutants. We generated a model of the 3A S31C mutant and in this model the 
Cys31 residues were predicted to be close to each other (data not shown). Thus, it is possible that 
an intermolecular disulfide bond is formed that contributes to dimerization. This possibility cannot 
be excluded, but the Y37A mutant already dimerized with wt efficiency, making it unlikely that an 
increase in dimerization is needed to rescue the growth defect caused by this mutation. How the 
S31C suppressor mutation can (partially) rescue the defect in vRNA replication remains to be 
established. 
 Are the determinants for CVB3 3A dimerization that we identified in this study conserved in 
PV? To gain more insight into the determinants for PV 3A dimerization, we optimized the published 
PV 3A structure using the YASARA NOVA force field package and validated it by WHAT_CHECK 
(data not shown). The hydrophobic interaction between the helical hairpins of both monomers was 
predicted for PV (Strauss et al., 2003) and was also visible in our optimized PV 3A model. In addition, 
an intermolecular salt bridge between Asp23 and Lys40 (which correspond to Asp24 and Lys41 in 
CVB3 3A) was predicted (data not shown). Thus, the determinants that we experimentally showed 
to contribute to CVB3 3A dimerization, seem to be conserved in PV 3A. A remarkable difference 
between PV and CVB3 3A is an intermolecular disulfide bond at Cys20, which is predicted in our 
optimized PV model but can not be formed in the CVB3 model, since it lacks the corresponding 
Cys residue (data not shown). There is no experimental data that supports the presence of this 
disulfide bond in the PV 3A dimer. Hence, it is unclear whether this difference between the PV and 
CVB3 dimer indeed exists.
 In conclusion, we showed that 3A dimerization is important for both efficient inhibition of 
protein transport and efficient support of vRNA replication. We identified two types of interactions 
that contributed to dimerization, namely a hydrophobic interaction between the helical hairpins of 
the individual monomers, and an intermolecular salt bridge. Furthermore, a domain was identified 
in the unstructured N terminus that plays an important role in inhibition of protein secretion. The 
combination of in vivo and in silico results obtained in this study provide important insights in both 
structural and functional aspects of 3A. Future studies on dimerization and interactions of 3A with 
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other viral proteins and cellular binding partners may benefit from the dimer model that we present 
here.
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Materials en Methods
 Cells. CVB3 (wild-type [wt] and mutants) were grown in Buffalo Green Monkey (BGM) kidney cells 
because this cell line allows efficient and high level CVB3 replication. BGM cells were grown in minimal essential 
medium (MEM) (Gibco) supplemented with 10% fetal bovine serum. COS-1 cells were grown in Dulbecco’s 
modified Eagle’s medium (Gibco) supplemented with 10% fetal bovine serum. Cells were grown at 37°C in a 
5% CO2 incubator.
 Site-directed mutagenesis. In vitro mutagenesis was performed with single-stranded DNA 
generated from a subgenomic pALTER phagemid construct that contained the XhoI (nt 2014) to SalI (nt 7438) 
fragment of CVB3, using the Altered Sites in vitro Mutagenesis System according to the recommendations of 
the manufacturer (Promega). The following synthetic oligonucleotides were used to introduce unique restriction 
sites without modifying the aa sequence at positions 5020 (at the end of the 2C coding region) and 5169 (in the 
middle of the 3A coding region): 5’- TGG TCC CTG GAA CAA GGC CTC AAG CGT GGT-3’ (primer p388.16, 
StuI site underlined) and 5’- GGA GTT GAT CTC CGG AAC CAA CCA-3’ (primer 388.17, BseAI site underlined), 
respectively. pALTER clones containing either the BseAI site (pALTER-3A[BseAI]) or both the StuI and BseAI 
sites (pALTER-2C[StuI]/3A[BseAI]) were generated. 
 Plasmids. pEGFP-3A mutants. For the construction of pEGFP-3A(BseAI), the 3A coding sequence 
including the BseAI restriction site was amplified from pALTER-3A(BseAI). The forward primer introduced XhoI 
and EcoICRI sites and amplified the 3A coding sequence without start codon in frame with EGFP (p416.2: 
5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGA CCA CCA-3’, XhoI and EcoICRI sites underlined) and 
the reverse primer introduced a stop codon followed by a BamHI restriction site (p120-5, 5’-GGG GGG GGA 
TCC CTA TTG AAA ACC CGC AAA GAG-3’, BamHI site underlined). The PCR product was cloned in pEGFP-
C2 (Clontech) using XhoI and BamHI. The mutant 3A proteins were generated by PCR amplification using 
primers that introduced specific mutations and in some cases silent mutations to introduce extra restriction 
sites for rapid identification of mutations (See supplemental Table S1). The PCR products were cloned in 
pEGFP-3A(BseAI) using either XhoI and ScaI restriction sites (3A- R6A/E7A/I8A/K9A/I10A, 3A-R6A, 3A-
E7A, 3A-I8A, 3A-K9A, 3A-I10A, 3A-D24A, 3A-L25A/L26A, and 3A-S28A) or XhoI and BseAI restriction sites 
(3A-Y37A). The nucleotide sequence of the mutant 3A proteins was verified by sequence analysis. The second 
site suppressor mutations that were found after RNA transfection were cloned from the p53CB3/T7 mutant 
clones into the EGFP-3A(BseAI) clone using Bst1107I and BseAI.
 p53CB3/T7 mutants. The CVB3 infectious cDNA clone used in this study was p53CB3/T7 (Wessels 
et al., 2005), which contains a full-length cDNA of CVB3 (strain Nancy) behind a T7 RNA polymerase promoter. 
For the construction of p53CB3/T7-StuI(5020)/BseAI(5169), the fragment containing the extra restriction sites 
was cut from pALTER-2C(StuI)/3A(BseAI) using the enzymes XbaI and BstEII and cloned in p53CB3/T7. 
p53CB3/T7 constructs containing mutant 3A sequences were generated by cloning mutant 3A sequences from 
pEGFP-3A (using BseAI and the blunt site EcoICRI) in p53CB3/T7-StuI(5020)/BseAI(5169), from which 3A 
was removed by cutting with StuI (blunt) and BseAI. In case a new and/or extra mutation was found in the 
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vRNA after RNA transfection, p53CB3/T7 constructs containing the mutant 3A sequences were generated by 
PCR. First RNA was isolated from the virus using the GenElute Mammalian Total RNA Miniprep Kit (Sigma) 
according to the instructions of the manufacturer. RT-PCR was performed with primer 5’-GAA CTC AAA GTC 
GAC TTA TTG CAC TTT TGC TTG CCT-3’ (p120.2, reverse primer 3B) via standard procedures. The RT-PCR 
product was used as template for a PCR reaction using primers 5’-CAG GTC AGA TAC TCT CTA GAC ATG-3’ 
(p305.10, forward primer containing a XbaI site (bold) in 2C) and 5’-GGA GTT GAT CTC CGG AAC CAA CCA-3’ 
(p388.17, reverse primer introducing a BseAI site (bold) at position 46 in 3A). The PCR product was cloned into 
p53CB3/T7(StuI/BseAI) using XbaI and BseAI. The nucleotide sequence of the mutant 3A sequences was 
verified by sequence analysis.
 pRib-CB3-LUC. Plasmid pRib-CB3-LUC, which contains the firefly luciferase gene in place of the 
P1 capsid-coding region, was described previously (van Ooij et al., 2006a). pRib-CB3-LUC-3A mutant clones 
were generated from p53CB3/T7-3A mutants using the restriction enzymes BssHII and PvuI.
 Mammalian two-hybrid plasmids. pACT, pBIND and pG5luc plasmids were obtained from the 
Checkmate Mammalian Two-Hybrid System (Promega). pACT-3A and pBIND-3A were described previously 
(Wessels et al., 2005). To obtain pACT and pBIND-3A mutant plasmids, the wt 3A sequence was replaced by 
mutant 3A sequences using the enzymes Bst1107I and BamHI. 
 pC-A1PI-EYFP-S-EGFP-3A mutants. pC-A1PI-EYFP-S-EGFP-3A was described previously (Wessels 
et al., 2005). pC-A1PI-EYFP-S-EGFP-3A mutants were obtained by replacing the EGFP-3A wt sequence for 
EGFP-3A mutant sequences using restriction enzymes AgeI and XbaI.
 Mammalian Two-Hybrid Analysis. COS-1 cells grown in 24-well plates were transfected with a 
total of 1 µg plasmid DNA (1:1:1 mix of the pACT:pBIND:pG5luc plasmids) using FuGENE 6 reagent according 
to the instructions of the manufacturer (Roche). At 48 h posttransfection, cells were lysed and both the 
firefly luciferase and renilla luciferase enzyme activities were measured from the same cell lysate using the 
Dual-Luciferase Reporter Assay System (Promega), as described previously (de Jong et al., 2002). Analysis 
of the Renilla luciferase activity, which is encoded by the pBIND plasmid and which allows monitoring of the 
transfection efficiency, revealed no gross differences in transfection efficiency among the different samples. 
For all mutants the luciferase activities of three sample combinations were measured: (i) the pACT-3A and 
pBIND-3A fusion proteins, (ii) the pACT-3A fusion protein with unfused pBIND, and (iii) the pBIND-3A fusion 
protein with unfused pACT. For all luciferase activities the background luciferase activity, which was produced 
upon expression of unfused pACT and pBIND proteins, was subtracted. The firefly luciferase activity produced 
in cells expressing the pACT-3A fusion proteins and unfused pBIND was always much higher than that of the 
pBIND-3A fusion proteins and unfused pACT. Dimerization efficiency was expressed as the ratio between the 
firefly luciferase activity measured in cells coexpressing pACT and pBIND fusion proteins versus that measured 
in cells coexpressing pACT fusion proteins and unfused pBIND. This ratio was set at 100% for wild-type 3A. 
Western Blot analysis using a polyclonal antibody raised against recombinant 3A(1-60) was performed to 
monitor expression of the  pACT-3A and pBIND-3A fusion proteins. 
 A1PI secretion assay. The A1PI secretion assay was performed as described previously (Wessels 
et al., 2005). In short, BGM cells were transfected with 2 µg of plasmid DNA per well and at 20 h after 
transfection incubated in MEM lacking methionine (Sigma) for 30 min at 37°C. Proteins were pulse-labeled 
with [35S]methionine for 30 min at 37°C, washed twice with PBS, after which 800 µl fresh serum-free MEM 
was added. After 2h of chase, the medium was collected and the cells were lysed in 1 ml of lysis buffer. 
Anti-EGFP rabbit polyclonal antiserum (1:1,000) was added to the cell lysate and culture medium, and the 
antibody-protein complexes were collected with protein A-Sepharose (Amersham Biosciences), washed and 
precipitated. Samples were resuspended in 25 µl of Laemmli sample buffer, boiled for 5 min, and analyzed by 
SDS-PAGE. The amount of radiolabeled A1PI-EYFP in the cell fraction and medium fraction was quantified 
using a phosphorimaging device (Bio-Rad Multi-Analyst version 1.0.1). The amount of A1PI in the medium 
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fraction was determined as the percentage of the total amount of A1PI and compared to that of control cells 
(for which the value was normalized to 100% A1PI secretion). Western blot analysis showed that all mutant 3A 
proteins were efficiently expressed (data not shown).
 Analysis of virus growth. Plasmids were linearized with MluI, purified, and transcribed in vitro by 
T7 RNA polymerase as described previously (van Kuppeveld et al., 1995). The RNA transcripts were checked 
by agarose gel electrophoresis. BGM cells grown in 25-cm2 flasks to subconfluency were transfected with 2.5 µg 
of RNA transcripts using DEAE-dextran as described previously (van Kuppeveld et al., 1995). After transfection, 
cells were grown at 37°C. When virus growth was observed, the cultures were incubated until cytopathic effect 
(CPE) was complete. In case no CPE was observed after five days, the cultures were subjected to three 
successive cycles of freezing and thawing, and 200 µl was passaged to fresh BGM monolayer cells, which were 
grown at 37°C for another five days. 
 Analysis of vRNA replication. BGM cells grown in 6-well plates to subconfluency were transfected 
with 1 µg of T7 RNA polymerase generated RNA transcripts of MluI-linearized pRib-CB3/T7-LUC plasmids as 
described above. At 8 h posttransfection, the cells were lysed and luciferase activity was assayed as described 
previously (van Kuppeveld et al., 1995). Transfected cells were grown in the absence or presence of guanidine 
hydrochloride (GuHCl), an inhibitor of enterovirus replication that is used to determine the luciferase levels in 
the absence of replication (under this condition, luciferase production reflects translation of the transfected 
replicon RNA). The level of replication is expressed as the ratio of luciferase produced in the presence or 
absence of GuHCl.
 
 Sequence analysis of vRNA. RNA was isolated from virus suspensions and reverse transcribed as 
described previously (van Kuppeveld et al., 1995). The 3A-coding region was amplified by PCR using SuperTaq 
DNA polymerase (HT Biotechnology) and subjected to sequence analysis. 
 Single-cycle growth analysis. BGM cell grown in flat bottom tubes to subconfluency were infected 
with virus at a multiplicity of infection (MOI) of 5 tissue culture infective dose (TCID50) for 30 min at 37°C. The 
cells were washed three times with PBS, supplied with MEM, grown at 37°C, and harvested at the indicated 
times. Viruses were released by three cycles of freezing and thawing, and virus titers were determined by 
end-point titration as described previously (Wessels et al., 2005). 
 Plaque assays. Plaque assays were performed as described in (van Ooij et al., 2006b). In short, BGM 
cells were grown in 6-well plates to subconfluency and infected with serial dilutions of CVB3 wt or mutants. At 
30 min postinfection, the virus was replaced for M199 medium containing 0.5% agarose. Cells were incubated 
at 37°C for 2 days, fixed and stained with crystal violet.
 Statistical analysis. The data are presented as the mean values ± standard error of the mean 
(SEM). The differences were tested for significance by Student’s t-test (Figs. 2, B and D, and 6B) or analysis 
of variance using Bonferroni’s multiple comparison test (Figs. 2C; 3, B-E; 5, B-D; and 6C) using GraphPad 
Prism.
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Table S1. Primers for introduction of specific mutations in pEGFP-3A.
Primer no. Mutation F/R Sequence
416.2 1 F 5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGA CCA CCA-3’
416.4 2 R 5’-GGG GGA GTA CTC CCT CAC AGC CTC ACT GTC-3’
420.2 R6A/E7A/I8A/K9A/I10A F
5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGA CCA CCA GTA 
TAC GCA GCG GCC GCA GCT AGC GTT GCA CCA GAG ACA-3’
420.9 D24A R 5’-GGG GGG AGT ACT CCC TCA CAG CCT CAC TGT CGA CCG ATT TGA GCA GGG CCG CAA TGG CGG GCG GTG G-3’
420.10 L25A/L26A R 5’-GGG GGG AGT ACT CCC TCA CAG CCT CAC TGT CGA CCG ATT TGG CCG CGT CCG CAA TGG CGG GCG GTG G-3’
420.16 R6A F 5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGG CCC CCA GTA TAC GCA GAG ATC AAA ATT AGC GTT GCA CCA GAG ACA-3’
420.17 E7A F 5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGG CCC CCA GTA TAC AGA GCG ATC AAA ATT AGC GTT GCA CCA GAG ACA-3’
420.18 I8A F 5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGA CCA CCA GTA TAT CGC GAG GCC AAA ATT AGC GTT GCA CCA GAG ACA-3’
420.19 K9A F 5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGA CCA CCA GTA TAT CGC GAG ATC GCA ATT AGC GTT GCA CCA GAG ACA-3’
420.20 I10A F 5’-GGG GGC TCG AGT GGA GCT CTG TTC CAG GGA CCA CCA GTA TAT CGC GAG ATC AAA GCT AGC GTT GCA CCA GAG ACA-3’
420.22 Y37A R 5’-GGG GGG GTC CGG AAC CAA CCA TCC TTT TTC TTT GCA GGC CTC CCT CAC AGC CTC ACT-3’
420.23 S28A R 5’-GGG GGG GGA GTA CTC CCT CAC AGC CTC ACT GTC TAC CGC TTT GAG CAG GTC CGC AAT -3’
1 Forward primer for mutants D24A, L25A/L26A, S28A and Y37A
2 Reverse primer for mutants R6A/E7A/I8A/K9A/I10A, R6A, E7A, I8A, K9A, and I10A
F, forward; R, reverse.
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Many viruses modify cellular processes for their own benefit. The enterovirus 3A protein inhibits endoplasmic reticulum (ER)-to-Golgi transport, a function previously suggested to be important for viral suppression of immune responses. 
Here, we show that a virus carrying a 3A protein defective in inhibiting ER-to-Golgi transport 
is indeed less virulent in mice, and we unravel the mechanism by which 3A inhibits this 
trafficking step. Evidence is provided that 3A inhibits the activation of the GTPase ADP-
ribosylation factor 1 (Arf1), which regulates the recruitment of the COP-I coat complex to 
membranes. 3A specifically inhibits the function of GBF1, a guanine nucleotide exchange 
factor for Arf1, by interacting with its N terminus. By specifically interfering with GBF1-
mediated Arf1 activation, 3A may prove a valuable tool in dissecting the early steps of the 
secretory pathway.
Introduction
 Enteroviruses (e.g. polioviruses, coxsackieviruses, and ECHOviruses), members of the 
family of Picornaviridae, are important human pathogens that are implicated in a wide spectrum 
of both acute and chronic conditions, including poliomyelitis, meningoencephalitis, pancreatitis, 
and myocarditis. Enteroviruses are nonenveloped, cytolytic viruses that contain a 7.5 kb single-
stranded RNA genome, which encodes four capsid proteins and a number of nonstructural 
proteins. The nonstructural proteins are involved in viral RNA replication and account for the virus-
induced alterations in host cell metabolism and structure, which serve to create an environment 
that is suitable for efficient viral RNA replication and/or to suppress anti-viral host cell responses. 
One of the most prominent morphological alterations in enterovirus-infected cells is the massive 
accumulation of membrane structures in the cytoplasm. These rearranged membranes, which are 
the sites at which viral RNA replication takes place, are most likely derived from the secretory 
pathway (Bienz et al., 1994). In addition, an autophagic mechanism for the formation of these 
membranes has been described (Suhy et al., 2000; Jackson et al., 2005). The viral 2BC protein 
plays an important role in this membrane rearrangement, possibly in conjunction with the 3A protein 
(Cho et al., 1994; Suhy et al., 2000; Jackson et al., 2005). 
 Another important modification is the inhibition of intracellular protein transport, 
which becomes apparent at 3-4 hours postinfection (Doedens and Kirkegaard, 1995). 
Ectopic expression of the individual nonstructural proteins showed that viral proteins 2B 
(and its precursor 2BC) and 3A were each able to inhibit protein transport in the 
absence of infection (Doedens and Kirkegaard, 1995; Wessels et al., 2005). The ability of the 
2B(C) protein to inhibit protein transport is most likely linked to its membrane rearranging activity 
and, thereby, to its function in replication. The ability of 3A to inhibit protein transport is not required 
for efficient replication but may serve to reduce infection-limiting host responses. Viruses carrying 
a mutation in 3A that rendered it defective in inhibiting transport replicated efficiently but showed 
a reduced ability to suppress cytokine secretion and MHC-I dependent antigen presentation in 
tissue culture cells (Deitz et al., 2000; Dodd et al., 2001 Wessels et al., 2005). Moreover, 3A 
has been demonstrated to reduce sensitivity of cells to TNF-α-induced apoptosis by eliminating 
TNF-α receptors from the plasma membrane (Neznanov et al., 2001). Thus, transport 
inhibition by 3A may be of importance for the in vivo infectivity of enteroviruses by suppressing 
both innate and adaptive immune responses as well as the extrinsic apoptotic pathway. 
3A blocks transport at a step between the endoplasmic reticulum (ER) and the Golgi complex 
(Doedens and Kirkegaard, 1995; Doedens et al., 1997; Wessels et al., 2005), but the mechanism 
remains to be elucidated.
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 Bidirectional transport between the ER and Golgi is mediated by tubulovesicular transport 
containers that depend on two coat complexes, COP-II and COP-I (Scales et al., 1997; Aridor et 
al., 1995). The COP-II coat is recruited to the membrane by the GTPase Sar1, and is involved in 
membrane deformation and vesicle formation at ER exit sites (ERES), specialized domains at the 
ER where secretory cargo is concentrated (Barlowe et al., 1994). Following budding, the vesicles 
fuse to form vesicular tubular clusters (VTCs), also called the ER-Golgi-intermediate compartment 
(ERGIC). VTCs are transported along microtubules to the cis side of the Golgi complex, where they 
fuse with Golgi membranes (Lippincott-Schwartz et al., 1998). The COP-I coat acts in retrograde 
transport within the Golgi (Orci et al., 1997) and from the Golgi and VTCs to the ER (Letourneur et al., 
1994), a pathway that co-exists with a COP-I-independent retrograde pathway (Girod et al., 1999). 
COP-I function is also required for ongoing anterograde transport (Rabouille and Klumperman, 
2005). Recruitment of the COP-I coat requires the membrane association of ADP-ribosylation 
factor 1 (Arf1), a small GTPase that cycles between an inactive (GDP-bound), cytosolic state and 
an active (GTP-bound), membrane bound state (reviewed in [Moss and Vaughan, 1998] and [Shin 
and Nakayama, 2004]). Cycling of Arf1 between its GTP- and GDP-bound state is catalyzed by 
guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). 
 In this study, we show the in vivo relevance of the transport inhibiting function of 3A using 
a mouse model and we unravel the molecular mechanism by which 3A protein inhibits ER-to-Golgi 
transport. Evidence is presented that 3A inhibits COP-I assembly by interfering with the function of 
GBF1, a GEF for Arf1, thereby blocking the activation of Arf1. 
Results  
A virus carrying a 3A protein that is unable to inhibit protein transport is less virulent in 
mice.
 It has been suggested that transport inhibition by 3A is of importance for the in vivo infectivity 
of enteroviruses, but this has not yet been experimentally demonstrated. Here, we investigated the 
in vivo relevance of the 3A-mediated transport inhibition during coxsackievirus B3 (CVB3) infection 
using a mouse model of CVB3-induced acute myocarditis (Henke et al., 1995). For this, a mutant 
virus was generated carrying a serine insertion at position 16 in 3A (the corresponding mutation 
was previously shown to disrupt the ability of poliovirus 3A to inhibit transport [Doedens et al., 
1997]). This mutation (3A-ins16S) rendered 3A defective in inhibiting protein transport, as shown 
by the inability of 3A-ins16S to inhibit secretion of a reporter protein (Fig. 1A), but did not interfere 
with the function of 3A in virus replication in tissue culture cells (Fig. 1B). 
 Upon intraperitoneal infection of C57BL/6 mice (4 x 107 TCID50 per mouse), wild-type (wt) 
CVB3 efficiently replicated in the pancreas (Fig. 1C) from where it disseminated to the heart (Fig. 
1D), as described earlier for this virus-induced myocarditis model (Henke et al., 1995). The mutant 
virus (CVB3-3AinsS16) showed a reduced infectivity; the virus titer in the pancreas was about 
100-fold reduced at 3 days postinfection and reached its maximum later than wt virus (Fig. 1C), 
and hardly any virus was detected in the heart (Fig. 1D). In addition, there were clear differences in 
histopathological changes induced in the heart; symptoms of myocarditis (i.e., myocyte necrosis, 
fibrotic alterations, and mononuclear cell infiltration) were observed in mice infected with wt virus 
but not in those infected with the mutant virus (Fig. 1E). Similar results were obtained in BALB/c 
mice (data not shown). Overall, these data provide evidence that inhibition of protein transport by 
3A is indeed of physiological importance for the virulence of the virus.   
 
Effects of 3A on steady-state distribution of early secretory pathway components.
 To obtain more insight into the mechanism by which the 3A protein inhibits ER-to-Golgi 
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transport, we examined protein trafficking and steady-state distribution of early secretory pathway 
components in Buffalo Green Monkey (BGM) kidney cells transiently expressing the CVB3 3A 
protein. The 3A protein was expressed as a myc-tagged protein or GFP fusion protein (Wessels 
et al., 2005), both of which were as efficient in inhibiting protein transport as untagged 3A (data 
not shown). Protein trafficking was examined using the temperature-sensitive ts045 mutant of the 
vesicular stomatitis virus glycoprotein (VSV-G) and soluble GFP targeted to the lumen of the ER 
(lum-GFP), well-known membrane-bound and soluble markers for secretory pathway transport, 
respectively. In 3A-expressing cells, both VSV-G (Fig. 2A) and lum-GFP (data not shown) 
accumulated in the ER and a punctate post-ER compartment, colocalizing with 3A. The punctate 
3A-containing structures overlapped with the COP-II coated ERES, as identified with antibodies 
against Sec24 (Fig. 2B) and Sec13 (data not shown). Since both Sec24 and Sec13 are recruited 
to the membrane as heteromultimers (Sec24/Sec23 and Sec13/Sec31, respectively) (Matsuoka 
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Fig. 1. Coxsackievirus carrying a 3A mutant that is unable to inhibit protein transport is less virulent in mice. 	
(A) Analysis of A1PI secretion in cells expressing no 3A, GFP-3A wt or a GFP-3A mutant containing a serine insertion at position 16	
(3A-ins16S). Average secretion (means ± SEM) of three independent experiments is shown. A1PI secretion was calculated 
as the percentage of A1PI secretion in control cells, which was normalized to 100%. (B) Single-cycle growth curves of wt 
virus and virus containing mutation 3A-ins16S at 37ºC. Cells were infected at a multiplicity of infection of 10 and the virus 
titers were determined at various times postinfection (p.i.) by endpoint titration and expressed in 50% tissue culture infective 
doses (TCID50) per ml. (C and D) Replication of wt virus and 3A-ins16S mutant virus in C57BL/6 mice (6-8 weeks old, 
male). The amount of infectious virus (TCID50 per 50 µl) in pancreas (C) and heart (D) was determined by endpoint titration 	
at 3, 5, or 7 days p.i.. Animal groups consisted of three to five mice, and experiments were repeated three times. The mean ± SEM 
is shown. (E) Histological analysis. The histological grades of heart lesions were scored as described earlier (Merkle et al., 2002). 	
The myocarditis index is the mean of the values for cellular infiltration, necrosis, and fibrosis. Animal groups consisted of 10 
mice and the mean ± SEM is shown.
et al., 1998), this finding suggests that the COP-II coat is intact. Strikingly, ERES morphology in 
3A-expressing cells was significantly altered. Control cells (shown in Fig. 2B and Fig. S1) typically 
contain many ERES that are distributed stochastically along the ER, with the highest density in 
the juxtanuclear region. In 3A-expressing cells, most ERES were found in the cell periphery and 
appeared enlarged, while their total number was reduced, suggesting clustering of individual ERES 
(Fig. 2B). VTC and Golgi morphology were also drastically altered in 3A-expressing cells. In control 
cells, ERGIC53, a marker for VTC, can be typically found in peripheral punctate structures close 
to the ERES and in the juxtanuclear region close to the cis-Golgi (Ward et al., 2001) (Fig. 2C). In 
3A-expressing cells, however, ERGIC53 localized almost exclusively to 3A-containing peripheral 
punctate structures (Fig. 2C). GM130, a Golgi matrix protein, was also redistributed to these 
peripheral punctate structures (Fig. 2D), whereas galactosyltransferase (GalT), a Golgi resident 
enzyme, was found both in the ER and the punctate structures (Fig. 2E). Similar results were 
obtained in several other cell lines, indicating that the effects of 3A on the early secretory pathway 
are not cell-type specific. The effects of 3A closely resembled those of Arf1-T31N, a dominant 
negative mutant of Arf1 (Dascher and Balch, 1994), and of a 2 h treatment with Brefeldin A (BFA), a 
well-known inhibitor of Arf1 activation, both of which cause redistribution of VTC and Golgi proteins 
into the ER, ERES, and arrested VTCs (Ward et al., 2001) (see Fig. S1). 
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Fig. 2. Effects of 3A on the distribution of early secretory pathway components. (A) Cells transfected with VSVG-GFP and	
3A-myc were incubated at 40°C for 16 h to accumulate VSV-G in the ER and subsequently shifted to 32°C for 2 h. 3A was 
stained with an antibody against myc. (B-L) GFP-3A-expressing cells (16 h after transfection) stained with antibodies against 
Sec24 (B), ERGIC53 (C), GM130 (D), α/γ-COP (F), Arf1 (G), GBF1 (H), ArfGAP1 (I), TGN46 (J), BIG1 (K), and BIG2 (L). 
One or more control cells are shown in all figures. (E) Cells co-expressing GalT-GFP and 3A-myc (16 h after transfection).	
Bars represent 10 µm. For full colour figure, see page 132.
 Next, we examined the effects of 3A on mediators of the COP-I machinery. Recruitment 
of the COP-I coat requires the activation of Arf1. In control cells, COP-I and Arf1 localize at VTC 
and Golgi membranes. In 3A-expressing cells, however, neither COP-I nor Arf1 were associated 
with membranes (Fig. 2F and 2G), suggesting that Arf1 resides in its inactive, cytosolic state. 
GBF1 and ArfGAP1, which have been implicated as a GEF and GAP for Arf1 in ER-to-Golgi 
transport, respectively, normally localize at VTC and Golgi membranes (Cukierman et al., 1995; 
Zhao et al., 2002; Niu et al., 2005). Expression of 3A resulted in redistribution of GBF1 from the 
Golgi region to a dispersed localization throughout the cell (Fig. 2H). ArfGAP1 was redistributed 
to the peripheral punctate structures (Fig. 2I). We also studied the effects of 3A on the TGN and 
the TGN-associated large Arf GEFs BIG1 and BIG2 (Zhao et al., 2002). Expression of 3A had a 
profound effect on the structure of the TGN, causing TGN46 to redistribute from its normal compact 
localization to a dispersed localization (Fig. 2J). Expression of 3A also resulted in a redistribution 
of BIG1 and BIG2 to a dispersed localization throughout the cell (Fig. 2K and 2L). Again, similar 
effects were observed in cells treated with BFA or expressing Arf1-T31N (Fig. S1).
Ultrastructural analysis and dynamics of early secretory pathway components in 3A-
expressing cells.
 From the immunofluorescence data it can be concluded that 3A is localized on 
COP-I-depleted membrane structures that contain markers for ERES, VTCs and Golgi. To investigate 
the structural organization and molecular composition of these membranes at the ultrastructural 
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Fig. 3. Immuno-electron microscopy of control (A, C, D) and 3A-expressing (B, E) Hela cells (32 h after transfection). (A) In 
control cells, COP-II (Sec23, 15 nm gold) was found on ER budding profiles (arrow) and associated vesicles. The asterisk 
indicates COP-II negative VTC membranes. (B) 3A expression (10 nm gold) leads to an accumulation of ER-associated vesicles 
and tubules that are sometimes also positive for COP-II (15 nm gold, arrowhead). The asterisk marks the VTC area. (C-D) 
ERGIC53 (15 nm gold) normally localizes to the cis-Golgi cisterna (arrowhead in [C]) and Golgi-associated VTC membranes 
(D). (E) In 3A (10 nm gold) expressing cells, ERGIC53 (15 nm gold) is found on a portion of the 3A-induced membrane clusters. 
The asterisk marks the VTC area. ER, endoplasmic reticulum; G, Golgi; M, mitochondrion; E, endosome; NE, nuclear envelope; 
N, nucleus. Bars, 200 nm. For full colour figure, see page 133.
level, we performed immuno-electron microscopy (EM) studies with antibodies against Sec23 
and ERGIC53. In control Hela cells, Sec23 was found on budding profiles on the ER as well as 
on associated vesicular-tubular membranes (Fig. 3A), whereas ERGIC53 was found in the cis-
most Golgi cisterna (Fig. 3C) and VTC membranes at the cis-side of the Golgi complex (Fig. 3D). 
3A expression resulted in a massive accumulation of 3A-positive vesicular and tubular membranes 
facing the ERES, which were partially positive for Sec23 (Fig. 3B) as well as ERGIC53 (Fig. 3E). 
Sometimes, the 3A-positive budding profiles were seen connected with the ER in the plane of the 
section (Fig. S2). 
 We also studied the dynamics of the COP-II coat and ERGIC53. Fluorescence recovery 
after photobleaching (FRAP) experiments on cells co-expressing 3A and Sec24-YFP or p58-ERGIC-
YFP, a rat ERGIC53 homologue, showed that the COP-II coat still cycled on and off membranes 
and that p58-ERGIC shuttled between the ER and the above described membrane structures 
(Fig. 4). However, the dynamic behaviour of these proteins was somewhat affected; the halftime 
of fluorescence recovery of Sec24-YFP was increased (17.0 ± 1.6 s vs. 8.4 ± 0.6 s in control 
cells) (Fig. 4A), whereas there was little effect on the halftime of fluorescence recovery of 
p58-ERGIC-YFP but its mobile fraction was increased (Fig. 4B). Similar features were observed in 
cells treated with BFA or expressing Arf1-T31N (Fig. 4). The reason for the observed alterations in 
dynamics of Sec24 and p58-ERGIC are yet unknown. Recently, a linkage was suggested between 
COP-II dynamics and the availability of secretory cargo (Forster et al., 2006). Reduced amounts 
of cargo were shown to reduce the halftime recovery of Sec23. Thus, the increase in the halftime 
recovery of Sec24 that we observed in the presence of 3A, BFA, or Arf1-T31N may be due to the 
accumulation of transport competent cargo in the ER.
3A blocks activation of Arf1 by inhibiting an Arf GEF. 
 To study the activation state of Arf1 in 3A-expressing cells, we performed pulldown 
experiments with a GST-GGA3-GAT domain fusion protein (Shinotsuka et al., 2002). The GAT 
domain of GGA3, an effector of Arf1, binds specifically and with high affinity to Arf1-GTP and 
provides a tool to monitor the amount of Arf1-GTP in cell lysates (Boman, 2001). To ensure that we 
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Fig. 4. Dynamics of Sec24-YFP and p58-ERGIC-YFP in 3A-expressing cells. (A-B) FRAP traces showing the relative 
fluorescence of cells stably expressing Sec24-YFP (A) or p58-ERGIC-YFP (B), either alone (control cells), co-expressing 	
CFP-3A or Arf1-T31N-CFP, or treated with BFA. The traces in all graphs show the average recovery and SEMs (n ≥ 9 cells, from 
at least two independent experiments). The fluorescence intensity before bleaching was normalized to 1 and the fluorescence 
intensity directly after the bleach to 0. The fluorescence intensity was corrected for bleaching of the cell during imaging and 
background fluorescence. Values for the halftime of fluorescence recovery are calculated from the traces depicted in panels A 
and B. For full colour figure, see page 133.
only measured the Arf1 activation state in 3A-expressing cells, we made use of a single construct 
expressing both 3A (from a CMV promoter) and GFP-tagged Arf1 (from a SV40 promoter). Low 
level expression of Arf1-GFP from the SV40 promoter (of which the expression level in BGM cells 
is considerably less than from the CMV promoter [Wessels et al., 2005]) did not interfere with 
the function of 3A, as shown by dissociation of COP-I and Arf1-GFP from membranes (Fig. S3). 
In 3A-expressing cells, the amount of Arf1-GTP was greatly reduced compared to control cells 
(Fig. 5A), indicating that 3A blocks activation of Arf1. In cells expressing the defective 3A-ins16S 
mutant, normal Arf1-GTP levels were observed (Fig. 5A) and both Arf1 and COP-I were observed 
at intact VTC and Golgi membranes (data not shown). These data strongly suggest that 3A inhibits 
ER-to-Golgi transport by blocking Arf1 activation.  
 We also examined the effect of 3A on the diffusion behaviour of Arf1-GFP by Fluorescence 
Correlation Spectroscopy (FCS), a technique that measures the diffusion of fluorescent proteins 
in living cells. The results show that Arf1 behaves as a cytosolic, freely diffusing protein, lending 
further support to the idea that Arf1 is persistently inactive in 3A-expressing cells (Fig. S3). 
 BFA blocks Arf1 activation by inhibiting the activity of the high-molecular-weight Arf GEFs 
GBF1, BIG1, and BIG2 (Moss and Vaughan, 1998; Peyroche et al., 1999; Niu et al., 2005). We 
tested whether 3A also blocks Arf1 activation by inhibiting an Arf GEF activity by in vitro GEF 
assays (Fig. 5B and Fig. S4). Recombinant myristoylated Arf1 and rat liver Golgi membranes (as 
a source of GEFs and membranes) were incubated in the presence of 35S-GTPγS together with 
or without recombinant 3A, after which the amount of membrane-bound label was determined. In 
these experiments, the N-terminal 60 aa of wt 3A and the defective 3A-ins16S mutant were tested 
(i.e., the cytosolic domain located upstream of the C-terminal membrane anchor of 3A [Fig. S5]). 
Addition of wt 3A, but not of 3A-ins16S, resulted in a strong reduction of Arf GEF activity (Fig. 5B). 
Together, these data suggest that 3A inhibits Arf1 activation by inhibiting an Arf GEF activity. 
3A interacts with GBF1 and Arf1-GDP. 
 To identify the Arf GEF that is inhibited by 3A, we tested possible interactions between 
the N-terminal 60 aa and the three-abovementioned high-molecular-weight GEFs by yeast two-
hybrid. For each of the three GEFs, three portions covering the complete protein were tested (the 
N-terminal part upstream of the catalytic Sec7 domain, the Sec7 domain itself, and the C-terminal 
part downstream of the Sec7 domain [Fig. 5C]). A strong interaction was observed between 3A 
and the N-terminal portion of GBF1 (Fig. 5D). No interactions were observed with any other of the 
tested GEF domains or with Arf1 (neither with wt Arf1, the inactive Arf1-T31N mutant, nor the active 
Arf1-Q71L mutant). The interaction of 3A with GBF1 was confirmed by an in vitro GST-pulldown 
approach from both mouse brain lysate and isolated rat liver Golgi membranes (Fig. 5E and data 
not shown), and by co-immunoprecipitation experiments (Fig. 5F). In these experiments, Arf1 was 
found to be associated with 3A (Fig. 5E and 5F). Since GBF1 binds with high affinity to Arf1-GDP, 
we reasoned that the interaction between 3A and Arf1 was mediated by GBF1. Consistent with 
this idea, more 3A was co-precipitated from cells expressing the inactive (GDP-bound) Arf1-T31N 
mutant than from cells expressing the active (GTP-bound) Arf1-Q71L mutant (Fig. 5G). Further 
evidence was obtained using an in vitro approach using recombinant Arf1-T31N and Arf1-Q71L, 
coupled to columns and saturated with GDP or GTP, respectively, which showed that upon loading 
of a 3A-containing cell lysate, 3A was predominantly retained on the Arf1-T31N column (Fig. 5H).
Overexpression of GBF1 or Arf1 suppresses the effects of 3A.
 The data described above strongly suggest that 3A interferes with Arf1-dependent COP-I 
assembly by inhibiting the function of GBF1, which is also one of the targets of BFA. Overexpression 
of either Arf1-Q71L or GBF1 has been described to protect against the effects of BFA (Claude 
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et al., 1999; Niu et al., 2005; Alvarez et al., 2003; Teal et al., 1994). We investigated whether 
overexpression of Arf1 and GBF1 could counteract the effects of 3A. To this end, Arf1-YFP or 
YFP-GBF1 were expressed to high levels from CMV promoters together with 3A. Overexpression 
of both Arf1 and GBF1 strongly suppressed 3A function, as shown by the reduced ability of 3A 
to cause COP-I dissociation (Fig. 6B). Both Arf1 and GBF1 colocalized with 3A to dispersed 
membrane structures (Fig. 6A), indicating partial rescue, or, occasionally, to intact Golgi structures 
(data not shown). Further evidence that overexpression of GBF1 suppresses the effects of 3A was 
obtained by GGA pulldown (Fig. 6C), which showed that GBF1 overexpression reversed the ability 
of 3A to block Arf1 activation, resulting in normal Arf-GTP levels. No such effect was seen upon 
overexpression of BIG2.
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Fig. 5. 3A blocks Arf1 activation by interacting with GBF1 and Arf1-GDP. (A) Arf1-GTP pulldown assay. COS7 cells were 
transfected with pCMS-Arf1-GFP, pC-3A-myc-S-Arf1-GFP or pC-3A-ins16S-myc-S-Arf1-GFP. The upper panel shows the 
total amount of Arf1-GFP in cells, the lower panel shows the amount of GTP-bound Arf1-GFP. (B) In vitro Arf1 GEF assay. 
Recombinant myristoylated Arf1 and rat liver Golgi membranes were incubated in the presence of 35S-GTPγS. The amount of 
membrane-bound label in the absence of 3A (-3A) was normalized to 100% and represents the Arf GEF activity. Recombinant 
3A(1-60) proteins (+3A or +3A-ins16S) were added at a concentration of 1 µM. The average values of two independent 
experiments are shown. (C) Schematic representation of 3A and the high-molecular weight Arf GEFs. HD, hydrophobic domain 
(aa 61-82); N, N-terminal part of GEFs (BIG1, aa 1-708; BIG2, aa 1-653; GBF1, aa 1-709); Sec7, Sec7 domain of GEFs 	
(BIG1, aa 709-892; BIG2, aa 654-837; GBF1, aa 710-895); C, C-terminal part of GEFs (BIG1, aa 893-1850; BIG2, aa 838-1786; 
GBF1, aa 896-1856) (D) Yeast two-hybrid analysis shows that the N-terminal 60 aa of 3A specifically interact with the N-terminal 
part of GBF1. Left panel shows growth of yeast on leucine- and tryptophane-deficient medium; middle panel shows growth 
on histidine-deficient medium; right panel shows growth on adenine-deficient medium. Interactions between binding partners 
result in white colonies on the leu, trp-deficient medium and in growth on his- and ade-deficient media. (E) The N terminal 60 
aa of 3A pull down GBF1 and Arf1 from mouse brain lysates. (F) Co-IP experiments. 3A-myc is specifically coprecipitated from 
cells co-transfected with YFP-GBF1 or Arf1-GFP. (G) Co-IP experiments with the dominant negative (T31N) and dominant 
active (Q71L) mutants of Arf1 show that 3A preferentially interacts with Arf1 in its inactive, GDP-bound form (Arf1-T31N). 	
(H) 3A in CVB3-infected BGM cell lysates preferentially binds to columns containing GDP-saturated, recombinant Arf1-T31N. 
WB, western blot; IP, immunoprecipitation. For full color figure, see page 134.
3A stabilizes GBF1 on membranes.
 Recently, it was reported that GBF1 under physiological conditions continuously cycles on 
and off membranes, and that both Arf1-T31N and BFA stabilize an intermediate complex of GBF1 
and Arf1-GDP on membranes (Niu et al., 2005; Szul et al., 2005). We investigated the effects of 3A 
on YFP-GBF1 dynamics. Upon coexpressing YFP-GBF1 and CFP-3A, GBF1 was mostly found on 
dispersed membranes (see Fig. 6A). FRAP experiments showed that the YFP-GBF1 fluorescence 
recovered very slowly and only to a limited amount in 3A-expressing cells compared to control 
cells, indicating that GBF1 is bound much more stably on membranes in cells expressing 3A 
(Fig. 7A). Analysis of the Arf-YFP dynamics, which similarly localized on dispersed membrane 
structures (see Fig. 6A), showed that the halftime of fluorescence recovery of Arf1-YFP in 
3A-expressing cells (4.2 ± 0.7 s) was significantly decreased compared to control cells 
(23.2 ± 1.8 s) (Fig. 7B). The 3A-ins16S mutant that was unable to block activation of Arf1 was 
considerably compromised in its ability to trap GBF1 on membranes and had only a minor effect on 
the cycling of Arf1 (Fig. 7A and 7B). These results indicate that 3A stabilizes GBF1 on membranes 
in a manner similar to BFA and Arf-T31N.   
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Fig. 6. Overexpression of GBF1 or Arf1 suppresses the effects of 3A. (A) BGM cells transiently co-transfected with 3A-myc 
and GFP, Arf1-GFP, YFP-GBF1, or GM130-GFP for 16 h were stained with an antibody against COP-I. Bars represent 10 µm. 
(B) Percentage of 3A-myc and GFP, Arf1-GFP, YFP-GBF1, or GM130-GFP co-expressing cells, in which COP-I is dissociated 
from membranes. Calculations were made from at least two independent experiments (of which a typical example is shown in 
panel A). In each experiment, at least 100 cells were analyzed. (C) Arf1-GTP pulldown assay. COS7 cells were transfected with 
pCMS-Arf1-GFP or pC-3A-myc-S-Arf1-GFP, either alone or in combination of with YFP-GBF1 or HA-BIG2. The upper panel 
shows the total amount of Arf1-GFP in cells, the lower panel shows the amount of GTP-bound Arf1-GFP. For full colour figure, 
see page 135.
 Discussion
 Most viruses have developed mechanisms to counteract infection-limiting host cell 
responses. Enteroviruses are non-enveloped, cytolytic RNA viruses that do not rely on an intact 
secretory pathway to release their progeny. Instead, these viruses induce a general inhibition of 
secretory pathway transport, most likely to reduce cytokine secretion and MHC-I exposure. The 
enterovirus 3A protein, a small membrane protein with multiple functions in the viral life cycle, 
has been suggested to play an important role in this inhibition by blocking ER-to-Golgi transport. 
Here, we showed the physiological relevance of this function in a mouse model of coxsackievirus 
infection. We showed that a coxsackievirus carrying a mutation in 3A that rendered it unable to inhibit 
ER-to-Golgi transport was less virulent in mice, as indicated by reduced virus titers and tissue 
damage in the target organs. Moreover, we have unraveled the molecular mechanism by which 
3A inhibits ER-to-Golgi transport. Evidence is presented that 3A interferes with COP-I assembly by 
blocking the activation of Arf1.
 Inhibition of COP-I assembly by 3A resulted in disassembly of VTC and Golgi structures 
and the accumulation of membrane structures at or close to the ERES. This inhibition was due to 
impaired Arf1 activation, as shown by reduced amounts of Arf1 on the membranes and reduced 
Arf1-GTP levels. Inhibition of Arf1 activation may be caused either by inhibition of GEF activity or, 
alternatively, by stimulation of GAP activity. Several results demonstrate that 3A interferes with Arf1 
activation by specifically inhibiting the function of GBF1, a GEF that has been shown to catalyze 
nucleotide exchange on Arf1 in the ER-Golgi system: (1) two-hybrid studies as well as GST-pulldown 
and co-immunoprecipitation experiments showed an interaction with GBF1, (2) the inhibition of 
Arf1 activation by 3A could be overcome by overexpression of GBF1, and (3) FRAP experiments 
showed that GBF1, which normally cycles between membranes and the cytosol, was trapped 
on membranes by 3A. Conversely, no interactions were observed between 3A and ArfGAP1 in 
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Fig. 7. Dynamics of GBF1 and Arf1 in 3A-expressing cells. (A-B) FRAP traces of cells expressing YFP-GBF1 (A) or Arf1-YFP 
(B), either alone (control cells), or together with CFP-3A or CFP-3A-ins16S. The traces in the graphs show the average recovery 
and SEMs (n ≥ 10 cells, from at least two independent experiments). The fluorescence intensity was calculated as described 
in Fig. 4. (C) Inset of panel B, showing traces of the first 40 sec after bleach. (D) Halftime of fluorescence recovery values of 
Arf1-YFP alone, together with CFP-3A or CFP-3A-insS16, as calculated from the traces in panel B. For full colour figure, see 
page 136.
pull-down or coimmunoprecipitation experiments (data not shown). Moreover, recombinant purified 
3A had no effect on ArfGAP1 activity in vitro (B. Antonny, personal communication), whereas at 
the same concentration we showed that it inhibited an Arf GEF activity in vitro. Together, these 
data indicate that 3A inhibits GBF1 activity rather than that it stimulates ArfGAP1 activity. In 
addition to GBF1, Arf1 was found to be associated with 3A in pulldown and co-immunoprecipitation 
experiments. Additional co-immunoprecipitation experiments showed that it was the inactive form 
of Arf1 (i.e., Arf1-GDP) that was pulled down along with 3A. No interaction between Arf1 and 3A 
was found in the yeast two-hybrid assay. Although this latter finding does not necessarily exclude 
a direct interaction, these data strongly suggest that 3A interacts indirectly with Arf1 through GBF1, 
which binds with high affinity to Arf1-GDP, but not Arf1-GTP. Together, our data support a model in 
which 3A inhibits ER-to-Golgi transport by stabilizing an intermediate GBF1-Arf1-GDP complex on 
membranes in a conformation that cannot proceed to nucleotide exchange.
 The amount of Arf1 present in cells largely exceeds that of GBF1. Therefore, almost all 
GBF1, but only a minor fraction of Arf1, will be trapped in the abortive 3A-GBF1-Arf1-GDP complex. 
A similar situation has been demonstrated for BFA treatment of cells, which stabilizes GBF1 and 
a minor fraction of Arf1 on membranes (Niu et al., 2005). In cells expressing 3A, it is this large, 
cytosolic Arf1 population that contributes most to our steady-state studies, explaining the lack of 
clear colocalization between 3A and Arf1. If 3A stabilizes an abortive GBF1-Arf1-GDP complex 
on membranes, why then do we find an increased cycling speed of Arf1? Recently, an increased 
cycling speed was observed for an Arf1 mutant that was targeted to the TGN, presumably because 
its activity was now controlled by trans-Golgi GEFs (BIG1 and BIG2) and GAPs (Honda et al., 
2005). The dispersed membrane structures to which Arf1 was redistributed in cells overexpressing 
3A and Arf1 not only contained GBF1, but also BIG1 and BIG2 (data not shown). Thus, a possible 
explanation for the increased Arf1 cycling speed in 3A-expressing cells is that Arf1 is now exclusively 
regulated by other GEFs than GBF1.
 The effects of 3A on both the steady-state distribution and the dynamic behaviour of early 
secretory pathway proteins closely resembled those of BFA. However, the molecular mechanisms 
of BFA and 3A are different. BFA interferes with the activity of all large multidomain Arf GEFs 
(i.e., GBF1, BIG1, and BIG2), by binding to the interface of their catalytic Sec7 domains and 
Arf1-GDP (Peyroche et al., 1999; Renault et al., 2003; Mossessova, et al., 2003). Conversely, 
overexpression of these proteins can counteract BFA-induced blockage of Arf1 activation (Claude 
et al., 1999; Shinotsuka et al., 2002; Smirnova and Jackson, data not shown). In contrast, 3A seems 
to specifically interfere with the function of GBF1. 3A specifically binds GBF1, but not BIG1 and 
BIG2, and only overexpression of GBF1 restored Arf1-GTP levels in 3A-expressing cells. Moreover, 
3A binds to the N terminus of GBF1 rather than to its catalytic Sec7 domain. In line with the idea 
that 3A does not directly target the Sec7 domain, 3A was found to be unable to inhibit nucleotide 
exchange on Arf1 by the Sec7 domain of BIG1 in vitro (J. Cherfils, personal communication) (in this 
experiment BIG1 Sec7 was used because all attempts to produce active recombinant GBF1 Sec7 
have been unsuccessful). Thus, 3A specifically inhibits GBF1-mediated Arf1 exchange through a 
mechanism that differs from that of BFA.
 Enteroviruses induce a dramatic rearrangement of secretory pathway membranes. The 
2BC protein triggers a massive accumulation of membrane structures at which viral genome 
replication takes place. The function of 3A is not required for this latter modification, since viruses 
carrying a 3A protein defective in inhibiting ER-to-Golgi transport replicated efficiently in tissue culture 
cells (Doedens et al., 1997; Wessels et al., 2005). Enterovirus genome replication is completely 
abolished in the presence of BFA when added to cells immediately after infection (Maynell et 
al., 1992). It may therefore seem remarkable that enteroviruses produce a protein that causes 
BFA-like effects. However, the inhibition of protein transport in infected cells occurs at a late stage 
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in infection (at 4-5 h postinfection), a time point at which the membrane rearrangements required 
for initiation of viral genome replication have already taken place. Accordingly, virus replication is 
not inhibited when BFA is added at late stages in infection (Maynell et al., 1992). 
 Recently, it was demonstrated that expression of poliovirus 3A results in increased 
membrane association of Arf1 in HeLa cell lysates (Belov et al., 2005). The reason why these 
authors find more Arf1 on membranes upon expression of 3A in vitro, whereas we find a dissociation 
of the majority of the Arf1 population in vivo, is yet unknown. Notwithstanding this difference, their 
results also point to a regulatory role of 3A in Arf1 function. In addition, these authors showed 
that also the viral 3CD protein can increase the membrane association of Arf1 and that Arf1 is 
redistributed to the membranes where the viral replication proteins localize (Belov et al., 2005). 
Together, the data suggest that early in infection active Arf1 is required for the accumulation of the 
membranes at which viral RNA replication takes place, whereas late in infection the function of Arf1 
may be inhibited to evade anti-viral host cell responses. More research is required to establish the 
relative contributions and importance of the Arf1-related membrane alterations induced by 3A and 
3CD in infected cells.   
 In another study, it was proposed that poliovirus 3A inhibits transport by binding and 
inactivating Lis1, a component of the dynein/dynactin motor complex (Kondratova et al., 2005). 
Given the observation that Lis-/- MEFs contain COP-I on their membranes (Sasaki et al., 2005), it 
seems unlikely that this activity is involved in the mechanism by which 3A inhibits Arf1-dependent 
COP-I assembly. The activity proposed by Kondratova et al. most likely occurs downstream of the 
mechanism that we described here and may constitute an additional function of 3A to suppress 
protein transport. 
 In conclusion, we have shown that the enterovirus 3A protein inhibits ER-to-Golgi 
transport by stabilizing the Arf GEF GBF1 on membranes and blocking its capacity to activate Arf1. 
To our knowledge, the 3A protein is the first viral protein that is recognized to interfere with Arf1 
activation and may prove to be a valuable tool in future research on the early steps of the secretory 
pathway.
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Materials and Methods
 Cells, antibodies and reagents. Experiments were performed with BGM cells, unless stated 
otherwise. The coxsackievirus that was used in this study is a recombinant virus that was derived from plasmid 
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p53CB3/T7, which contains a full-length and infectious cDNA of coxsackievirus B3 (CVB3, strain Nancy) behind 
a T7 promoter (Wessels et al., 2005). The 3A-ins16S mutant virus was generated by oligonucleotide-directed, 
in vitro mutagenesis as described (Wessels et al., 2005). The following antibodies were used: rabbit polyclonal 
antibodies against the first 60 aa of CVB3 protein 3A (raised against recombinant MBP-3A(1-60)); Arf1 (B. 
Helms, Biochemie-Zentrum Heidelberg, Germany); ArfGAP1 (M. Roth, University of Texas Southwestern 
Medical Center at Dallas, USA); BIG1 and BIG2 (M. Vaughan and J. Moss, NIH, Bethesda, USA); α/γ-COP 
(K. Frey, Biochemie-Zentrum Heidelberg, Germany); GFP (raised against recombinant GST-GFP); the 
myc-epitope (ABR); Sec13 (B.-L. Tang, National University of Singapore); Sec23 (ABR, Affinity Bioreagents 
Inc.); Sec24 (J.-P. Paccaud, University of Geneva, Switzerland); TGN46 (Serotec, Oxford, UK); mouse 
monoclonal antibodies against ERGIC53 (J. Fransen, University of Nijmegen, The Netherlands/ H.P. Hauri, 
Biocenter Basel, Switzerland); GBF1 (BD Bioscience); GM130 (BD); the myc-epitope (Sigma); and anti-rabbit 
and anti-mouse antibodies conjugated with Alexa Fluor 594 and Alexa Fluor 488 (Molecular Probes, The 
Netherlands). Myristoylated Arf1 was kindly provided by S. Paris and B. Antonny. Brefeldin A was obtained from 
Sigma.
 Constructs. The following plasmids were kind gifts: pVSVG-GFP (P. Keller and K. Simons, Max 
Planck Institute of Molecular Biology and Genetics, Dresden, Germany); pArf1-GFP, pArf1-Q71L-GFP, and 
pArf1-T31N-GFP (G. Romero, University of Pittsburgh, USA); p58-ERGIC-YFP (J. Lippincott-Schwarz, NIH, 
Bethesda, USA); pGM130-GFP (F. Barr, Imperial Cancer Research Fund, London, UK). pYFP-GBF1 (Niu et al. 
2005), p3A-myc and pGFP-3A (Wessels et al., 2005) were described previously. pC-3A-myc-S-Arf1-GFP and 
pC-A1PI-YFP-S-GFP-3A were derived from pCMS-EGFP (Clontech), a plasmid that contains both a CMV (C) 
and a SV40 (S) promoter.
 A1PI secretion assay. This method was performed as described previously with small modifications 
(Wessels et al., 2005).
 Single cycle growth curve. This method was performed as described previously (Wessels et al., 
2005). Samples were taken at 2, 4, 6, and 8 h p.i.
 Mouse experiments. Mouse experiments were performed as described (Henke et al., 1995). 
Histological analyses were performed as described in Merkle et al., (2002). All animal procedures were officially 
approved in accordance with the German Animal Protection Law. 
 Immunofluorescence and immuno-electron microscopy. These techniques were performed as 
described (Wessels et al., 2005; Slot et al., 1991).
 FRAP experiments. Live cell confocal microscopy was performed on a Zeiss LSM510Meta confocal 
microscope (Carl Zeiss GmbH, Jena, Germany) equipped with a temperature controlled stage and CO2 incubator 
(type S). FRAP measurements were made from movies that were taken at 37°C at a rate of 1 frame per s 
(Sec24, GBF1 and Arf1) or 1 frame per 10 s (p58-ERGIC) using a 63x, 1.4 NA objective and pinhole settings 
such that < 2 µm optical slices were imaged. To study the effects of CFP-3A and Arf1-T31N-CFP on protein 
dynamics, cells were selected on the basis of co-expression. FRAP imaging was performed using the 514 nm 
argon line using low laser power conditions (40% power, 0.1% transmission) in order to prevent photobleaching 
during monitoring. Regions of interest (ROI) were selectively photobleached using the 514 nm line at 100% 
transmission, the number of iterations ranging from 25-70 s in order to accomplish a ~50% reduction of the 
initial ROI intensity. The p58-ERGIC-YFP expressing cells were incubated on ice for 30 min and treated with 
1 µg/ml nocodazole before imaging to prevent microtubule-dependent motion of pre-Golgi intermediates (Ward 
et al., 2001). Where indicated, cells were treated with BFA (5 µg/ml) for 30 min before imaging.
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 Arf1-GTP pulldown assay. To assess the amount of activated Arf1-GTP in cells, we performed 
a GGA pull-down assay as described (Niu et al., 2005). Briefly, COS7 cells were transfected with a pCMS 
vector expressing Arf1-GFP alone or expressing Arf1-GFP and 3A together, either alone or co-transfected with 
plasmid expressing YFP-GBF1 or HA-BIG2, and incubated for 20 h. Cell lysates were prepared and incubated 
for 1 h at 4°C with glutathione-sepharose beads pre-bound with a GST-GGA3-VHS-GAT domain fusion protein 
(Shinotsuka et al., 2002). Bound proteins were eluted from beads and subjected to Western analysis. Both YFP-
GBF1 and HA-BIG2 were efficiently expressed as detected by Western analysis (data not shown). 
 In vitro Arf GEF activity assays. This assay was performed as described in Donaldson et al., (1992) 
with minor modifications. Incubations were carried out in 50 µl reaction mixtures containing 25 mM HEPES-
KOH pH 7.0, 25 mM KCl, 2.5 mM MgCl2, 0.2 M sucrose, 1 mM DTT, 1 mM ATP, 5 mM creatine phosphate, 
10 U creatine kinase, 0.5 µM myristoylated Arf1, 0.5 µCi 35S-GTPγS, 10 µM GTPγS and 2.5 µg rat liver Golgi 
membranes (based on protein contents) at 37°C for 1 hr. Rat liver Golgi membranes were isolated as described 
in Hui et al., (1998). Where indicated, 1 µM His-tagged 3A(1-60) protein was added. Protein-bound 35S-GTPγS 
was recovered by filtration through 0.45 µm nitrocellulose filters. The total amount of radioactive label on the 
filters was determined by liquid scintillation counting. 
 Interaction studies. Yeast 2-hybrid studies were performed in strain AH109 (Clontech). The Arf GEF 
regions and the Arf proteins were cloned into pGADT7 creating Gal4 activation domain fusions, and the first 
60 amino acids of 3A were cloned into pGBT7 to produce a Gal4 DNA binding domain fusion protein. Co-
immunoprecipitation was performed as described for the A1PI secretion assay in Wessels et al., (2005). GST 
fusion proteins were purified from E.coli. Murine brain lysates were prepared from adult F13wt mice in RIPA 
buffer. Rat liver Golgi fractions were isolated as described in Hui et al., (1998). For pulldown experiments, 
2.5 mg of murine brain lysate proteins or 0.5 mg of rat liver Golgi fractions were added to GST-3A(1-60) protein 
in 1.5 ml IPP150 and allowed to bind for 1 h at 4°C. Proteins were bound to glutathione Sepharose for 1 h at 
4°C, washed three times with IPP150 and analyzed by immunoblotting. The Arf1 column binding assay was 
performed as described in Trautwein et al., (2004) with minor modifications.
 FCS measurements. FCS measurements were carried out with a ConfoCor2 (Carl Zeiss GmbH, 
Jena, Germany) using a C-Apochromat 40x/1.2W objective, a 488-nm laser, a 505-550-nm bandpass and 
a pinhole width of 2 Airy units. In all cases, at least 15 fluorescence time series (F(t)) of 30 s were recorded 
and analyzed with FCS ACCESS software (EVOTEC/Zeiss, version 1.0.12) using two-component diffusion 
models. FCS was measured at different locations outside the nucleus and Golgi and in multiple cells. Cells that 
showed >30% bleaching, were not taken along in the calculations. Results are means ± SEM of at least 15 
measurements in different cells.
 In vitro Arf GEF activity assays. In this approach, we made use of Golgi membranes that were 
depleted of GEFs by KCl treatment (Clary and Rothman, 1990), and rat liver cytosol as a source of Arf1 and 
GEFs (Malhotra et al., 1989). In short, incubations were carried out in 50 µl reaction mixtures containing 
25 mM HEPES-KOH pH 7.0, 25 mM KCl, 2.5 mM MgCl2, 0.2 M sucrose, 1 mM DTT, 1 mM ATP, 5 mM creatine 
phosphate, 10 U creatine kinase, 0.1 µg KCl-washed Golgi membranes (based on protein contents), 3 µg rat 
liver cytosol (based on protein contents) and either 25 µM GTPγS or 25 µM GDP at 37°C. Where indicated, 
1 µM His-tagged 3A(1-60) was added. The reaction was stopped by chilling on ice. Membrane-bound Arf was 
pelleted by centrifugation for 10 min at 16,000 x g and 4°C. Samples were boiled in Laemmli sample buffer and 
proteins were separated on 12.5% SDS-PAGE gels. Arf1 was detected by Western analysis using an anti-Arf1 
antiserum (gift of J.B. Helms). 
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Fig. S1. Effects of BFA treatment (2h, 5 µg/ml) or Arf1-T31N expression (16 h after transfection) on the distribution of various 
early secretory pathway components; Sec24 (A), ERGIC53 (B), GM130 (C), Gal-T (D), α/γ-COP (E), Arf1 (F), GBF1 (G), 
ArfGAP1 (H), TGN46 (I), BIG1 (J), BIG2 (K). Bars represent 10 µm. A 2h BFA treatment was used to mimic the long-lasting 
effects of 3A or Arf1-T31N expression. For full colour figure, see page 137.
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Fig. S2. EM picture of a 3A-expressing cell. In 3A (10 nm gold) expressing cells, ERGIC53 (15 nm gold) is found on a portion 
(arrowheads) of the 3A-induced membrane clusters (asterisk). The arrow points to an elongated 3A-positive budding profile 
associated with the ER. Bar, 200 nm. ER, endoplasmic reticulum. For full colour figure, see page 138.
Fig. S3. Determination of the diffusion coefficient D of Arf1 in the cytosol of living cells using Fluorescence Correlation 
Spectroscopy (FCS). (A) In cells transfected with the plasmid pC-3A-myc-S-Arf1-GFP, 3A is localized in the ER and punctate 
structures, whereas both Arf1-GFP and COP-I are dissociated from membranes. Bars represent 10 µm. (B) FCS measurements 
on Arf1-GFP in BGM cells. Total Arf1 in control cells is comprised of two populations, a fast and a slow diffusing population. The 
fast population (high D) represents monomeric, cytosolic Arf1, whereas the slow population (low D, typically ~ 1 µm2	s-1 [Altan-
Bonnet et al., 2003]) is Arf1 bound in a large protein complex or membrane-bound Arf1 (Elsner et al., 2003). In 3A-expressing 
cells, the fraction of slowly diffusing Arf1 in the cytosol was not considerably altered compared to control cells. The D of the 
fast Arf1 population in 3A-expressing cells was not decreased relative to that in control cells, instead it was a little increased, 
indicating that Arf1 is not associated to small membrane structures (which could hav  r mained after Golgi disassembly and 
are not resolvable by confocal microscopy, and which would have caused a decreased D). Similar effects were found in 	
Arf1-T31N-expressing cells and BFA-treated cells. These data support the idea that Arf1 is persistently inactive in 3A-expressing 
cells. For full colour figure, see page 138.
Fig. S4. 3A inhibits an Arf GEF activity in vitro. (A) In this approach, KCl-washed rat liver Golgi membranes (as a source of 
membranes) and rat liver cytosol (as a source of GEFs and Arf1) were incubated in the presence of either GTPγS or GDP 
for different time intervals and then the amount of Arf1 was determined by Western blot analysis. Arf1 translocated to the 
membranes in the presence of GTPγS, but not GDP. (B) Translocation of Arf1 was strongly reduced in the presence of 1 µM 
recombinant 3A(1-60).
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Fig. S5. Membrane association and topology of the 3A protein of CVB3. (A) Amino acid sequence. The hydrophobic domain is 
represented in the boxed area. (B) Cells were transfected with GFP-3A or GFP-3A(1-60) and membranes were collected at 24 h 
post-transfection. Extraction of membranes using different buffers showed that full-length 3A was released from the membranes 
only in the presence of Triton X-100, indicating that it is a membrane-integral protein. 3A(1-60) lacks the hydrophobic domain 	
(aa 61-82) and is cytosolic. (C) Cells were transfected with 3A-myc and after 16h, fixed and treated with saponin (to permeabilize 
the plasma membrane, but not the ER membrane) or Triton X-100 (to permeabilize all membranes). Cells were stained with 
antibodies ragainst the N-terminal 60 aa of 3A (α-3A(1-60)) and against the C-terminal myc-tag (α-myc). While the N terminus 
of 3A-myc was readily detectable under all conditions, the myc-tag could only be detected after Triton X-100 permeabilization, 
indicating that the N terminus is cytosolic while the C terminus is located in the ER-lumen. 
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The 3A protein of coxsackievirus B3 (CVB3), a small membrane protein that forms homodimers, inhibits endoplasmic reticulum (ER)-to-Golgi transport. Recently, we described the underlying mechanism by showing that the CVB3 3A protein binds 
to and inhibits the function of GBF1, a guanine-nucleotide exchange factor for ADP-
ribosylation factor 1 (Arf1), thereby interfering with Arf1-mediated COP-I recruitment. This 
study was undertaken to gain more insight into the molecular determinants underlying the 
interaction between 3A and GBF1. Here, we show that 3A mutants that have lost the ability to 
dimerize are no longer able to bind to GBF1 and trap it on membranes. Moreover, we identify 
a conserved region in the N terminus of 3A that is crucial for GBF1 binding but not for 3A 
dimerization. Analysis of the binding domain in GBF1 showed that the extreme N terminus, 
the dimerization/cyclophilin binding (DCB) domain, as well as the homology upstream of 
Sec7 (HUS) domain are required for the interaction with 3A. In contrast to full-length GBF1, 
overexpression of a GBF1 mutant lacking its extreme N terminus failed to rescue the effects 
of 3A. Together, these data provide insight into the molecular requirements of the interaction 
between 3A and GBF1.
Introduction
 Enteroviruses (e.g. coxsackievirus, poliovirus, and ECHOvirus) belong to the family 
of the Picornaviridae. They are nonenveloped, cytolytic viruses that contain a small positive-
stranded RNA genome. The viral RNA encodes a single, large polyprotein that is processed into 
the individual capsid proteins and nonstructural proteins. The nonstructural proteins are involved 
in viral RNA replication and account for the virus-induced alterations in host cell metabolism and 
structure, which serve to create an environment suitable for efficient viral RNA replication and/or 
to suppress anti-viral host cell responses (Porter, 1993; Wimmer et al., 1993; van Kuppeveld et 
al., 2005). Enteroviruses do not rely on an intact secretory pathway to release their virus progeny. 
Instead, they have been shown to induce a general blockage of protein secretion. Inhibition of 
protein secretion is also observed upon individual expression of the nonstructural proteins 2B and 
3A (Doedens and Kirkegaard, 1995; Wessels et al., 2005). The 3A-mediated inhibition of protein 
transport is not essential for virus replication but most likely serves to suppress antiviral host cell 
responses such as cytokine secretion and antigen presentation (Deitz et al., 2000; Dodd et al., 
2001; Wessels et al., 2006a). 
 Coxsackievirus B3 (CVB3) 3A is a small (89 aa) membrane integral protein that is 
anchored in the membrane through its C-terminal hydrophobic domain (Wessels et al., 2006a). 
Elucidation of the structure of the soluble, cytosolic region upstream the membrane anchor of 
the poliovirus 3A protein by NMR suggested that 3A forms homodimers (Strauss et al., 2003). 
Each monomer was proposed to consist of two amphipathic α-helices, which are bended 180° 
to form a helical hairpin, flanked by unstructured N and C termini. The structural data suggested 
that dimerization was mediated by a hydrophobic surface, formed mainly by hydrophobic residues 
in the central amphipathic α-helices, that form a dimer interface with the hydrophobic surface of 
the other molecule. Based on this structure, we generated a molecular model of CVB3 3A and 
used this model for an extensive structure-function relationship study of CVB3 3A (Wessels et al., 
2006b). Through this approach, experimental evidence for the functional relevance of CVB3 3A 
dimerization and important insight into the structural requirements for dimerization was obtained. 
The results supported the importance of a hydrophobic interaction between the monomers for 
dimerization. In addition, regions that are important for 3A functioning but not for dimerization were 
identified (Wessels et al., 2006b).
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 Recently, we elucidated the mechanism by which the CVB3 3A protein inhibits protein 
transport (Wessels et al., 2006a). We showed that expression of 3A resulted in the disassembly 
of the vesicular tubular cluster (VTC) and the Golgi complex (Wessels et al., 2006a). As a result, 
components of VTC and Golgi flow back to the ER and accumulate at or close to the COP-II 
coated ER exit sites, where 3A is also localized. 3A inhibits ER-to-Golgi transport by blocking 
activation of the ADP-ribosylation factor 1 (Arf1) protein. Arf proteins play a central role in protein 
transport and organelle structure and maintenance (D’Souza-Schorey and Chavrier, 2006). Like 
other small GTPases, Arf proteins cycle between an inactive GDP-bound and an active GTP-bound 
state. Nucleotide exchange on Arfs is catalyzed by guanine-nucleotide exchange factors (GEFs) 
(Donaldson and Jackson, 2000). GBF1 is a GEF that has been implicated in endoplasmic reticulum 
(ER)-to-Golgi transport (Zhao et al., 2002). Under physiological conditions, GBF1 continuously 
cycles on and off membranes (Niu et al., 2005; Szul et al., 2005). We showed that the CVB3 
3A protein inhibits activation of Arf1 through interacting with and inhibiting the function of GBF1 
(Wessels et al., 2006a). As a result, the COP-I coat complex, which plays an important role in 
bidirectional transport between the ER and Golgi (Rabouille and Klumperman, 2005), cannot be 
recruited to membranes and protein transport is inhibited. The poliovirus 3A protein was recently 
also shown to modify Arf1 membrane associatio (Belov et al., 2005).
 This study was undertaken to gain more insight into the molecular determinants of the 
CVB3 3A-GBF1 interaction. To this end, we tested the ability of a number of 3A mutants to interfere 
with COP-I recruitment. Furthermore, the effect of 3A mutations on GBF1 binding and dynamics 
was investigated. Finally, we identified regions in the N terminus of GBF1 that are important for the 
interaction with 3A. 
Results
Inhibition of COP-I recruitment by mutant 3A proteins.
 Previously, we constructed several 3A mutants and characterized them for their ability to 
dimerize and inhibit secretion of a reporter protein (Wessels et al., 2005; Wessels et al., 2006a; 
Wessels et al., 2006b). A number of 3A mutants were obtained that were no longer able to inhibit 
reporter protein secretion. We reasoned that this might be due to an impaired ability to interfere 
with COP-I recruitment to membranes. To investigate this, C-terminal Myc fusions of a number of 
selected 3A mutants were generated. These mutants are summarized in Fig. 1A and described 
below (in order of the position of the mutations, from N to C terminus). 
 (i) 3A-R6A/E7A/I8A/K9A/I10A, a mutant in which Arg6, Glu7, Ile8, Lys9, and Ile10 are 
substituted for Ala residues. These residues are located in the N terminus of 3A, a region that was 
predicted to be unstructured and not to be involved in dimerization. Indeed, we found that mutant 
3A-R6A/E7A/I8A/K9A/I10A showed efficient dimerization. Nevertheless, this mutant was unable 
to inhibit reporter protein secretion. (ii) 3A-ins16S, a mutant in which a Ser residue is inserted at 
position 16 in 3A. (iii) 3A-P17A/P18A/P19A, a mutant in which Pro17, Pro18, and Pro19 are substituted 
for Ala residues. The latter two mutants contain amino acid alterations in the region immediately 
upstream of the first α-helix (aa 20-27). Although this region was not predicted to be important 
for dimerization, both mutants were defective in 3A dimerization and inhibition of reporter protein 
secretion, which may be due to overall effects on protein folding. (iv) 3A-L25A/L26A, a mutant in 
which Leu25 and Leu26 are substituted for Ala residues. These residues are located in the first α-helix 
and predicted to be involved in the hydrophobic packing between the 3A monomers. Consistent 
with this, mutant 3A-L25A/L26A was unable to dimerize and inhibit secretion of a reporter protein. 
For reasons of simplicity, the mutants 3A-R6A/E7A/I8A/K9A/I10A, 3A-P17A/P18A/P19A, and 
3A-L25A/L26A, and will be further referred to in this study as 3A-REIKI, 3A-PPP, and 3A-LL. 
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 We also generated C-terminal Myc fusions of two new 3A mutants, both of which were 
able to inhibit reporter protein secretion (data not shown). These mutants contain substitutions 
of residues in the middle part of 3A that are conserved among the different enteroviruses. The 
mutants are: (v) 3A-VDSE, a mutant in which Val29, Asp30, Ser31, and Glu32 are substituted for Ala 
residues, and (vi) 3A-VREY, a mutant in which Val34, Arg35, Glu36, and Tyr37 are substituted for Ala 
residues. 
 Immunofluorescence microscopy of cells using anti-COP-I antibodies showed that COP-I 
was typically localized at Golgi membranes in control cells. In line with previous results, COP-I was 
redistributed to the cytoplasm in cells expressing the wild-type (wt) 3A protein (Fig. 1B) (Wessels 
et al., 2006a). In these cells, 3A localized at the ER and at or close to the COP-II coated ER exit 
sites (Fig. 1B) (Wessels et al., 2006a). In cells expressing 3A-REIKI, 3A-ins16S, 3A-PPP, and 
3A-LL (i.e., the 3A mutants that were unable to inhibit protein transport), COP-I was localized at 
Golgi membranes (Fig. 1C-F and I). The 3A-ins16S, 3A-PPP, and 3A-LL mutants were found to 
localize at the Golgi (Fig. 1D, E, and F), whereas the 3A-REIKI mutant localized mainly to the ER 
and partially to the Golgi (Fig. 1C). In contrast, the 3A-VDSE and 3A-VREY mutants (i.e., the 3A 
mutants that were able to inhibit protein transport) localized similarly to 3A wt and redistributed 
COP-I to the cytoplasm (Fig. 1G, H, and I). Together, the data demonstrate that defective 3A mutants 
cannot inhibit protein transport since they can no longer interfere with COP-I recruitment.
 Interestingly, long thread-like tubulovesicular structures were occasionally observed in 
cells expressing wt 3A (Fig. 2). These structures contained the 3A protein, an integral membrane 
protein, at their surface and are therefore most likely membrane tubules. No such structures were 
observed in cells expressing any of the defective 3A mutants.
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Fig. 1. Inhibition of COP-I recruitment to membranes by mutant 3A proteins. (A) Amino acid (aa) sequence of CVB3 3A. The C-
terminal hydrophobic domain (aa 61 to 82) is depicted in the boxed area. Aa that are mutated are indicated by asterisks and the 
Ser insertion at position 16 is also indicated. (B-H) BGM cells expressing Myc-tagged 3A wt (B), 3A-REIKI (C), 3A-ins16S (D), 
3A-PPP (E), 3A-LL (F), 3A-VDSE (G), and 3A-VREY (H) are stained for the Myc tag and COP-I. (I) Table summarizing the ability 
of 3A mutants to inhibit protein transport and COP-I recruitment. 1, Wessels et al., 2006a; 2, Wessels et al., 2006b; 3, Wessels 
et al., 2005. 3A-REIKI, 3A-R6A/E7A/I8A/K9A/I10A; 3A-PPP, 3A-P17A/P18A/P19A; 3A-LL, 3A-L25A/L26A; 3A-VDSE, 3A-V29A/
D30A/S31A/E32A; 3A-VREY, 3A-V34A/R35A/E36A/Y37A. Bars represent 10 µm. For full colour figure, see page 139.
Ability of mutant 3A proteins to bind GBF1 and trap it on membranes.
 GBF1 is an Arf1 GEF that normally cycles rapidly on and off Golgi membranes (Niu et al., 
2005; Szul et al., 2005). GBF1 activation of Arf1 is required for COP-I recruitment to membranes. 
We showed that wt 3A interferes with COP-I recruitment by binding to (the N-terminal part of) GBF1 
and trapping it on membranes (Wessels et al., 2006a). The observation that the above-described 
3A mutants are defective in interfering with COP-I recruitment may be explained by their inability 
to bind GBF1. Alternatively, these mutants may still bind GBF1 but no longer be able to trap it on 
membranes. To discriminate between these possibilities, binding of these mutants to GBF1 as well 
as their effects on GBF1 dynamics were tested.  
 Binding of the 3A mutants to the N-terminal part of GBF1 was investigated both by yeast 
two-hybrid (Fig. 3A) and mammalian two-hybrid (Fig. 3B) analyses. In yeast, the cytosolic part of 3A 
(i.e., the 60 amino acids upstream of its hydrophobic membrane anchor) was expressed, whereas 
full-length 3A was expressed in the mammalian system. All 3A mutants that are unable to inhibit 
protein transport and to inhibit COP-I recruitment to membranes (3A-REIKI, 3A-ins16S, 3A-PPP, 
3A-LL) were severely reduced in their ability to bind GBF1 (Fig. 3A and B). In contrast, the two 
mutants that were able to inhibit protein transport and cause release of COP-I into the cytoplasm 
(3A-VDSE and 3A-VREY) showed a strong interaction with GBF1 (Fig. 3A and B). These data 
clearly indicate that the 3A-REIKI, 3A-ins16S, 3A-PPP, and 3A-LL mutants are unable to inhibit 
COP-I recruitment and protein transport because they cannot bind GBF1. 
 Putative effects of the 3A mutant proteins on the dynamics of GBF1 were tested 
using Fluorescence Recovery After Photobleaching (FRAP). Previously, we showed that upon 
coexpressing YFP-GBF1 and CFP-3A wt, GBF1 was mostly found on dispersed membranes 
(Wessels et al., 2006a). Remarkably, localization of GBF1 and the 3A proteins differed among the 
various mutants. GBF1 and 3A colocalized at dispersed membrane structures in all cells expressing 
3A wt, 3A-ins16S, 3A-PPP, or 3A-LL. In contrast, colocalization at dispersed membrane structures 
was only occasionally observed in cells co-expressing GBF1 and 3A-VDSE. In the majority of the 
cells co-expressing GBF1 and 3A-VDSE, these proteins were found to colocalize at the ER. GBF1 
localized mainly at the ER in cells co-expressing 3A-REIKI and in control cells (i.e., in the absence 
of 3A expression). Because GBF1 dynamics may depend on its localization, FRAP results of 
3A-expressing cells in which GBF1 is localized either at dispersed membrane structures (Fig. 3C) 
or at the ER (Fig. 3D) were compared separately. FRAP measurements on GBF1 that localized 
at dispersed membrane structures showed that the 3A mutants that are unable to inhibit protein 
transport (3A-ins16S, 3A-PPP, and 3A-LL) were unable to trap GBF1 on membranes, whereas 
3A-VDSE trapped GBF1 on membranes as efficiently as 3A wt (Fig. 3C). FRAP measurements 
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Fig. 2. Membrane tubules in 3A-expressing BGM cells. (A, C) BGM cells expressing Myc-tagged 3A wt that are stained for the 
Myc tag. (B, D) Higher magnification pictures of the parts of the cell indicated by the white box in panel A (B) and C (D), showing 
the tubules in more detail. (A, C) Bars represent 10 µm; (B, D) Bars represent 2 µm.
on GBF1 that localized at the ER showed that 3A-REIKI had no effect on GBF1 dynamics at all 
(Fig. 3D). ER-localized 3A-VDSE severely reduced cycling of GBF1, although its effect differed 
from that observed when it localized at dispersed membrane structures. In summary, these findings 
indicate that all four 3A mutants that are unable to inhibit COP-I recruitment to membranes and 
block protein transport are also unable to trap GBF1 on membranes.
 Previously, we showed that expression of 3A resulted in an increased cycling time of 
Arf1-YFP (Wessels et al., 2006a). Although the underlying reason for this phenomenon is unclear, 
it seems likely that it is linked to the 3A-mediated inhibition of GBF1. To gain more insight into 
this possible correlation, we tested the effects of the 3A mutants on Arf1 dynamics (Fig. 4). In 
cells expressing 3A mutants that were able to inhibit GBF1 activity (3A-VDSE and 3A-VREY), the 
halftime of fluorescence recovery of Arf1-YFP was decreased to an extent similar to that in cells 
expressing 3A wt, whereas in cells expressing 3A mutants that were not able to inhibit protein 
transport (3A-REIKI, 3A-ins16S, 3A-PPP, and 3A-LL), the halftime of fluorescence recovery of 
Arf1-YFP was similar to that in control cells (Fig. 4). These results provide support for a correlation 
between the activity of GBF1 and the dynamics of Arf1. 
Identification of regions in the N terminus of GBF1 that are important for the interaction with 
3A.
 The N-terminal part upstream of the Sec7 domain of GBF1 is sufficient for the interaction 
with 3A (Wessels et al., 2006a). To gain more insight into the region(s) of GBF1 that is (are) 
responsible for the interaction with 3A, we made deletion constructs of the N terminus of GBF1 
(Fig. 5A) and tested them for interaction with 3A by mammalian two-hybrid (Fig. 5B). Two homology 
domains have been identified in the N-terminal part of GBF1: the dimerization/cyclophilin binding 
(DCB) domain and the homology upstream of Sec7 (HUS) domain (Mouratou et al., 2005). Deletion 
of the DCB domain (GBF1-II) completely abrogated the interaction with 3A. Combined deletion of 
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Fig. 3. Interaction of 3A mutants with GBF1 and effect on GBF1 dynamics. (A) Interaction of 3A wt, 3A-REIKI, 3A-ins16S, 
3A-PPP, 3A-LL and 3A-VREY with the N-terminal part of GBF1 in yeast two-hybrid. The upper, middle, or lower panel show 
growth of yeast on non-selective medium (leucine- and tryptophane-deficient medium), selective medium lacking histidine 
(-His), or selective medium lacking adenine (-Ade), respectively. (B) Interaction of 3A wt, 3A-REIKI, 3A-ins16S, 3A-PPP, 	
3A-LL and 3A-VREY with the N-terminal part of GBF1 in mammalian two-hybrid. The firefly luciferase activity measured at 48 h 
posttransfection is depicted. The activity measured with wild-type 3A and the GBF1 N terminus was set at 100%. (C) Dynamics 
of YFP-GBF1 when localized at dispersed membrane structures. FRAP traces of cells expressing YFP-GBF1 together 
with CFP-fusion proteins of 3A wt, 3A-ins16S, 3A-PPP, 3A-LL, or 3A-VDSE. (D) Dynamics of YFP-GBF1 when localized at 	
ER membranes. FRAP traces of cells expressing YFP-GBF1 either alone (no 3A), or together with CFP-fusion proteins of 
3A-REIKI or 3A-VDSE. The traces show the average recovery (n ≥ 10 cells) from at least two independent experiments. 	
The fluorescence intensity before bleaching was normalized to 1 and the fluorescence intensity directly after bleach to 0. The 
fluorescence intensity was corrected for bleaching of the cell during imaging and background fluorescence. For full colour 
figure, see page 140.
the HUS domain and the C-terminal region downstream of this domain (GBF1-III) also abolished 
the interaction with 3A, whereas deletion of the C-terminal region alone (GBF1-IV) had no effect. 
Deleting the extreme N terminus, i.e., the region upstream the DCB domain (GBF1-V), also 
abrogated the interaction with 3A. The importance of this latter region for the interaction with 3A 
was confirmed by showing that a GBF1 mutant in which the extreme N terminus was deleted from 
(full-length) GBF1 (GBF1∆N) was no longer able to interact with 3A in co-immunoprecipitation 
experiments (Fig. 5C). Together, these data indicate that both the extreme N terminus of GBF1 as 
well as the DCB and HUS domains are important for the 3A-GBF1 interaction.
A GBF1 mutant that lacks the extreme N terminus cannot rescue the effects of 3A.
 Previously, we showed that overexpression of GBF1 suppressed 3A function (Wessels 
et al., 2006a). Whereas COP-I is redistributed to the cytoplasm in almost all 3A-expressing cells, 
COP-I was still associated to membranes in most of the cells co-expressing GBF1 and 3A. In these 
latter cells, either an intact Golgi or dispersed membrane structures, which contained 3A, GBF1 and 
several Golgi markers, were observed (Wessels et al., 2006a). We sought to investigate whether 
the extreme N terminus of GBF1, which is important for the 3A-GBF1 interaction, is essential for 
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Fig. 4. Effect of 3A mutants on Arf1 
dynamics. The upper panel shows 
FRAP traces of cells expressing 	
Arf1-YFP either alone (no 3A), or 
together with CFP-fusion proteins of 	
3A wt, 3A-REIKI, or 3A-VDSE. The 
FRAP traces of Arf1-YFP in cells 
expressing 3A-ins16S, 3A-PPP, or 
3A-LL are similar to that observed in 
cells expressing 3A-REIKI. The FRAP 
trace of Arf1-YFP in cells expressing 
3A-VREY is similar to that in cells 
expressing 3A-VDSE. The lower panel 
shows halftime of fluorescence recovery 
values of Arf1-YFP when expressed 
alone, or together with 3A wt, 3A-REIKI, 
3A-ins16S, 3A-PPP, 3A-LL, 3A-VDSE, 
or 3A-VREY. The traces show the 
average recovery (n ≥ 10 cells) from at 
least two independent experiments. The 
fluorescence intensity was calculated as 
described in the legend to Fig. 2. For full 
colour figure, see page 140.
Fig. 5. Characterization of the interaction between GBF1 and 3A. (A) Schematic representation of the deletion mutants of the 
N terminus of GBF1. (B) Interaction of 3A with GBF1 deletion mutants in a mammalian two-hybrid system. The firefly luciferase 
activity measured at 48 h posttransfection is depicted. Average values and SEM of three experiments are shown. In each 
experiment, the activity measured with 3A and the intact GBF1 N terminus was set at 100%. (C) Co-IP experiments. 3A-myc 
is specifically coprecipitated from cells co-transfected with YFP-GBF1 but not from cells co-transfected with YFP-GBF1∆N or 
Golgi-GFP. GBF1-I, aa 1-710 of GBF1; GBF1-II, aa 1-52 and 295-710 of GBF1; GBF 1-III, aa 1-392 of GBF1 ; GBF1-IV, aa 
1-566 of GBF1 ; GBF1-V, aa 52-710 of GBF1; GBF1∆N, GBF1 lacking aa 1-37.
this effect. Overexpression of GBF1 or GBF1∆N had little, if any, effect on the localization of COP-I 
(Fig. 6A). Consistent with previous results, co-expression of GBF1 and 3A gave rise to dispersed 
membrane structures that contained both proteins and that also contained COP-I (Fig. 6B and C) 
(Wessels et al., 2006a). In contrast, COP-I was redistributed to the cytosol in cells co-expressing 
GBF1∆N and 3A, indicating that the N terminus of GBF1 is required for its ability to counteract the 
effects of 3A (Fig. 6C). In these cells, 3A localization was similar to that in cells expressing 3A alone 
and no colocalization with GBF1∆N was observed (Fig. 6B).  
Discussion
 Previously, we showed that the CVB3 3A protein interferes with ER-to-Golgi transport 
by binding GBF1, a GEF that catalyzes Arf1 activation, and trapping it on membranes, thereby 
inhibiting Arf1-mediated COP-I recruitment (Wessels et al., 2006a). This study was undertaken to 
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Fig. 6. A GBF1 mutant that lacks the extreme N terminus cannot rescue the effects of 3A. (A) Cells expressing YFP-GBF1 or 
YFP-GBF1∆N are stained for COP-I. (B) Images showing GBF1 (left) and 3A (right). Cells expressing YFP-GBF1 and 3A-myc 
or YFP-GBF1∆N and 3A-myc are stained for the Myc tag. (C) Images showing GBF1 (left) and COP-I (right). Cells expressing 
YFP-GBF1 and 3A-myc or YFP-GBF1∆N and 3A-myc are stained for COP-I. GBF1∆N, GBF1 lacking aa 1-37. Bars represent 
10 µm. For full colour figure, see page 141.
gain more insight into the molecular determinants that are required for the interaction between 3A 
and GBF1. We characterized a number of 3A mutants and found that mutants that were unable 
to inhibit protein transport were no longer able to inhibit COP-I recruitment because they were 
unable to bind to GBF1 and trap it on membranes. We have shown that dimerization is important 
for efficient inhibition of protein transport (Wessels et al., 2006b). Here, we show that mutants that 
are impaired in dimerization (3A-ins16S, 3A-PPP, and 3A-LL [Wessels et al., 2006a; Wessels et 
al., 2006b]) are unable to bind GBF1, providing an explanation for their inability to inhibit transport. 
The 3A-REIKI mutant is also unable to inhibit protein transport. However, this mutant showed 
efficient dimerization (Wessels et al., 2006b) and therefore we speculated that the REIKI region 
might be involved in binding of a cellular partner. Here, we provide experimental evidence for this 
hypothesis by showing that the 3A-REIKI mutant is no longer able to bind GBF1. We hypothesize 
that dimerization is required for efficient exposure of the REIKI residues. In addition, dimerization 
may create other contact sites in 3A (i.e., other than the REIKI region) for the interaction with 
GBF1. 
 We also sought to identify the binding domain of 3A in GBF1. All ArfGEFs identified to 
date have a Sec7 domain, a conserved module of ~200 amino acids that carries the guanine-
nucleotide exchange activity and that has been studied extensively (Chardin et al., 1996; Jackson 
and Casanova, 2000). In contrast to the Sec7 domain, only little is known about the functions of 
the other GEF domains, which are likely to determine intracellular localization and intermolecular 
interactions (Chardin, 1996; Cullen and Chardin, 2000; Lee and Pohajdak, 2000; Derrien et al., 
2002; Mansour et al., 2002). The N-terminal part of GBF1 has been shown to be sufficient for 3A 
binding (Wessels et al., 2006a). By further deleting the N terminus of GBF1 we were able to show 
that at least the extreme N terminus as well as the DCB and HUS domains were important for the 
3A-GBF1 interaction. It remains to be established whether each of these regions contains contact 
sites for the interaction with 3A or, alternatively, that different parts of the protein fold together into a 
higher-order structure that provides a binding site for 3A. Elucidation of the structure of GBF1 would 
help to further define the binding domain of 3A in GBF1. 
 Previously, we showed that overexpression of GBF1 could rescue the 3A-mediated 
inhibition of Arf1 activation and COP-I recruitment (Wessels et al., 2006a). It is yet unknown how 
this rescue effect is mediated. Here, we showed that the extreme N terminus of GBF1 (i.e., the 
region that is required for interaction with 3A) is required for the GBF1 mediated suppression of 3A 
function. Despite this correlation, it remains to be established whether an interaction between 3A 
and GBF1 is important for the rescue effect. 
 The wt 3A protein localizes at the ER and a dispersed post-ER compartment, but most 
3A mutants that were defective in inhibiting protein transport localized at the Golgi complex. It can 
be speculated that upon its generation, 3A is first transported to the Golgi, where the majority of 
the endogenous GBF1 is localized (Kawamoto et al., 2002; Zhao et al., 2002; Cornell et al., 2006). 
Inhibition of GBF1 by 3A will lead to inactivation of Arf1, resulting in dissociation of COP-I from Golgi 
membranes. This will lead to disassembly of the Golgi since COP-I is required for the maintenance 
of the structural integrity of the Golgi (Lippincott-Schwartz et al., 1990). Treatment of cells with BFA 
has been shown to result in a rapid Golgi disassembly and redistribution of the Golgi proteins into the 
ER via membrane tubules that are formed in a highly dynamic manner and that mediate retrograde 
transport to the ER (Lippincott-Schwartz et al., 1990; Presley et al., 1998). Membrane tubules were 
occasionally observed in 3A-expressing cells. Thus, as in BFA-treated cells, Golgi disassembly and 
backflow into the ER in 3A-expressing cells probably occurs via membrane tubulation. 3A mutants 
that cannot inhibit GBF1 function and COP-I recruitment will remain localized at the Golgi complex. 
Remarkably, the 3A-REIKI mutant, which is also defective in GBF1 binding and inhibiting protein 
transport, localized mainly at the ER and only partially at the Golgi. We do not know why this mutant 
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localizes differently than the other mutants that are defective in inhibiting protein transport. It might 
be that the REIKI region contains determinants that are important for the export of 3A from the ER. 
However, the observation that human rhinovirus 2 3A, which is quite similar to CVB3 3A but which 
lacks the corresponding REIKI residues, is exported to the Golgi (chapter 6) argues against this 
possibility.
 Our FRAP experiments showed that all 3A mutants that were unable to inhibit transport 
(3A-REIKI, 3A-ins16S, 3A-PPP and 3A-LL) were no longer able to trap YFP-GBF1 on membranes. 
Remarkably, large differences were observed between the halftime of fluorescence recovery value 
(t1/2) of GBF1 in control cells and the defective mutant 3A-REIKI on the one hand (~4 s) and the 
defective mutants 3A-ins16S, 3A-PPP, and 3A-LL on the other hand (~20 s). The main difference 
between these mutants, which are all severely impaired in inhibiting COP-I recruitment and binding 
to GBF1, is their localization and effect on YFP-GBF1 localization. YFP-GBF1, which acts at multiple 
membrane sites from the ER through the medial Golgi, localized at the ER in control cells and 
in cells expressing the 3A-REIKI mutant. In contrast, in cells expressing the mutants 3A-ins16S, 
3A-PPP, and 3A-LL, YFP-GBF1 localized at dispersed membrane structures, which were shown 
previously to contain several Golgi markers (Wessels et al., 2006a). The idea that GBF1 dynamics 
is influenced by its localization is further supported by the observation that the t1/2 of YFP-GBF1 
that we measured in control cells (~4 s), where it localized at the ER, was quite different from that 
of GFP-GBF1 measured in the study by Szul et al. (~17 s), where it mainly localized at the Golgi 
(Szul et al., 2005). Although YFP-GBF1 localization in the mutant 3A-expressing cells is similar to 
that in cells expressing wt 3A, the t1/2 of GBF1 measured in these cells significantly differs from wt 
3A-expressing cells. This indicates that the inability of these defective 3A mutants to trap GBF1 
on membranes is not caused by differences in localization of GBF1, but rather by their severely 
reduced ability to bind to GBF1.
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Materials and Methods
 Cells and viruses. Buffalo green monkey (BGM) kidney cells were grown in minimal essential 
medium (MEM) (Gibco) supplemented with 10% fetal bovine serum. COS-1 cells were grown in Dulbecco’s 
modified Eagle’s medium (Gibco) supplemented with 10% fetal bovine serum. Cells were grown at 37°C in 
a 5% CO2 incubator. BGM cell monolayers were grown to subconfluence on coverslips in 24-well plates for 
immunofluorescence assays or in glass bottom dishes (WillCo Wells BV) for FRAP experiments and then 
transfected with 0.5 µg or 1 µg of plasmid DNA, respectively. Transfections were performed using FuGENE 6 
(Roche) according to the manufacturer’s instructions.
 Plasmids. p3A-myc constructs. The plasmids coding for the mutant 3A-myc proteins were generated 
by PCR amplification using pGFP-3A mutants as template. The forward and reverse primers for all mutants 
except the 3A-ins16S mutant introduced SalI and BamHI sites, respectively. The forward and reverse primers 
for the 3A-ins16S mutant introduced EcoRI and BamHI sites, respectively. The PCR products were cloned 
in p3A-myc (Wessels et al., 2005), from which the 3A coding sequence was removed using the restriction 
enzymes SalI and BamHI. Sequence analysis showed that all PCR products contained correct sequences. 
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 pCFP-3A constructs. pCFP-fusion constructs were generated by replacing the GFP coding sequence 
with the CFP coding sequence using the restriction enzymes NheI and SspBI. 
 pGBT9-3A constructs. pGBT9-3A was described before (Wessels et al., 2006a). The other constructs 
were generated by PCR on the 3A coding sequences of the mutants and cloning these PCR products in pGBT9 
using the restriction enzymes EcoRI and BamHI. 
 Mammalian two-hybrid constructs. pACT-3A was described before (Wessels et al., 2005). 
pACT-3A mutant plasmids were obtained by replacing the 3A wt sequence with mutant 3A sequences by using 
the enzymes Bst1107I and BamHI. Deletion mutants of GBF1 were first generated as YFP-fusion proteins by 
PCR amplification. The PCR products were cloned in pEYFP-C1 (Clontech) using the restriction enzymes BglII 
and SalI. Subsequently, the GBF1 coding sequences were removed using the restriction enzymes BclI and SalI 
and cloned in pBIND that was cut with BamHI and KpnI. 
 Venus-GBF1 constructs. Venus is a variant of YFP (Nagai et al., 2002) and will be referred to as YFP 
in the text. YFP-GBF1 was described previously (Niu et al., 2005). YFP-GBF1ΔN was constructed by deleting 
nucleotides 1-111 from the GBF1 coding region. 
 Immunofluorescence. Immunofluorescence assays were performed as described before (de Jong 
et al., 2003). The effect of 3A mutant proteins on COP-I was studied by staining 3A-myc expressing cells with 
a monoclonal anti-myc antiserum (Sigma; 1:200 diluted) and a polyclonal anti-COP-I (against α- and γ-COP) 
antiserum (from K. Frey and F. Wieland, Biochemie-Zentrum Heidelberg, Germany; 1:200 diluted). Pictures 
were taken under a Leica TCS NT microscope (Leica Lasertechnik GmbH, Heidelberg, Germany). Alexa fluor 
594 goat anti-rabbit immunoglobulin G and Alexa fluor 488 anti-mouse immunoglobulin G were obtained from 
Molecular Probes.
 FRAP experiments. The FRAP experiments were performed on a Zeiss LSM510Meta Confocal 
Microscope (Carl Zeiss GmbH, Jena, Germany) as described previously (Wessels et al., 2006a). Briefly, FRAP 
measurements were performed on time-lapse series that were taken at 37°C at a rate of 1 frame per sec using 
a 63x, 1.4 NA objective and pinhole settings such that < 2 µm optical slices were imaged. Cells were selected 
on the basis of co-expression of CFP-3A and YFP-GBF1 or Arf1-YFP. Regions of interest were selectively 
photobleached using the 514 nm line at 100% transmission.
 Yeast two-hybrid analysis. Yeast two-hybrid analysis was performed in strain AH109 (Clontech) 
as described previously (Wessels et al., 2006a). Briefly, the pGADT7 and pGBT9 fusion constructs were 
transformed into yeast by the Lithium Acetate method using carrier DNA and plated on non-selective plates 
(lacking leucine and tryptophan). After growth, the colonies were transferred to selective plates (lacking histidine 
or adenine).  
 Mammalian two-hybrid analysis. COS cells grown in 24-wells plates were transfected with a total 
of 0.75 µg plasmid DNA (1:1:1 mix of the pACT, pBIND, and pG5luc plasmids). At 48 h posttransfection, the 
cells were lysed, and both the firefly luciferase and Renilla luciferase enzyme activities were measured from 
the same cell lysate by use of a dual-luciferase reporter assay system (Promega), as described previously (De 
Jong et al., 2002). An analysis of the Renilla luciferase activities, encoded by the pBIND plasmid and allowing 
monitoring of the transfection efficiency, revealed no gross differences in efficiencies of transfection among 
the different samples. All pACT- and pBIND-fusion proteins were efficiently expressed (data not shown). The 
3A-GBF1 interaction was expressed as the firefly luciferase activity in co-expressing 3A and GBF1 fusion 
proteins and was normalized to 100% for cells co-expressing wild-type 3A and the complete N terminus of GBF1. 
The firefly luciferase activity measured in cells co-expressing mutant 3A and GBF1 proteins was normalized to 
the activity measured in cells co-expressing wild-type 3A and GBF1 fusion proteins (which was set at 100% in 
each experiment).  
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 Co-immunoprecipitation. Co-immunoprecipitation experiments were performed as described 
previously (Wessels et al., 2006a). Briefly, GFP- or YFP-fusion proteins that were co-expressed with 3A-myc in 
BGM cells were immunoprecipitated using an anti-GFP antibody (raised against recombinant GST-GFP). The 
presence of 3A-myc in these samples was checked by Western analysis using a polyclonal anti-myc antiserum 
(Affinity BioReagents).
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The 3A protein of the coxsackievirus B3 (CVB3), an enterovirus that belongs to the family of the picornaviruses, inhibits endoplasmic reticulum (ER)-to-Golgi transport. Recently, we elucidated the underlying mechanism by showing that CVB3 3A interferes 
with ADP-ribosylation factor (Arf)1-dependent COP-I recruitment to membranes by binding 
and inhibiting the function of GBF1, a guanine nucleotide exchange factor that is required 
for the activation of Arf1 (Wessels et al., 2006a). Here, we show that the 3A protein of 
poliovirus, another enterovirus, is also able to interfere with COP-I recruitment through the 
same mechanism. No interference with protein transport or COP-I recruitment was observed 
for the 3A proteins of any of the other picornaviruses tested here (human rhinovirus [HRV], 
encephalomyocarditis virus, foot-and-mouth disease virus, and hepatitis A virus). We 
show that the 3A proteins of HRV, which are the most closely related to the enteroviruses, 
are unable to inhibit COP-I recruitment, due to a reduced ability to bind GBF1. When the 
N terminal residues of the HRV 3A proteins are replaced by those of CVB3 3A, chimeric 
proteins are produced that have gained the ability to bind GBF1 and, by consequence, to 
inhibit protein transport. These results show that the N terminus of the CVB3 3A protein is 
important for binding of GBF1 and its transport inhibiting function. Taken together, our data 
demonstrate that the activity of the enterovirus 3A protein to inhibit GBF1-dependent COP-I 
recruitment is unique among the picornaviruses.
Introduction
 Picornaviruses are small viruses with a single-stranded RNA genome of positive polarity. 
The picornavirus family contains the enteroviruses (e.g. poliovirus [PV], human enterovirus A [HEV-
A], HEV-B, which include the coxsackieviruses B [CVB], HEV-C, and HEV-D), rhinoviruses (e.g. 
human rhinovirus [HRV]), cardioviruses (e.g. encephalomyocarditis virus [EMCV]), aphthoviruses 
(e.g. foot-and-mouth disease virus [FMDV]), hepatoviruses (e.g. hepatitis A virus [HAV]), 
parechoviruses, erboviruses, kobuviruses, and teschovirus (Stanway et al., 2000). They share 
essentially one common genome organization (Stanway et al., 2000). The viral genome contains 
one single open reading frame that encodes a large polyprotein. The polyprotein is processed by 
virus-encoded proteases to generate the individual structural and nonstructural proteins, as well 
as some relatively stable cleavage intermediates. Many functions have been connected to the 
nonstructural proteins, but their exact role in the viral life cycle is still not fully understood (Leon et 
al., 2002). 
 One of the nonstructural proteins is the 3A protein, a small hydrophobic membrane protein. 
Among the picornaviruses, the 3A protein of the enteroviruses is studied best. Several mutations 
in the enterovirus 3A protein were shown to cause defects in viral RNA replication (Bernstein et al., 
1986; Giachetti et al., 1992; Hope et al., 1997; Teterina et al., 2003; Wessels et al., 2005, Xiang 
et al., 1995). Moreover, amino acid (aa) changes in the 3A protein have been shown to alter host 
range and tropism of enterovirus, HRV, and FMDV, although it is not known how this is mediated 
(Beard and Mason, 2000; Harris and Racaniello, 2005; Lama et al., 1998; Nunez et al., 2001). 
Finally, the enterovirus 3A proteins inhibit ER-to-Golgi transport (Doedens and Kirkegaard, 1995, 
Wessels et al., 2005). This inhibition is not absolutely required for replication in tissue culture cells. 
Instead, the results of several in vitro and in vivo studies suggest that the inhibition of protein 
transport plays a role in the evasion of immune responses (Deitz et al, 2000; Dodd et al., 2001; 
Neznanov et al., 2001; Wessels et al., 2006a). 
 We recently identified the mechanism by which the CVB3 3A protein inhibits ER-to-Golgi 
transport (Wessels et al., 2006a). Bidirectional transport between the ER and Golgi depends on 
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COP-II and COP-I coat complexes (Aridor et al., 1995; Scales et al., 1997). Recruitment of the 
COP-I coat to membranes is regulated by the GTPase ADP-ribosylation factor-1 (Arf1) (Donaldson 
et al., 1991). Arf1 is converted from its inactive, GDP-bound state to an active, GTP-bound state 
by guanine nucleotide exchange factors (GEFs), like GBF1 (Donaldson and Jackson, 2000). We 
showed that CVB3 3A blocks Arf1 activation by interacting with GBF1 and trapping it on membranes 
(Wessels et al., 2006a). As a result, COP-I can no longer be recruited to membranes and protein 
transport is inhibited. 
 In addition to this transport inhibiting function, the PV 3A protein, and also the 3CD protein, 
were recently shown to recruit Arf proteins to membranes when expressed alone in an in vitro 
system using HeLa cell extracts (Belov et al., 2005). This activity is proposedly involved in the 
recruitment of Arf to the viral replication complexes. How the 3A protein can be involved in two 
such seemingly opposed functions (i.e., inhibition of transport by inhibiting Arf activation on the one 
hand and replication complex formation by recruiting Arf to membranes on the other hand) is yet 
unknown, but both observations clearly indicate that the Arf machinery is an important target of the 
enterovirus 3A protein.    
 This study focuses on the possible transport inhibiting function of the 3A proteins of other 
picornaviruses. This function of the enterovirus 3A protein is not necessarily conserved among 
the different genera since the nomenclature of the picornavirus proteins is solely based on their 
position in the viral RNA genome. Here, we investigated the putative transport inhibiting function of 
the picornavirus 3A proteins, with a special focus on their ability to inhibit GBF1-dependent COP-I 
recruitment to membranes. 
Results and Discussion
Only enterovirus 3A proteins, but none of the other picornavirus 3A proteins, interfere with 
COP-I recruitment to membranes.
 We investigated the ability of the 3A proteins of CVB3, PV1, HRV2 (a group A HRV), 
HRV14 (a group B HRV), EMCV, FMDV, and HAV to interfere with COP-I recruitment to 
membranes (Fig. 1A). Since antibodies against all of the picornavirus 3A proteins used in this 
study were not readily available, we generated C-terminal Myc fusions of the 3A proteins. BGM 
cells expressing the 3A proteins were stained with antibodies against the Myc tag and COP-I. Due 
to differences in transfection efficiencies of the different constructs, we assayed the effects of the 
picornavirus 3A proteins on COP-I localization by examining similar, large numbers of individual 
cells with comparable expression levels. 3A-expressing cells were divided into three categories 
based on their COP-I localization: (i) COP-I-positive intact Golgi structures, (ii) COP-I-positive 
dispersed membrane structures, and (iii) COP-I exclusively in the cytosol. In non-transfected 
control cells, COP-I was typically localized to Golgi membranes (Fig. 1A). In the majority of cells 
expressing CVB3 3A, COP-I was redistributed to the cytosol and the 3A protein localized in the 
ER and a post-ER compartment that was partially positive for COP-II, as described previously 
(Fig. 1A and B) (Wessels et al., 2006a; Wessels et al., 2005). COP-I localization in cells expressing 
PV1 3A varied among cells. In the majority of the PV1 3A-expressing cells, COP-I recruitment 
was strongly affected. In about half of these cells, COP-I was redistributed to the cytosol. In these 
cells, PV1 3A showed a localization pattern that was similar to that of CVB3 3A. In the other 
half of the cells, which were generally cells with lower PV1 3A expression levels, 3A and COP-I 
were associated with dispersed membrane structures (Fig. 1A and B). Remarkably, this was not 
observed in cells expressing lower levels of CVB3 3A, suggesting that this protein is a little more 
potent than PV 3A in inhibiting COP-I recruitment to membranes. 
 No effect on COP-I recruitment and localization was observed upon expression of the 
Transport inhibition by picornavirus 3A proteins
85
3A proteins of HRV14 or HRV2, both of which localized to the Golgi complex (Fig. 1A and B). 
In addition, no effect on COP-I recruitment was observed in cells expressing the 3A proteins 
of EMCV and FMDV, both of which localized in the ER (as shown by colocalization with an ER 
marker, data not shown), or HAV, which localized to an unidentified compartment that showed no 
overlap with markers for the ER, Golgi, ER exit sites, endosomes, lysosomes and mitochondria 
(Fig. 1A and B). 
 We also tested the effects of these picornavirus 3A proteins on intracellular transport. To 
this end, we monitored the trafficking of the temperature-sensitive mutant of the vesicular stomatitis 
virus glycoprotein (VSVG), a well-known marker for protein trafficking that at 40°C accumulates 
in the ER, but after shifting to the permissive temperature (32°C) is transported to the plasma 
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Fig. 1. Effects of picornavirus 3A proteins on COP-I recruitment to membranes and VSVG trafficking. (A) Graph representing 
COP-I distribution in 3A-expressing cells. The bars show the means ± standard error of the mean (SEM) of the percentage of 
cells in which COP-I was redistributed to the cytosol, or localized at intact Golgi or dispersed membrane structures, as calculated 
from at least 400 cells, which were counted in groups of ~100 cells in two independent experiments. As a control, we determined 
COP-I localization in cells expressing the CVB3 2B protein (no 3A). (B) BGM cells expressing Myc-tagged CVB3, PV1, HRV14, 
HRV2, EMCV, FMDV, or HAV 3A proteins are stained for the Myc tag and COP-I (α/γ-COP). Asterisks indicate 3A-positive 
cells. (C) Graph showing the percentage of cells in which the VSVG protein was localized to the plasma membrane. At 40°C, 
VSVG is improperly folded, and as a consequence retained in the ER. Upon shifting to the permissive temperature (32°C), 
VSVG is correctly folded and transported to the plasma membrane. The graph shows the means ± SEM of the percentage of 
cells in which VSVG localized at the plasma membrane, calculated from at least 200 cells, which were counted in groups of 	
~50 cells in two independent experiments. CVB3, coxsackievirus B3; PV1, poliovirus; HRV14, human rhinovirus 14; HRV2, 
human rhinovirus 2; EMCV, encephalomyocarditis virus; FMDV, foot-and-mouth disease virus; HAV, hepatitis A virus. a, 
significantly different from control cells without 3A (calculated by Student t-test, P < 0.05). 
membrane. In the majority of cells expressing CVB3 3A or PV1 3A, transport of VSVG out of the ER 
was blocked at the permissive temperature (Fig. 1C). This strongly suggests that transport is also 
inhibited in the PV1 3A-expressing cells in which COP-I was observed at dispersed membranes. 
None of the other picornavirus 3A proteins tested interfered with VSVG trafficking to the plasma 
membrane (Fig. 1C). 
 Together, these data indicate that only the 3A proteins of CVB3 and PV1, both belonging 
to the genus enterovirus, inhibit transport and do so by interfering with COP-I recruitment. While 
this work was in progress, the group of Kirkegaard reported similar results (Choe et al., 2005). 
These authors showed that only the 3A proteins of PV1, PV3, and CVB3, but not those of HRV14, 
enterovirus type 71, HAV, Theiler’s virus (a cardiovirus), and FMDV were able to inhibit ER-to-Golgi 
transport, as monitored by the acquisition of Golgi-specific modifications resulting in endoglycosidase 
H resistance of the VSVG protein. Our finding that the 3A proteins of CVB3 and PV1 interfere with 
COP-I recruitment to membranes provides a plausible explanation for their observations. Moreover, 
our finding that the 3A proteins of the other picornaviruses do not interfere with trafficking of VSVG 
to the plasma membrane demonstrates that these proteins have no inhibitory effect on transport 
through or beyond the Golgi complex. The inability to block transport of FMDV 3A, EMCV 3A and 
HAV 3A is likely related to the large differences in amino acid sequence between those proteins and 
the enterovirus 3A (data not shown). 
The HRV 3A proteins do not trap GBF1 on membranes.
 Enteroviruses and HRVs are very closely related in sequence and functional terms and 
it has even been suggested that they be combined into one genus (Stanway et al., abstract A05, 
Europic 2005, Lunteren, The Netherlands). Alignment of the 3A proteins of CVB3, PV1, HRV14, 
and HRV2 (Fig. 2A) showed that the 3A protein of PV1 shares 51% identity and 85% homology with 
CVB3 3A. HRV14 3A shares 50% identity and 81% homology with CVB3 3A and 49% identity and 
82% homology with PV1 3A. Notwithstanding this high sequence homology, the transport inhibiting 
activity is not conserved in the HRV 3A proteins.
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Fig. 2. The HRV 3A proteins have a reduced ability to bind GBF1 and inhibit its function. (A) Alignment of enterovirus and 
HRV 3A proteins. Gray boxes indicate the hydrophobic regions of the 3A proteins, as predicted using the Kyte and Doolittle 
method. (B) FRAP traces of cells expressing YFP-GBF1 either alone (no 3A), or together with CFP-fusion proteins of the 
3A proteins of CVB3, PV, HRV14, or HRV2. The traces in the graphs show the average recovery (n > 10 cells), from at 
least two independent experiments. The fluorescence intensity before bleaching was normalized to 1 and the fluorescence 
intensity directly after bleaching to 0. The fluorescence intensity was corrected for bleaching of the cell during imaging and for 
background fluorescence. (C) Interaction of the 3A proteins of CVB3, PV1, HRV14 and HRV2 with the N-terminal part of GBF1 
as assayed by yeast two-hybrid analysis. Upper, middle, and lower panels show growth of yeast on non-selective medium 
(leucine- and tryptophane-deficient medium), selective medium lacking histidine (-His) and selective medium lacking adenine 
(-Ade), respectively. CVB3, coxsackievirus B3; PV1, poliovirus 1; HRV14, human rhinovirus 14; HRV2, human rhinovirus 2. For 
full colour figure, see page 142.
 We reasoned that the inability of the HRV 3A proteins to block COP-I recruitment to 
membranes is most likely due to their inability to inhibit the function of Arf1, the GTPase that is 
responsible for COP-I recruitment. We have shown that CVB3 3A interferes with Arf1 activation 
by inhibiting the dynamic behavior and function of GBF1 (Wessels et al., 2006a), a GEF for Arf1 
that under normal conditions rapidly cycles on and off membranes (Niu et al., 2005). We studied 
the dynamics of GBF1 in cells co-expressing YFP-GBF1 and CFP-fusions of the 3A proteins of 
CVB3, PV1, HRV14 and HRV2 by Fluorescence Recovery After Photobleaching (FRAP) analysis 
(Fig. 2B). In control cells expressing YFP-GBF1, which localized mainly at the ER but to some 
extent also at the Golgi, the fluorescence recovered rapidly to the bleached region. In cells co-
expressing CVB3 or PV1 3A and GBF1, which colocalized on dispersed membranes (Wessels 
et al., 2006a), the YFP-GBF1 fluorescence recovered very slowly and only to a limited extent, 
indicating that these 3A proteins trap GBF1 on the dispersed membranes (Fig. 2B). In cells co-
expressing HRV2 3A and GBF1, which colocalized mainly in the ER and at dispersed membranes, 
fluorescence recovered rapidly to the bleached region with a kinetics similar to that observed in 
control cells. Recovery of fluorescence was also observed in cells co-expressing HRV14 3A and 
GBF1, which colocalized mainly at Golgi structures and dispersed membranes, but the kinetics was 
slower than that observed in control cells and HRV2 3A-expressing cells (Fig. 2B). 
 It is likely that the reduced ability of the HRV 3A proteins to trap GBF1 on membranes is 
due to a reduced ability of these proteins to interact with GBF1. To study this, we tested the binding 
between the 3A proteins and GBF1. Previously, we have shown an interaction in a yeast two-
hybrid system between the cytosolic part of CVB3 3A (3A[1-60]) and the N terminal part of GBF1 
(i.e., the region upstream of the catalytic Sec7 domain) (Wessels et al., 2006a). We used this yeast 
two-hybrid system to test whether the corresponding regions of the 3A proteins of PV1, HRV2 and 
HRV14 were able to bind to GBF1 (Fig. 2C). A strong interaction between the two proteins results in 
the growth of white colonies on both selective media lacking histidine or adenine, whereas a weak 
interaction results in the growth of red colonies on selective medium lacking histidine. Both the 
CVB3 and PV1 3A proteins strongly interacted with GBF1 (Fig. 2C). In contrast, HRV14 3A showed 
a weak interaction with GBF1, whereas no interaction between HRV2 3A and GBF1 was detected 
(Fig. 2C). Together, it can be concluded that the inability of the HRV 3A proteins to interfere with 
COP-I recruitment to membranes is a result of their reduced ability to bind GBF1.
 
Importance of the N terminus of 3A to inhibit protein transport.
 All human enteroviruses sequenced to date contain a residue with positive charge at 
position 9 (numbering refers to CVB3 3A). Strikingly, the HRV14 3A protein contains a negatively 
charged residue at the corresponding position. Choe et al. showed that substitution of this negatively 
charged residue for a positively charged residue conferred a partial ability to the HRV14 3A protein 
to inhibit protein secretion (Choe et al., 2005). To investigate whether this single difference in the 
N terminus of HRV14 3A could increase its ability to inhibit GBF1, we substituted the negatively 
charged Glu in HRV14 3A for a positively charged Lys (HRV14 3A-E8K). The HRV14 3A-E8K 
mutant showed an increased ability to interfere with VSVG transport and COP-I recruitment to 
membranes compared to HRV14 3A wt (Fig. 3A and B). In ~35% of the cells expressing HRV14 
3A-E8K, COP-I was redistributed to the cytoplasm. In these cells, HRV 3A-E8K showed a 
localization pattern that was similar to that of CVB3 3A (Fig. 3C). HRV14 3A-E8K was expressed to 
similar levels as HRV14 3A wt, making it unlikely that its increased ability to block transport is due 
to a higher expression level.
 Next, we investigated whether the E8K mutation also increased the ability of HRV14 3A 
to bind GBF1. Indeed, the HRV14 3A-E8K mutant showed a strong interaction with GBF1 in yeast 
two-hybrid analysis, whereas HRV14 3A wt showed only a weak interaction with GBF1 (Fig. 3D). 
Chapter 6
88
In cells co-expressing HRV14 3A-E8K and GBF1, which colocalized on dispersed membranes, 
YFP-GBF1 fluorescence recovered very slowly and only to a limited extent, indicating that the 
HRV14 3A-E8K mutant is much more potent to trap GBF1 on membranes than the HRV14 3A wt 
protein (Fig. 3E). Together, these results indicate that a single substitution in the N terminus of the 
HRV14 3A protein improved its ability to bind and inhibit GBF1 and thereby conferred the ability to 
inhibit protein transport.
 It may seem remarkable that mutation E8K conferred only a partial ability to interfere 
with protein trafficking and COP-I recruitment to HRV14 3A, whereas the HRV14 3A-E8K mutant 
interacted with GBF1 and trapped it on membranes as efficiently as CVB3 3A (which is far more 
potent in inhibiting COP-I recruitment to membranes and VSVG trafficking). These differences may 
be explained by the semi-quantitative nature of the yeast-two hybrid test and the selective analysis 
of cells in the FRAP experiments. In the FRAP experiments only cells expressing higher levels of 
CFP-3A were taken into account, since cells with low or moderate 3A expression were in general 
poorly visible due to the relatively low fluorescence yield of CFP. 
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Fig. 3. The N terminus of 3A is very important for its transport inhibiting function. (A) Graph showing the percentage of cells in 
which the VSVG protein was localized at the plasma membrane. The percentages were calculated as described in the legend 
to Fig. 1. (B) Graph showing the COP-I localization in cells expressing HRV14 3A-E8K, C3H14 3A, C3H2 3A, or C3PV 3A. The 
percentages were calculated as described in the legend to Fig. 1. (C) BGM cells expressing Myc-tagged mutant or chimeric 3A 
proteins (HRV14 3A-E8K, C3H14 and C3H2) are stained for the Myc tag to show their localization. (D) Interaction of the mutant 
or chimeric 3A proteins (HRV14 3A-E8K, C3H14 and C3H2) with the N-terminal part of GBF1 as assayed by yeast two-hybrid 
analysis. The results are depicted as described in the legend to Fig. 2. (E) FRAP traces of cells co-expressing YFP-GBF1 and 
CFP-fusion proteins of HRV14 3A (wild-type or E8K). Traces were calculated as described in the legends to Fig. 2. HRV14, 
human rhinovirus 14; HRV2, human rhinovirus 2; C3H14, CVB3/HRV14 3A chimeric protein; C3H2, CVB3/HRV2 3A chimeric 
protein; C3PV, CVB3/PV1 3A chimeric protein. a, significantly different from HRV14 3A wt expressing cells; b, significantly 
different from HRV2 3A wt expressing cells; c, significantly different from PV1 3A wt expressing cells (calculated by Student 
t-test, P < 0.05). For full colour figure, see page 143.
 The above-mentioned HRV14 3A-E8K mutation provides only a partial ability to interfere 
with COP-I recruitment and to inhibit VSVG transport. We asked ourselves whether substitution 
of other residues in the N terminus might further increase the transport inhibiting activity of the 
HRV14 3A protein. To investigate this, we constructed a chimeric protein in which the N-terminal 14 
aa of HRV14 3A were replaced by the corresponding 16 aa of CVB3 3A (note that the N terminus 
of HRV14 3A lacks 2 residues compared to that of CVB3 3A, Fig 2A). The chimeric CVB3/HRV14 
3A protein (C3H14), which was expressed at similar levels as HRV14 3A wt, was very potent 
in interfering with VSVG transport and COP-I recruitment to membranes (Fig. 3A and 3B), and 
showed a localization pattern that was similar to that of CVB3 3A (Fig. 3C). As expected, the 
C3H14 3A chimeric protein showed a strong interaction with GBF1 (Fig. 3D). Thus, substitution of 
the N terminus of HRV14 3A for the corresponding region of CVB3 3A further improved the ability 
to interfere with transport and COP-I recruitment compared to the HRV14 3A-E8K mutant. Taken 
together, the results of the mutant and chimeric HRV14 3A proteins show that the N terminus of 3A 
is very important for the protein transport inhibiting function.
 The HRV2 3A protein shares 38%, 37% and 40% identity with CVB3, PV1, and HRV14 
3A, respectively (Fig. 2A). Among these four viruses, the N terminus of HRV2 3A in particular differs 
strongly from the N termini of the three other 3A proteins: it lacks 9 aa in its N terminus compared 
to CVB3 3A. Also in the rest of the HRV2 3A protein, there are some major differences compared 
to the other 3A proteins (Fig. 2A). To investigate whether these latter differences affect a putative 
transport inhibiting function, we constructed a chimeric protein in which the N terminal 7 aa of HRV2 
3A were replaced by the corresponding 16 aa of CVB3 3A. The ability of this C3H2 3A chimeric 
protein to interfere with VSVG transport and COP-I recruitment to membranes was significantly 
increased compared to the wild-type HRV2 3A and was similar to that of CVB3 3A and the above-
described C3H14 chimeric 3A (Fig. 3A and B). Also the localization of C3H2 3A was similar to that 
of CVB3 3A and C3H14 3A, and C3H2 3A showed a strong interaction with GBF1 (Fig. 3C and D). 
Thus, although the HRV2 3A protein shows a number of distinct differences compared to the 3A 
proteins of enteroviruses and HRV14, substitution of its N terminus by that of CVB3 3A provides the 
capability to inhibit protein transport with high efficiency. 
 We also constructed a chimeric PV1 3A protein containing the N-terminal 16 aa of 
CVB3 (C3PV 3A). This chimeric protein was generated based on the observation that COP-I was 
redistributed to the cytosol in almost all CVB3 3A-expressing cells, whereas in about half of the 
PV1 3A-expressing cells only an intermediate effect on COP-I was observed (i.e., some COP-I 
was found on dispersed membrane structures) (Fig. 1A). This finding suggested that CVB3 3A is 
(a little bit) more potent in inhibiting COP-I recruitment to membranes than PV1 3A. Indeed, we 
found that a chimeric PV1 3A protein containing the N-terminal 16 aa of CVB3 was much more 
potent in redistributing COP-I to the cytoplasm than PV1 3A (Fig. 3B), supporting the idea that small 
differences in the N terminus make the CVB3 3A more active in inhibiting transport. Our findings 
that PV1 3A was equally potent as CVB3 3A in interacting with GBF1 in yeast two-hybrid and that 
GBF1 is trapped on membranes equally efficient by CVB3 3A and PV1 3A does not argue against 
this idea, because of the same reasons as described above for the HRV-E8K mutant (i.e., semi-
quantitative nature of yeast two-hybrid and selective analysis of high expressing cells in FRAP 
experiments). 
 
Implications for the viral life cycle. 
 As shown above, the N terminus of 3A is important for its protein transport inhibiting 
function. The 3A proteins of CVB3, PV1 and PV3 inhibit protein transport (Choe et al., 2005; 
Doedens and Kirkegaard, 1995; Wessels et al., 2005). CVB3 belongs to the HEV-B species 
(which include all CVB and ECHOviruses, CVA9 and some unassigned enterovirus serotypes). 
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The N termini of the 3A proteins of all members of this species are nearly identical, suggesting 
that all of them inhibit protein transport. The high similarity between the 3A proteins of the HEV-B 
and HEV-D species (which includes enterovirus types 68 and 70) suggests that the 3A proteins 
of these latter viruses also inhibit transport. The strong resemblance between the N termini of the 
3A proteins of PV and enteroviruses belonging to the HEV-C species (which include a number of 
CVA), suggests that the transport inhibiting function is also conserved in HEV-C 3A proteins. In 
contrast, the 3A protein of enterovirus type 71, a member of the HEV-A species (which furthermore 
includes enterovirus types 76, 89, 90, and 91, and a number of CVA), was found to be unable to 
inhibit transport (Choe et al., 2005). Remarkably, this virus (and also all other HEV-A members 
and the bovine and porcine enteroviruses sequenced to date) contain a proline at position 7 in 3A, 
whereas all other enteroviruses contain a negatively charged residue at this position. It remains to 
be established whether this amino acid is responsible for the inability of the enterovirus type 71 3A 
protein to inhibit transport. If so, then it is likely that the other HEV-A members and the non-human 
enteroviruses mentioned above are also impaired in this function. 
 The inhibition of protein transport by PV and CVB3 has been suggested to be important 
for the suppression of immune responses such as cytokine secretion and MHC exposure (Deitz 
et al., 2000; Dodd et al., 2001; Neznanov et al., 2001; Wessels et al., 2006a). Picornavirus 3A 
proteins that are unable to inhibit protein transport can likely not aid in the inhibition of trafficking 
of cytokines and MHC molecules. Possibly, transport inhibition by other viral proteins aids in this 
immune evasion. The 2B proteins of enterovirus (Doedens and Kirkegaard, 1995; de Jong et al., 
2006) and HRV14 (de Jong and van Kuppeveld, unpublished data) as well as the 2BC protein of 
FMDV have also been reported to inhibit protein transport (Moffat et al., 2005). Whether EMCV 
and HAV also express proteins that can inhibit protein transport is unknown. Furthermore, it should 
be emphasized that the inhibition of protein transport is not the only viral activity that determines 
immune evasion. Several other mechanisms have been described by which picornaviruses can 
evade the immune responses. Several picornaviruses shut off host cell transcription (enterovirus, 
HRV, and FMDV) and translation (enterovirus, HRV, EMCV, and FMDV), thereby interfering with 
the production of host cell proteins with anti-viral function (Borman and Keane, 1997; Devaney 
et al., 1988; Ehrenfeld, 1982; Gingras et al., 1996; Tesar and Marquardt, 1990; Weidman et al., 
2003). Moreover, enteroviruses, HRV, and EMCV inhibit nuclear import pathways, possibly to 
prevent signal transduction into the nucleus (Justin and Sarnow, 2002; Lidsky et al., 2006). The 
consequence of the inability of picornavirus 3A proteins to inhibit protein transport for the evasion 
of immune responses is hence difficult to define. 
 All picornaviruses replicate their RNA genome at modified membranes that accumulate 
in the cytosol of infected cells. However, the mechanisms by which the replication complexes 
are formed differ among the different picornaviruses, as shown by different sensitivities towards 
the inhibitory action of the drug Brefeldin A (BFA). Enterovirus, rhinovirus and HAV replication is 
blocked by BFA, whereas BFA has little effect on replication of EMCV and FMDV (Blank et al., 
2000; Gazina et al., 2002; Irurzun et al., 1992; O’Donnell et al., 2001). For enteroviruses, it has 
been suggested that these rearranged membranes are derived from the secretory pathway through 
the action of the viral 2BC protein (Bienz et al., 1994), possibly in conjunction with the 3A protein 
(Suhy et al., 2000). Alternatively, or in addition, it has been suggested that enteroviruses subvert 
constituents of the cellular autophagy pathway to form membrane scaffolds for viral RNA replication 
through the combined actions of the 2BC and 3A proteins (Jackson et al., 2005). Subversion of 
constituents of the autophagy pathway was also observed in cells infected with HRV (Jackson et 
al., 2005). The observation that enteroviruses carrying a mutation in 3A that rendered it defective 
in inhibiting transport replicated with wild-type characteristics suggested that, irrespective of the 
underlying mechanism, the 3A-mediated transport inhibition is not required for the accumulation 
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of the modified membranes (Doedens et al., 1997; Wessels et al., 2005). HRV infection leads to 
similar membrane rearrangements as observed in enterovirus-infected cells (Harris and Racaniello, 
2005). The finding that the 3A protein of HRV is unable to inhibit transport further supports the idea 
that the accumulation of the membranes at which viral replication takes place does not rely on 
transport inhibition by 3A.
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Materials and Methods
 Cells and DNA transfections. Buffalo green monkey (BGM) kidney cells were grown in minimal 
essential medium (Gibco) supplemented with 10% fetal bovine serum. Cells were grown at 37°C in a 
5% CO2 incubator. BGM cell monolayers were grown to subconfluency on coverslips in 24-well plates for 
immunofluorescence assays or in glass bottom dishes (WillCo Wells BV) for FRAP experiments and then 
transfected with 0.5 µg or 1 µg of plasmid DNA, respectively. Transfections were performed using FuGENE 6 
(Roche) according to the manufacturers instructions. Cells were grown at 37°C until further analysis, unless 
stated otherwise. 
 Plasmids. p3A-myc constructs. The plasmids coding for the different picornavirus 3A proteins were 
generated by PCR amplification using specific primers for the 3A coding sequences (See Table S1 in the 
supplemental material). The forward and reverse primers introduced SalI and BamHI sites, respectively. The 
PCR products were cloned in p2B-myc (de Jong et al., 2003), from which the 2B coding sequence was removed 
using the restriction enzymes SalI and BamHI. The following templates were used for PCR: pXPA (for PV) 
(Racaniello and Baltimore, 1981), pWR3.26 (for HRV14) (Lee et al., 1993), pHRV2/1 (for HRV2) (Duechler et 
al., 1989), pM16.1 (for EMCV, strain Mengo virus) (Duke and Palmenberg, 1989), pMR15 (for FMDV) (Rian et 
al., 1989), pHAV/7 (for HAV) (Cohen et al., 1987). Sequence analysis showed that all PCR products contained 
correct sequences. 
 pCFP-3A constructs. pCFP-fusion constructs were generated by cloning the 3A coding sequences 
of the different picornavirus 3A-myc constructs (using SalI/BamHI) into a modified EGFP-C3 vector cut with 
XhoI/BamHI. The GFP coding sequence was subsequently replaced with the CFP coding sequence using the 
restriction enzymes NheI and SspBI. 
 pGBT9-3A constructs. pGBT9-3A (CVB3) was described before (Wessels et al., 2006). The other 
constructs were generated by PCR amplifying the 3A coding sequences of the different picornaviruses and 
cloning these PCR products in pGBT9 using the restriction enzymes EcoRI and BamHI. The primers are 
depicted in Table S2 in the supplemental material. 
 pVSVG-GFP. The plasmid pVSVG-GFP (Toomre et al., 1999), which encodes the ts045 vesicular 
stomatitis virus glycoprotein (VSVG) fused to enhanced green fluorescent protein (EGFP) at its C terminus, was 
kindly provided by P. Keller and K. Simons (Max Planck Institute of Molecular Biology and Genetics, Dresden, 
Germany). 
 pYFP-GBF1. This plasmid was described previously (Niu et al, 2005).  
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 Immunofluorescence and VSVG trafficking. The effect of different picornavirus 3A proteins on 
COP-I membrane association was studied by staining 3A-myc expressing cells with a monoclonal anti-myc 
antiserum (Sigma; 1:200 diluted) and a polyclonal anti-COP-I (against α- and γ-COP) antiserum (from K. 
Frey and F. Wieland, Biochemie-Zentrum Heidelberg, Germany; 1:200 diluted). The subcellular localization of 
VSVG-GFP was determined as described previously (de Jong et al., 2003). Briefly, BGM cells expressing either 
VSVG-GFP alone or VSVG-GFP together with the picornavirus 3A-myc proteins were incubated at 40°C. After 
a 2 h temperature shift to 32°C, the cells were fixed and stained with anti-myc antiserum to detect the 3A-myc 
proteins, and a polyclonal anti-EGFP antiserum (raised against recombinant GST-EGFP) (1:200 diluted) to 
enhance the VSVG signal. The samples were analyzed using a Leica DMR microscope and pictures were taken 
under a Leica TCS NT microscope (Leica Lasertechnik GmbH, Heidelberg, Germany). Fluorescent conjugates 
were obtained from Molecular Probes. 
 FRAP experiments. The FRAP experiments were performed on a Zeiss LSM510Meta Confocal 
Microscope (Carl Zeiss GmbH, Jena, Germany) as described previously (Wessels et al., 2006). Briefly, FRAP 
measurements were performed on time-lapse series that were taken at 37°C at a rate of 1 frame per sec using 
a 63x, 1.4 NA objective and pinhole settings such that < 2 µm optical slices were imaged. Cells were selected 
on the basis of co-expression of CFP-3A and YFP-GBF1. Regions of interest were selectively photobleached 
using the 488 nm and 514 nm line at 100% transmission.
 Yeast two-hybrid analysis. Yeast two-hybrid analysis was performed in strain AH109 (Clontech) as 
described previously (Wessels et al., 2006). Briefly, the pGADT7 and pGBT9 fusion constructs were transformed 
into yeast by the Lithium Acetate method using carrier DNA and plated on non-selective plates (lacking leucine 
and tryptophan). After growth, the colonies were transferred to selective plates (lacking histidine or adenine). 
 Statistical analysis. Data are presented as mean values ± standard errors of the means. Differences 
were tested for significance by Student t-test. 
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Table S1. Primers for generation of 3A-myc fusion proteins of several picornaviruses.
Primer no. F/R 3A Sequence
389.1a F PV1 5’-GGG GGG GTC GAC GCC ACC ATG GGA CCA CTC CAG TAC AAA GAC -3’
389.2 R PV1, C3PV ch. 5’- GGG GGG GGA TCC CTG GTG TCC AGC AAA CAG TTT -3’
389.3 F HRV14 5’- GGG GGG GTC GAC GCC ACC ATG GGA CCA GTG TAT AAA GAT TTA -3’
389.4 R HRV14,C3H14 ch. 5’- GGG GGG GGA TCC TTG AGT TTG AGC AAA CAA TTT -3’
389.5 F HRV2 5’- GGG GGG GTC GAC GCC ACC ATG GGG CCA ATT GAT ATG AAA AAC -3’
389.6 R HRV2, C3H2 ch. 5’- GGG GGG GGA TCC CTG TAA TGT GCA AAA AAG TTT -3’
389.7 F EMCV 5’- GGG GGG GTC GAC GCC ACC ATG GGG CCT GTT GAT GAA GTT AGC -3’
389.8 R EMCV 5’- GGG GGG GGA TCC CTG TTC TTG CTC ATC CAG CTG -3’
389.9 F FMDV 5’- GGG GGG GTC GAC GCC ACC ATG ATC TCA ATT CCT TCT CAA AAA -3’
389.10 R FMDV 5’- GGG GGG GGA TCC TTC AGC TTG TGG TTG CTC CTC -3’
389.11a F HAV 5’- GGG GGG GTC GAC GCC ACC ATG GGA ATT TCA GAT GAC AAT GCA -3’
389.12 R HAV 5’- GGG GGG GGA TCC TTC AGC TGG GAT TGG TTC CTC -3’
389.16 F C3H14 ch.
5’- GGG GGG GTC GAC GCC ACC ATG GGA CCA CCA GTA TAC AGA 
GAG ATC AAA ATT AGC GTT GCA CCA GAG ACA CCA CCT CCA GAA 
TGT ATC AAC-3’
389.14 F C3H2 ch.
5’- GGG GGG GTC GAC GCC ACC ATG GGA CCA CCA GTA TAC AGA 
GAG ATC AAA ATT AGC GTT GCA CCA GAG ACA CCA CCA CCA CCT 
GCT ATT ACT-3’
389.15 F C3PV ch.
5’- GGG GGG GTC GAC GCC ACC ATG GGA CCA CCA GTA TAC AGA 
GAG ATC AAA ATT AGC GTT GCA CCA GAG ACA CCC CCT CCT GAA 
TGT ATC AAT-3’
389.17 F HRV143A-E8K
5’- GGG GGG GTC GAC GCC ACC ATG GGA CCA GTG TAT AAA GAT 
CTT AAG ATT GAT GTT TGC AAC ACA CCA-3’
F (forward primer): SalI site underlined; R (reverse primer): BamHI site italic
BfrI site bold for rapid identification of mutation E8K
C3PV ch., CVB3/PV1 3A chimera; C3H14 ch., CVB3/HRV14 3A chimera; C3H2, CVB3/HRV2 3A chimera
Table S2. Primers for generation of pGBT9-3A constructs of several picornaviruses.
Primer no. F/R 3A Sequence
389.18 F PV1 5’- GGG GGG GAA TTC AGT ATG GGA CCA CTC CAG TAC AAA-3’
389.19 R PV1 5’- GGG GGG GGA TCC CTA GAT GTT CCT TTC TGT TTG-3’
389.20 F HRV14 5’- GGG GGG GAA TTC AGT ATG GGA CCA GTG TAT AAA GAT-3’
389.21 R HRV14 5’- GGG GGG GGA TCC CTA CAT AGC CCT TTC TAT GTT-3’
389.22 F HRV2 5’- GGG GGG GAA TTC AGT ATG GGG CCA ATT GAT ATG AAA-3’
389.23 R HRV2 5’- GGG GGG GGA TCC CTA TTC TGC TGG AAT TAT CCA-3’
F (forward primer): EcoRI site underlined; R (reverse primer): BamHI site italic
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Chapter 7
SUMMARY AND GENERAL DISCUSSION
 Enteroviruses belong to the Picornaviridae, a family of small, positive-stranded RNA 
viruses. The best known enterovirus is the poliovirus (PV). Other viruses that belong to this genus 
are coxsackieviruses and ECHO viruses. Although many enterovirus infections are subclinical or 
mild, they can cause acute diseases, like myocarditis, viral meningitis, encephalitis, and paralysis. 
Furthermore, they have been implicated in some chronic diseases, like diabetes mellitus. The 
enteroviral genome contains one large open reading frame that is translated into a single polyprotein. 
Processing of the polyprotein yields several structural and nonstructural proteins. The nonstructural 
proteins are involved in vRNA replication and/or account for the virus-induced alterations in host 
cell metabolism and structure. These alterations serve to create an environment that is suitable 
for efficient vRNA replication and/or to suppress antiviral host cell responses. An extended review 
on the enterovirus classification, pathogenesis, genome organization, genome replication, and the 
enterovirus-induced modifications of the host cell is provided in chapter 1. 
 Enteroviruses are nonenveloped, cytolytic viruses that do not need an intact secretory 
pathway to release their virus progeny. Instead, infection with PV results in inhibition of protein 
transport and the 3A protein has been shown to play an important role in this inhibition (Doedens 
and Kirkegaard, 1995). The investigations described in this thesis were undertaken to elucidate the 
mechanism by which 3A interferes with protein transport and to gain more insight into the structure-
function relationship of the 3A protein.  
Summary of the main findings.
 To gain more insight into the structure and function of the enterovirus 3A protein, we used 
the coxsackievirus B3 (CVB3) 3A protein as a model protein in this study. In chapter 2, we provided 
evidence that both CVB3 infection and expression of the CVB3 3A protein inhibit transport of the 
membrane-bound secretory marker VSVG and the secreted soluble reporter protein A1PI. In CVB3 
infected cells or cells expressing the 3A protein alone, VSVG was found to accumulate in the ER 
and a dispersed post-ER compartment. 
 In the chapters 2 and 3, we described a structure-function analysis of the CVB3 3A 
protein. We generated a molecular model of the CVB3 3A protein, which is based on the NMR 
structure of the cytosolic part of PV 3A that was published while this project was ongoing (Strauss 
et al., 2003). The model showed that 3A forms a homodimer that contains two α-helices that form 
a helical hairpin, whereas the remaining N- and C-terminal tails seem to be unstructured. Based on 
this model and on sequence conservation amongst enteroviruses, we substituted several residues 
that were predicted to be involved in 3A dimerization. The constructed 3A mutants were tested for 
their ability to dimerize, to inhibit protein transport and to support vRNA replication. Following this 
approach, we showed that a hydrophobic interaction between the monomers and an intermolecular 
salt bridge are major determinants required for dimerization (chapter 3). Furthermore, dimerization 
was shown to be important for efficient inhibition of protein transport and for virus replication 
(chapter 3). 
 At the start of this project, the mechanism by which the enterovirus 3A protein inhibits 
ER-to-Golgi transport was unknown. Transport of proteins from the ER is mediated by the action 
of the COP-II coat complex. The action of the COP-I coat complex is required for the subsequent 
transport via the vesicular tubular complexes (VTC) to the Golgi. In chapter 4, we showed that 
expression of 3A in mammalian cells causes loss of COP-I from membranes and, by consequence, 
disassembly of VTC and Golgi structures. As a result, components of VTC and Golgi flow back to 
the ER and accumulate at or close to the COP-II coated ER exit sites, where 3A is also localized. 
Furthermore, our results provided evidence that 3A blocks activation of ADP-ribosylation factor-1 
(Arf1), the GTPase that recruits COP-I to membranes. 3A was shown to interact with GBF1, a 
guanine nucleotide exchange factor (GEF) that catalyzes activation of Arf1. GBF1, which normally 
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cycles rapidly on and off membranes, was trapped on membranes by 3A. Taken together, these 
results support a model in which 3A inhibits protein transport by interfering with GBF1 function, 
thereby inhibiting Arf1-mediated COP-I assembly.
 In chapter 5 we further characterized the interaction between 3A and GBF1. 
We demonstrated that mutant 3A proteins, which were shown to be defective in inhibiting secretion 
of a reporter protein (chapters 2 to 4), were unable to inhibit COP-I recruitment. We hypothesized 
that this could be explained by their inability to bind GBF1, or, alternatively, these mutants may still 
bind GBF1 but may no longer be able to affect its dynamics. We showed that 3A mutant proteins 
that were unable to inhibit COP-I recruitment could not inhibit GBF1 due to a severely reduced 
ability to bind to GBF1, supporting the first hypothesis. In addition, experiments were undertaken to 
further identify regions in GBF1 that were essential for the interaction with 3A. Therefore, several 
deletion mutants of GBF1 were tested for their ability to interact with 3A. We showed that at least 
two regions in the N terminus of GBF1 were essential for the interaction with 3A.
 The nomenclature of the picornavirus proteins is based on their position in the viral 
RNA genome. So, all picornaviruses have a 3A protein, but this does not necessarily imply that 
there is a conservation of function between the different genera. In chapter 6 we investigated 
the protein transport ability of the 3A proteins of several picornaviruses. The 3A protein of PV, 
another enterovirus, was able to interfere with COP-I recruitment through the same mechanism as 
CVB3 3A. In contrast, no interference with protein transport or COP-I recruitment was observed 
upon expression of any of the other picornavirus 3A proteins tested. We also showed that the 3A 
proteins of human rhinoviruses (HRV), which are most closely related to the enteroviruses, have a 
reduced ability to bind GBF1, due to differences in their N terminus compared to the enterovirus 3A 
protein.
Structure-function relationship of 3A.
 The structural model that is described in chapter 3 showed that CVB3 3A forms a 
homodimer. Each monomer consists of two α-helices, connected by a relatively large loop. 
A hydrophobic surface, which is made up from conserved residues in the α-helices or loop region 
(i.e. Ile22, Leu25, Leu26, Val29, and Val34), was predicted to form a dimer interface with the hydrophobic 
surface of the other molecule. Upon mutation of Leu25 and Leu26 to Ala residues, dimerization of 
3A was disturbed, suggesting that this hydrophobic packing is indeed important for dimerization. 
These residues were also indispensable for inhibition of protein transport and vRNA replication.
 Upon mutation of Asp24 to Ala (D24A), a number of viruses were isolated carrying 
second site suppressor mutations in 3A (chapter 3). All of the second site suppressor mutations 
occurred at residues Lys27 and Lys41, suggesting that residues at positions 24, 27 and 41 are 
functionally linked. These residues probably form intra- and intermolecular salt bridges, as was 
predicted in our model of the 3A protein. The intermolecular salt bridge between Asp24 and Lys41 
was predicted to be important for dimerization. The D24A mutant was indeed unable to form 
homodimers and, most likely by consequence, to inhibit protein transport and support vRNA 
replication. Second site suppressor mutations for D24A that conferred a (partial) ability to dimerize 
to the D24A mutant also improved inhibition of protein transport and vRNA replication, supporting 
the idea that dimerization of 3A is required for efficient inhibition of protein transport and vRNA 
replication. 
 Based on the structural model, several residues were predicted to be important for 
dimerization. However, mutation of the conserved Pro17, Pro18, and Pro19 immediately upstream of 
the first α-helix, which were not predicted to be involved in dimerization, also abolished dimerization 
(chapter 2). Mutation of these three residues simultaneously might disturb the overall structure of 
3A, rather than that these residues play a direct role in dimerization.
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 The conserved Arg6, Glu7, Ile8, Lys9, and Ile10 in the N terminus of 3A (further referred to as 
REIKI) were shown to be not important for dimerization (chapter 3). Mutation of all REIKI residues 
simultaneously disturbed vRNA replication and protein transport inhibition, whereas mutation of 
REIKI residues individually disturbed only protein transport inhibition, but not vRNA replication. 
Together, these data suggest that the REIKI residues play an important role in binding to a cellular 
partner. 
 Remarkably, the second site suppressor mutation S31C was found to rescue both 
the defect in vRNA replication caused by mutation P17A/P18A/P19A and by Y37A (chapters 2 
and 3). Introduction of the S31C mutation in wt 3A reduced vRNA replication, whereas it 
increased vRNA replication in the Y37A and P17A/P18A/P19A mutants. It is unlikely that this 
S31C mutation rescues the defect in vRNA replication by increasing dimerization, since no 
obvious increase in multimerization was observed upon introduction of the S31C mutation into the 
P17A/P18A/P19A mutant and the Y37A mutant already dimerized with wt efficiency. Further 
research is required to establish how the S31C suppressor mutation can (partially) rescue the 
defect in vRNA replication.
Interaction of 3A and GBF1.
 CVB3 3A was shown to inhibit a GEF activity for Arf1 (chapter 4). Presently, there are three 
high-molecular-weight GEFs known (GBF1, BIG1, and BIG2). Yeast two-hybrid results indicate that 
3A interacts specifically with GBF1, but not with BIG1 and BIG2 (chapter 4). This makes 3A the first 
viral protein that specifically inhibits the function of GBF1, thereby inhibiting protein transport. Other 
viral proteins have also been described to inhibit protein transport and for some of these proteins 
the underlying mechanism has been elucidated. However, untill now, the molecular mechanism 
that is used by 3A to inhibit protein transport is unique.
Requirements in 3A for the interaction with GBF1. 
 The results of 3A mutants, which were tested for their ability to dimerize and to 
bind GBF1, showed that 3A homodimerization is required for the interaction with GBF1 
(chapters 2, 3 and 5). Furthermore, the conserved REIKI residues, which were not required 
for dimerization, were shown to be important for the interaction with GBF1 (chapters 3 
and 5). Additional evidence for the importance of the REIKI residues came from the experiments 
described in chapter 6. In that chapter it was shown that the 3A proteins of HRV14 and HRV2, 
which are similar to CVB3 3A but in which the REIKI residues are different or not present at all, 
respectively, have a severely reduced ability to bind GBF1. Upon substitution of the negatively 
charged Glu8 in HRV14 3A (which corresponds to Lys9 in CVB3 3A) for a positively charged Lys 
residue, which results in a REIKI region that is similar to that of CVB3 3A with regard to charge 
and hydrophobicity, the HRV14 3A protein gained the ability to bind GBF1. Thus, we have obtained 
insight into the requirements of 3A for the interaction with GBF1. Structural studies using NMR 
or crystallography may help to elucidate the exact molecular and structural requirements for this 
interaction. 
Requirements in GBF1 for the interaction with 3A. 
 The exact binding domain of 3A in GBF1 is not known. Most research on the high-
molecular-weight GEFs has focused on their Sec7 domains. The sequences outside the Sec7 
domain are highly divergent among these GEFs and most likely play important roles in determining 
substrate specificity, dimerization and intracellular membrane localization. In contrast to the well-
studied Sec7 domain, the rest of the high-molecular-weight GEFs has not been studied extensively. 
At least the extreme N terminus and the homology upstream of Sec7 (HUS) region of GBF1 were 
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shown to be important for the 3A-GBF1 interaction (chapter 5). Elucidation of the structure of 
(the N terminus of) GBF1 might help to determine the surfaces of the interaction with 3A and to 
investigate how the conserved residues in the N terminus of 3A play a role in the interaction with 
GBF1. 
How does 3A affect the function of GBF1? 
 The 3A protein interacts with the N terminus of GBF1 (chapters 4 and 5), whereas the 
guanine nucleotide exchange activity of GBF1 resides within its catalytic Sec7 domain. It is unknown 
how 3A inhibits GBF1 functioning by binding to its N terminus. The pathogen Legionella pneumophila 
produces the RalF protein that can function as a GEF for Arf (Nagai et al., 2002). The RalF protein 
is made up of two domains: an N-terminal Sec7 domain and a C terminal Sec7 capping domain. 
The Sec7 domain is homologous to the mammalian Sec7 domains, but no sequence homology 
exists between the C-terminal half of RalF and any mammalian Arf GEF. The C-terminal domain 
forms a cap over the active site in the Sec7 domain, and release of this Sec7 capping domain from 
the Sec7 domain is necessary for activation of RalF (Amor et al., 2005). Similarly, the Sec7 activity 
of GBF1 might be dependent on its N- or C-terminal parts. The N terminus of GBF1 might contain 
a part that functions as a cover for the Sec7 domain, similar as the RalF Sec7 capping domain. 
Dissociation of this cover would be necessary for GBF1 activation. By binding to the N terminus of 
GBF1, 3A might stabilize this cover on the Sec7 domain, thereby inhibiting its function. Alternatively, 
binding of 3A to the N terminus of GBF1 might interfere with the overall structure of the GBF1 
protein, including the Sec7 domain, thereby inhibiting its function.
Function of 3A in the enterovirus life cycle
Role of 3A in vRNA replication. 
 In the chapters 2 and 3 we showed that several mutations in 3A abolished virus growth. 
It is unknown whether these mutations abolish virus growth by affecting a function of 3A in 
vRNA replication or, alternatively, by affecting a function of 3AB or a larger 3A-containing 
precursor protein. The 3A protein, mostly in its 3AB precursor form, has been suggested to be 
involved in multiple steps in the process of vRNA replication. However, the precise role of 3A in 
vRNA replication is still unknown. The membrane bound 3AB protein is probably the donor of 
the primer for vRNA synthesis (3B) to the replication complex. Furthermore, the results of 
several in vitro experiments suggest that 3AB acts as a cofactor for the binding of 3CDpro to the 
RNA genome, the self-cleavage of 3CDpro to 3Cpro and 3Dpol, and the polymerase activity 
of 3Dpol (a more detailed description of the suggested functions of 3A in vRNA replication 
is provided in chapter 1). 
 Most likely, 3A functions in RNA replication by interacting with viral and/or cellular proteins. 
Some of the above-mentioned functions of 3A(B) in vRNA replication depend on the complex 
formation that has been described between 3AB and 3CDpro. Recently, genetic and biochemical 
evidence was obtained for interactions of 3A (or its precursor 3AB) with 2B, 2C and 2BC (Towner et 
al., 2003; Teterina et al., 2006). Whether these interactions are functional and what their functions 
are remains to be established. 
 The mutations in 3A, which have been characterized in this thesis (chapters 2 and 3), 
may specifically affect one of the suggested functions of 3A in replication, or, alternatively, they may 
disturb multiple functions of 3A by disrupting the overall structure of 3A or 3AB. Testing the effect 
of these 3A mutations in the above-mentioned in vitro assays may help to understand how the 
mutations in CVB3 3A affect vRNA replication.
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The 3A-mediated transport inhibition is not essential for replication complex formation.
 Enterovirus infection of cells induces a massive accumulation of membrane vesicles 
on which vRNA replication takes place. The mechanism of this membrane remodeling is largely 
unknown, even though components of the secretory and/or autophagy pathway have been 
implicated (Gazina et al., 2002; Rust et al., 2001; Jackson et al., 2005). The viral 2BC protein 
plays an important role in the membrane rearrangements, possibly in conjunction with the 3A 
protein (Cho et al., 1994; Suhy et al., 2000; Jackson et al., 2005). It has been suggested that the 
3A-mediated inhibition of protein transport is necessary for the accumulation of membrane 
vesicles. However, some mutant viruses carrying a 3A protein defective in inhibition of protein 
transport grew with wild-type characteristics, indicating that inhibition of protein transport is not 
essential for vRNA replication (chapters 2 and 3; Dodd et al., 2001). It should be mentioned that 
the growth characteristics of mutant viruses were mainly determined in tissue culture cell lines 
(HeLa or BGM), but are not well established in more cell types (e.g. primary cells). Nevertheless, our 
data show that the 3A-mediated inhibition of protein transport is not absolutely required for vRNA 
replication in tissue culture cells. This conclusion fits well with the suggested timing of these events 
during infection: the membrane rearrangements start early in infection (from 2-3 h postinfection), 
whereas the inhibition of protein transport during enterovirus infection starts later in infection 
(at 4-5 h postinfection).
 Enterovirus RNA replication is completely abolished when Brefeldin A (BFA), a drug 
that inhibits protein transport, is added to cells immediately after infection (Maynell et al., 1992). 
Remarkably, the 3A protein that is produced by enteroviruses induces BFA-like effects. However, 
as mentioned above, the inhibition of protein transport in infected cells occurs at a late stage in 
infection, a time point at which the membrane rearrangements required for initiation of viral genome 
replication have already taken place. Accordingly, virus replication is not inhibited when BFA is 
added at late stages in infection (Maynell et al., 1992).
 Upon individual expression, the enterovirus 3A protein blocks activation of Arf1.  As a result, 
Arf1 is expected to be inactivated in enterovirus infected cells. However, preliminary experiments of 
the group of Dr. E. Ehrenfeld (NIH, USA) showed an increase, rather than the expected decrease, 
in Arf1-GTP levels in PV infected cells, indicating that Arf1 is activated by one or more viral proteins 
(E. Ehrenfeld and C. Jackson, personal communication). A likely candidate for a viral protein that 
activates Arf1 is the 3CD protein, since expression of this protein results in increased membrane 
association of Arf1 in HeLa cell lysates (Belov et al., 2005). Thus, different viral proteins seem to 
differentially affect the Arf1 activation state in infected cells. The relative contribution of 3A and 
3CD to the Arf1 activation state in infected cells requires further investigation. It might be that 
early in infection active Arf1 is required for the accumulation of the membranes at which viral 
RNA replication takes place, whereas late in infection the function of Arf1 may be inhibited to 
evade immune responses. The putative role of Arf1 in enterovirus replication requires further 
investigation. In future experiments, expression of Arf1 can be knocked-down by RNA interference 
and, subsequently, enteroviruses replication and morphology of rearranged membranes can 
be studied in these cells. Similar experiments can be performed to test a possible role of other 
Arf isotypes or the large GEFs GBF1, BIG1, and BIG2 in enterovirus replication.
Role of 3A-mediated transport inhibition in evasion of antiviral immune responses.
 If inhibition of protein transport is not required for vRNA replication, what is than the 
biological function of the 3A-mediated inhibition of protein transport? PV infection and expression 
of the PV 3A protein were shown to reduce secretion of cytokines and antigen presentation via 
MHC-I molecules in tissue culture cells, suggesting that the inhibition of protein transport by 3A is 
important for viral suppression of immune responses (Deitz et al., 2000; Dodd et al., 2001). On basis 
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of these data, Dodd et al. suggested that the ability of the PV 3A protein to inhibit protein transport 
might affect viral pathogenesis within the host by reducing virus-associated inflammation, increasing 
virus yield, or both (Dodd et al., 2001). In chapter 4, we used a mouse model of CVB3-induced 
acute myocarditis and demonstrated that a mutant virus carrying a 3A protein defective in inhibition 
of protein transport is indeed less virulent in mice. The mutant virus showed a reduced infectivity of 
the target organs and no symptoms of myocarditis were observed upon infection with the mutant 
virus. These data strongly suggest that 3A indeed affects viral pathogenesis by increasing virus 
yield, most likely by evading the antiviral immune responses. Although these results provide clear 
evidence for the in vivo importance of the 3A-mediated inhibition of protein transport, extended 
in vivo studies are required to get more understanding in the role of 3A in evasion of the immune 
response and its contribution to viral pathogenesis. Future studies should focus on comparing the 
circulating cytokine levels in mice infected with wild-type CVB3 or a mutant CVB3, carrying a 3A 
protein that is defective in transport inhibition.  
3A as a tool in cell biology.
 The drug BFA is probably one of the most frequently used tools to study protein 
transport through the secretory pathway. BFA has been suggested to affect the function of all 
high-molecular-weight GEFs (GBF1, BIG1 and BIG2) (Zeeh et al., 2006). Since 3A specifically 
inhibits the function of GBF1, it may provide an important tool for future research on the secretory 
pathway. Examples of applications for 3A are discussed below. 
 Coat proteins (e.g. COP-I, COP-II, clathrin and AP-complexes) play an important role 
in intracellular protein transport. It is still unclear how different coat proteins are recruited to their 
site of action. Different Arf-GEFs might determine where different Arf isotypes are activated, and 
activated Arfs in turn determine where distinct coated vesicles are formed. The five Arf isotypes in 
humans (Arf1, Arf3, Arf4, Arf5, and Arf6) share the ability to regulate the budding and formation of 
vesicles in the endocytic and exocytic pathways. Arf1, Arf3, Arf4, and Arf5 are involved in transport 
along the secretory pathway, but not much is known about their regulation. It is e.g. unknown which 
GEFs activate different Arf isotypes. 3A can only block activity of Arf isotypes that are activated by 
GBF1. Therefore, 3A may be a valuable tool in studying the relative contribution of GBF1 to the 
activation of different Arf isotypes and, thereby, also in studying the role of the different Arf isotypes 
in the recruitment of different coat proteins. 
 Several steps of the secretory pathway have been individually reconstituted in simplified 
in vitro systems. Thus far, it has been impossible to generate recombinant, active GBF1. Therefore, 
GBF1 could not be used in such in vitro systems, e.g. in an in vitro exchange activity assay. 
Recombinant 3A protein (in the form of its cytosolic part, i.e. the first 60 aa) is active, since addition 
of this protein inhibited a GEF activity in vitro (chapter 4). Therefore, recombinant 3A may provide 
a tool to pull down large amounts of GBF1 from cells. Most likely, this will not result in a fraction 
containing GBF1 only, since the results of co-immunoprecipitation and GST-pulldown experiments 
showed that at least Arf1 is present in the 3A and GBF1-containing complex (chapter 4). Proteomics 
analysis of the purified GBF1 fraction that is pulled down using 3A will reveal whether 3A and GBF1 
form part of a large protein complex and will give insight into the content of this putative complex.   
Concluding remarks
 The main objective of the studies described in this thesis was to obtain more insight into 
the functional and structural aspects of the enterovirus 3A protein. The extensive structure-function 
analysis that is described in this thesis has given new insight into the structure of the 3A homodimer 
and in the importance of dimerization for viral RNA replication and the 3A-mediated inhibition of 
protein transport. The precise function of 3A in virus replication has not been determined. However, 
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the results of this study confirm the suggestion that 3A plays a role in viral RNA replication and in 
evasion of the immune response. Furthermore, the results described in this thesis have led to a 
putative molecular mechanism by which 3A inhibits protein transport (Fig. 1). 3A represents the 
first viral protein that is recognized to inhibit protein transport by blocking Arf1-dependent COP-I 
assembly. Since it specifically inhibits GBF1 function, 3A might turn out to be a valuable tool to 
study cell biology and more specifically the early steps in the secretory pathway. Future studies 
are required to elucidate the exact role of 3A in (i) viral RNA synthesis, (ii) replication complex 
formation, and (iii) evasion of the antiviral host cell response. Together, these findings will result in 
a better understanding of how the virus exploits the cell for efficient replication.  first viral protein 
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Fig. 1. Putative molecular mechanism by which the enterovirus 3A protein inhibits protein transport. (A) COP-I recruitment by 
Arf1. GBF1 and Arf1-GDP are recruited to membranes. GDP is replaced by GTP and GBF1 is released from the membrane. 
Active Arf1-GTP recruits the COP-I complex to membranes, where it facilitates transport. (B) COP-I recruitment is inhibited 
by 3A. 3A binds to GBF1, thereby stabilizing it on membranes. As a result Arf1 activation is blocked, COP-I is not recruited to 
membranes, and transport is blocked. 
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SAMENVATTING
Enterovirussen
 Enterovirussen behoren tot de familie van de Picornavirussen. Deze familie bestaat 
uit kleine virussen, waarvan het genetisch materiaal bestaat uit een RNA-streng met positieve 
polariteit. Het best bekende enterovirus is het poliovirus. Andere virussen die tot dit genus behoren, 
zijn de coxsackievirussen en ECHO-virussen. Hoewel veel enterovirusinfecties subklinisch 
of mild zijn, kunnen ze acute ziektes zoals myocarditis (ontsteking van de hartspier), virale 
meningitis (hersenvliesontsteking), encephalitis (hersenontsteking) en verlamming veroorzaken. 
Enterovirussen worden ook in verband gebracht met een aantal chronische ziektes zoals diabetes 
mellitus (suikerziekte). Het RNA-genoom van enterovirussen bestaat uit twee niet-coderende 
regio’s met daartussen de eiwitcoderende regio. Deze eiwitcoderende regio bevat een open-
reading-frame dat codeert voor een groot polyproteïne. Uit dit polyproteïne ontstaan verschillende 
structurele en niet-structurele eiwitten door middel van processing. De structurele eiwitten vormen 
de viruscapside. De niet-structurele eiwitten zijn betrokken bij de replicatie (vermenigvuldiging) 
van het virale RNA en/of veroorzaken veranderingen in het metabolisme en de structuur van 
de gastheercel. Deze veranderingen vinden plaats om een omgeving te creëren die geschikt is 
voor efficiënte replicatie van het virale RNA en/of om antivirale reacties van de gastheercel te 
onderdrukken. 
 Enterovirussen hebben geen virusenvelop en zijn cytolytische virussen. Dit wil zeggen 
dat het nageslacht van de virussen de cel verlaat door lysis (openbarsten) van de cel te induceren. 
Deze virussen hebben dus geen intacte secretieroute nodig om hun nageslacht te verspreiden. 
Het is aangetoond dat eiwittransport door de secretieroute geremd is tijdens een poliovirusinfectie. 
Het 3A-eiwit van het poliovirus (één van de niet-structurele eiwitten) speelt een belangrijke rol in 
deze eiwittransportremming. Het onderzoek, dat beschreven is in dit proefschrift, was erop gericht 
om het mechanisme op te helderen waarmee het 3A-eiwit eiwittransport remt en om meer inzicht 
te krijgen in de structuur van het 3A-eiwit (met name met betrekking tot zijn functie). Om dit te 
bereiken hebben we in deze studie het 3A-eiwit van het coxsackievirus B3 (CVB3) als modeleiwit 
gebruikt. In hoofdstuk 2 laten we zien dat (net als voor poliovirus) eiwittransport geremd is na 
infectie met CVB3 of na expressie van alleen het CVB3 3A-eiwit. 
Structuur-functie relatie van het enterovirus 3A-eiwit
 In de hoofdstukken 2 en 3 beschrijven we een structuur-functie analyse van het CVB3 
3A-eiwit. Terwijl deze studie bezig was, is de NMR-structuur van het cytosolische deel van het 
poliovirus 3A-eiwit gepubliceerd. We hebben deze NMR-structuur gebruikt om een moleculair 
model te maken van het cytosolische deel van het CVB3 3A-eiwit. Uit het model blijkt dat 3A een 
homodimeer vormt. Elke 3A-monomeer bestaat uit twee helices die een haarspeldstructuur vormen. 
Aan de hand van dit model en conservering van de sequenties van verschillende enterovirus 
3A-eiwitten werd van verschillende aminozuren in CVB3 3A voorspeld dat ze een rol zouden 
spelen in dimerisatie van 3A. We hebben deze aminozuren vervangen door een ander aminozuur 
en gekeken of de op deze manier ontstane 3A mutanten nog kunnen dimeriseren, transport kunnen 
remmen en virale RNA-replicatie kunnen ondersteunen. 
 Ons model van het 3A-eiwit voorspelde dat de geconserveerde aminozuren Ile22, Leu25, 
Leu26, Val29, en Val34 een hydrofobe oppervlakte vormen, dat samen met de hydrofobe oppervlakte 
van het andere 3A-molecuul (bestaande uit dezelfde aminozuren) een hydrofobe binding tussen 
de 3A-monomeren zou verzorgen. We hebben twee aminozuren van de voorspelde hydrofobe 
oppervlaktes vervangen door een ander aminozuur (Leu25 en Leu26 zijn vervangen door Ala-
residuen) en de hierdoor ontstane mutant vormde geen homodimeer meer. Hieruit blijkt dat de 
hydrofobe oppervlaktes inderdaad belangrijk zijn voor dimerisatie. In hoofdstuk 3 laten we ook 
zien dat deze mutant geen eiwittransport meer kan remmen en dat deze mutaties replicatie van het 
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virus verstoren.  
 Door Asp24 te vervangen door een Ala-residu hebben we een aantal virussen kunnen 
isoleren die second-site suppressor mutaties in 3A bevatten. Deze second-site suppressor mutaties 
gebeurden allemaal op de posities Lys27 en Lys41. Dit was een aanwijzing dat de aminozuren op 
positie 24, 27 en 41 functioneel gekoppeld zijn. Waarschijnlijk vormen deze aminozuren intra- en 
intermoleculaire zoutbruggen, zoals voorspeld werd in ons model. Het model voorspelde dat de 
intermoleculaire zoutbrug tussen Asp24 en Lys41 belangrijk is voor dimerisatie. In hoofdstuk 3 laten 
we zien dat het mutante 3A-eiwit waarin Asp24 vervangen is door een Ala-residu inderdaad geen 
homodimeren kan vormen. Waarschijnlijk als een consequentie hiervan verstoort deze mutatie de 
functie van 3A in eiwittransportremming en in replicatie van het virus. De second-site suppressor 
mutaties voor deze mutant versterkten de dimerisatie van de mutant en ze verbeterden ook de 
eiwittransportremmende functie en de mogelijkheid om virusreplicatie te ondersteunen. Deze 
resultaten ondersteunden onze hypothese dat dimerisatie van 3A nodig is voor efficiente remming 
van eiwittransport en efficiente replicatie van het virale RNA. 
 De geconserveerde Arg6, Glu7, Ile8, Lys9, en Ile10 zijn niet belangrijk voor dimerisatie 
(hoofdstuk 3). Wanneer we al deze residuen tegelijkertijd vervangen, verliest het 3A-eiwit zijn 
functie in de replicatie van het virale RNA en de eiwittransportremmende functie. Wanneer we 
slechts één van de residuen vervangen, kan het 3A-eiwit nog wel de replicatie van het virale RNA 
ondersteunen, maar vindt er geen eiwittransportremming meer plaats. In hoofdstuk 5 laten we zien 
dat dit komt, omdat deze residuen belangrijk zijn voor het binden aan de cellulaire bindingspartner 
van 3A. 
 
Welk mechanisme gebruikt het 3A-eiwit om eiwittransport te remmen?
 Toen dit project begon, was het mechanisme dat het 3A-eiwit gebruikt om eiwittransport 
te remmen onbekend. Eiwittransport vanuit het endoplasmatisch reticulum (ER) wordt tot stand 
gebracht door het COP-II coat complex. Vervolgens is het COP-I coat complex nodig voor het 
daaropvolgende transport via de vesiculaire tubulaire complexen (VTC) naar het Golgi-complex. In 
hoofdstuk 4 hebben we laten zien dat expressie van het 3A-eiwit in zoogdiercellen leidt tot verlies 
van COP-I van de membranen met als gevolg het uit elkaar vallen van de VTC- en Golgi-structuren. 
Hierdoor stroomt de inhoud van het VTC en Golgi terug naar het ER en de eiwitten hopen zich 
op (dicht) bij de met een COP-II coat bedekte ER-exit-sites. Op deze plaats bevindt zich ook het 
3A-eiwit. Uit onze resultaten blijkt dat het 3A-eiwit de activering van ADP-ribosylation factor-1 
(Arf1) remt. Arf1 is een GTPase dat in zijn actieve staat zorgt voor binding van de COP-I coat aan 
membranen. We hebben laten zien dat 3A bindt aan GBF1, een guanine nucleotide exchange 
factor (GEF), die als katalysator optreedt voor de activering van Arf1. Normaal gesproken bindt 
GBF1 aan membranen, waarna het weer loslaat en vervolgens opnieuw kan binden en loslaten. 
Het 3A-eiwit zorgt ervoor dat het GBF1 eiwit gebonden blijft aan membranen en dus inactief is. 
Alles bij elkaar genomen, steunen onze resultaten een model waarin het 3A-eiwit eiwittransport 
remt door de GBF1 functie te verstoren en daardoor Arf1-afhankelijke membraanbinding van 
COP-I te remmen. 
 In hoofdstuk 5 hebben we de interactie tussen het 3A-eiwit en GBF1 verder onderzocht. 
Uit de structuur-functie relatie van 3A, die beschreven is in hoofdstuk 3, bleek dat dimerisatie 
van 3A nodig is voor de eiwittransportremming door 3A. In hoofdstuk 5 laten we zien dat dit komt 
doordat dimerisatie van 3A nodig is om GBF1 te kunnen binden. Ook zijn de eerdergenoemde 
aminozuren Arg6, Glu7, Ile8, Lys9, en Ile10 nodig om GBF1 te kunnen binden. We laten zien dat 
mutante 3A-eiwitten, die geen eiwittransport kunnen remmen, geen interactie met GBF1 aangaan 
en GBF1 niet aan de membraan gebonden kunnen houden. In dit hoofdstuk laten we niet alleen 
zien welke gebieden in 3A nodig zijn om aan GBF1 te binden, maar ook welke gebieden in GBF1 
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nodig zijn om aan 3A te binden. 
Wat is de biologische functie van de eiwittransportremming door 3A?
 Enterovirusinfectie induceert een enorme ophoping van membraanblaasjes. Op deze 
membraanblaasjes vindt replicatie van het virale RNA plaats. Het is grotendeels onbekend via welk 
mechanisme deze membraanveranderingen verlopen. Er zijn aanwijzingen dat de componenten 
van de secretieroute en de autofagieroute een rol spelen bij de membraanveranderingen. Het 
virale 2BC eiwit speelt een belangrijke rol in de membraanveranderingen. Mogelijk is het 
3A-eiwit ook betrokken bij de membraanveranderingen. Andere onderzoekers hebben gesuggereerd 
dat eiwittransportremming door 3A nodig is voor de ophoping van de membraanblaasjes. In 
de hoofdstukken 2 en 3 beschrijven we mutante virussen, die een 3A-eiwit hebben dat geen 
eiwittransport meer kan remmen, maar die wel efficient repliceren. Deze mutante virussen tonen 
aan dat de eiwittransportremming niet nodig is voor de replicatie van het virale RNA en dus niet 
essentieel is voor de ophoping van de membraanblaasjes. 
 De eiwittransportremming door 3A is dus niet nodig voor de replicatie van het virale 
RNA. Maar wat is dan de biologische functie van de eiwittransportremming? In het verleden heeft 
men laten zien dat infectie met poliovirus en expressie van alleen het 3A-eiwit van poliovirus de 
uitscheiding van cytokines en de antigeenpresentatie via MHC-I-moleculen remt. Deze resultaten 
zijn een aanwijzing voor een mogelijke rol van de eiwittransportremming door 3A in de virale 
onderdrukking van immuunresponsen. In hoofdstuk 4 beschrijven we de data die verkregen zijn 
uit een studie, waarbij we een muismodel van CVB3 geïnduceerde acute myocarditis (ontsteking 
van de hartspier) gebruikt hebben. Onze resultaten laten zien dat een mutant virus, dat een 
3A-eiwit heeft dat geen eiwittransport meer kan remmen, inderdaad minder virulent is in muizen. Het 
mutante virus was minder infectieus en de infectie met het mutante virus leidde niet tot symptomen 
van myocarditis. Deze data geven sterke aanwijzingen dat de eiwittransportremming door 3A het 
virus helpt de antivirale immuunresponsen in de gastheer te ontduiken.
Is de eiwittransportremming door 3A geconserveerd binnen andere picornavirussen?
 De naamgeving van de eiwitten die gemaakt worden door de picornavirussen is gebaseerd 
op hun plaats in het genoom. Alle picornavirussen maken een 3A-eiwit, maar dit betekent niet dat 
de functie van de 3A-eiwitten van de verschillende virussen gelijk is. In hoofdstuk 6 hebben we 
onderzocht of de 3A-eiwitten van andere picornavirussen ook eiwittransport remmen. We laten 
zien dat poliovirus 3A de membraanbinding van COP-I verstoort via hetzelfde mechanisme als 
CVB3 3A. In tegenstelling tot de 3A-eiwitten van deze twee enterovirussen, remde geen van de 
andere onderzochte 3A-eiwitten van picornavirussen eiwittransport. De humane rhinovirussen 
(veroorzakers van verkoudheid) zijn nauw verwant aan de enterovirussen, maar hun 3A-eiwit bindt 
nauwelijks aan GBF1. In hoofdstuk 6 laten we zien dat dit komt door kleine verschillen in het begin 
van het eiwit (in de N-terminus). Als we het begin van het rhinovirus 3A-eiwit vervangen door het 
begin van het enterovirus 3A-eiwit, kan dit chimere 3A-eiwit wel eiwittransport remmen en binden 
aan GBF1.
Concluderende opmerkingen
 Het belangrijkste doel van de studie die beschreven is in dit proefschrift was om meer inzicht 
te krijgen in de functionele en structurele aspecten van het enterovirus 3A-eiwit. De uitgebreide 
structuur-functie analyse die beschreven is in dit proefschrift heeft nieuwe inzichten gegeven in 
de structuur van de 3A homodimeer en in het belang van dimerisatie voor replicatie van het virale 
RNA en voor de eiwittransportremming door 3A. De hier beschreven resultaten bevestigen een rol 
voor 3A in het ontduiken van de antivirale immuunresponsen. Onze resultaten hebben geleid tot 
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een beschrijving van het moleculaire mechanisme waarmee het 3A-eiwit eiwittransport remt. Het 
3A-eiwit is het eerste virale eiwit waarvan verondersteld wordt dat het eiwittransport remt door te 
interfereren met de Arf1-afhankelijke binding van COP-I aan membranen. Omdat 3A specifiek de 
functie van GBF1 remt, zou 3A een waardevol hulpmiddel binnen de celbiologie kunnen zijn. 
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DANKWOORD
 Zo, vier en een half jaar promotieonderzoek zit erop. De resultaten van dit onderzoek 
vormen het grootste gedeelte van dit boekje, maar dit dankwoord vormt waarschijnlijk het meest 
gelezen gedeelte van dit boekje. Daarom is dit een mooie plaats om iedereen te bedanken die 
bijgedragen heeft aan het tot stand komen van dit proefschrift. 
 Mijn promotor Joep wil ik bedanken voor de gelegenheid die hij mij heeft gegeven om 
dit onderzoek uit te voeren. Op deze plaats wil ik ook mijn beide co-promotores Frank en Willem 
bedanken. Frank, tijdens mijn stage had ik al gemerkt dat ik heel prettig kon werken onder jouw 
begeleiding. Gelukkig was de stage van beide kanten goed bevallen en hebben jij en Willem mij de 
kans geboden om mijn promotieonderzoek op de afdeling virologie uit te voeren. Ten opzichte van 
mijn stage waren er veel dingen veranderd (o.a. een mooi nieuw gebouw), maar jouw enthousiasme 
voor het onderzoek was gelukkig niet veranderd. Ik heb ontzettend veel van je geleerd en heb veel 
bewondering voor de energie waarmee je het onderzoek leidt. Ondanks de drukte vond je altijd 
tijd om mijn schrijfsels binnen zeer korte tijd en met goede ideeën of aanvullingen terug te geven. 
Voor jou was de celbiologie van de secretieroute ook een betrekkelijk nieuw veld en ik heb het 
heel leuk gevonden om hierin samen onze weg te vinden. Heel erg bedankt voor alle jaren van 
zeer prettige samenwerking. Willem, jij hebt ervoor gezorgd dat ik in de gaten kreeg hoe leuk het 
onderzoek op de afdeling virologie is. Tijdens mijn research practicum heb jij je enthousiasme voor 
virologisch onderzoek overgedragen. Ik heb er daarna voor gekozen om de celbiologische kant 
van de virologie uit te gaan, waardoor Frank mijn directe begeleider werd. Maar jij bent altijd heel 
betrokken gebleven en ik heb jouw steun heel erg gewaardeerd. Ook wil ik je heel erg bedanken 
voor de frisse blik waarmee je al mijn artikelen gelezen hebt.  
 Kjerstin en Miranda, ik ben blij dat jullie mijn paranimfen willen zijn. Kjerstin, jij was mijn 
eerste student en gelukkig kon je daarna blijven als analist. Tijdens dit promotieonderzoek heb ik 
heel veel aan je gehad, zowel qua werk (je staat niet voor niets boven vier van de vijf artikelen) als 
qua emotionele steun. Bedankt dat je er altijd was om mijn frustraties aan te horen en vooral om 
een leuke sfeer op het lab te brengen. Miranda, jij hebt me niet alleen tijdens dit promotieonderzoek 
fantastisch gesteund, maar ook tijdens onze middelbare school periode en onze studie biologie in 
Nijmegen. Tijdens alle weekendjes weg, avondjes uit, en andere gelegenheden kon ik altijd mijn 
verhaal bij jou kwijt. Bedankt voor ruim 16 jaar vriendschap! 
 In chronologische volgorde wil ik hier ook mijn collega’s bedanken. Jan, in elk dankwoord 
wordt je droge humor genoemd. Die traditie wil ik niet breken, want jouw zeer gevatte opmerkingen 
hebben mij maar al te vaak heerlijk aan het lachen gemaakt. Daarnaast wil ik je ook bedanken 
voor alle nuttige opmerkingen tijdens werkbesprekingen. Judith (B.) en Patrick, ook al zaten jullie 
al aan de overkant toen ik begon met mijn promotieonderzoek, bedankt voor jullie bijdrage aan de 
gezelligheid op en rond het lab. Arjan, bedankt voor de gezellige tijd in onze U2B (die tegenwoordig 
volledig bezet is door “the 3A team”) en voor alles wat ik van je geleerd heb. Bij jou kon ik alvast 
zien wat mij te wachten stond… Daardoor keek ik er niet raar van op dat er meer dan 100 versies 
nodig waren tot het artikel eindelijk in Developmental Cell stond. Ook na jouw promotie heb ik 
mogen genieten van je hulp en gezelligheid (leuk dat je laatst een etentje met de “oude garde” 
hebt geïnitieerd; we moeten het zeker een keer met jou erbij over doen). Ina, bedankt voor alle 
constructen die je voor het 3A werk gemaakt hebt. Dirk, heel erg bedankt voor de vrolijke sfeer die 
jij op het lab bracht (kippenvel!), je interesse in mijn onderzoek, en niet te vergeten alle hulp met 
mijn computerproblemen. Mark, bedankt voor het wegwijs maken in het uitvullen van de cellen en 
je interesse in mijn onderzoek. Succes met je eigen promotie. Mike, door jou kon ik op een rijdende 
trein springen met het 3A onderzoek. Zoals het met jouw verhalen ook gaat, is deze 3A trein via een 
heleboel tussenstations (Helsinki [zware werkdag was dat], Arnhem [wat moesten we daar ook al 
weer?], Ede-Wageningen [gelukkig hoefden we er pas om 7.30 uur te zijn]; dit alles te bereiken via 
een tom-tom short cut) op de bestemming aangekomen. Ik wil je bedanken voor alle hulp onderweg 
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(jij was een waardig vervanger voor Dirk in het oplossen van mijn computerproblemen) en in het 
bijzonder voor de hulp bij het bereiken van het eindstation, dit prachtige boekje. Zonder jou had dit 
boekje er niet zo mooi uitgezien. Bedankt voor de gezellige tijd! Daniëlle, je bent maar korte tijd op 
het lab geweest, maar ik heb jouw gezelschap altijd heel gezellig gevonden. Judith (K.), bedankt 
voor alle steun in de vorm van het regelen van algemene labzaken en de leuke sfeer. Het werd stil 
op het lab toen jij naar de overkant ging. Danny, na een wat moeizame start hebben we er een hele 
prettige en vruchtbare samenwerking van kunnen maken. Tijdens mijn schrijffase was je niet alleen 
een steun door al mijn schrijfsels te lezen, maar ook door mij vrij te houden van experimenten. 
Qua droge humor kan jij er ook wat van: kan de andere 99% Patrick de gel opruimen? Vooral wat 
betreft de “pure” biochemie heb ik veel van je geleerd. Bedankt! Stanley, Fabrizio, Barbara en 
Kelly, jullie kwamen op het lab toen ik al een heel eind op weg was. Bedankt voor jullie interesse en 
bijdrage aan de gezelligheid. Stanley, Barbara en Kelly, veel succes met jullie promotieonderzoek. 
Kjerstin, Judith, Judith, Barbara en Kelly, volgende Lady’s Night in Heidelberg? Onze vaste virologie 
groep werd bijna altijd aangevuld met studenten. Bij deze wil ik alle studenten bedanken voor hun 
bijdrage aan de gezelligheid op het lab. De studenten van het 3A team wil ik graag met naam 
noemen. Kjerstin, Sander (J.) en Bart, ik heb het heel leuk gevonden om jullie te begeleiden. Ik 
realiseer me dat ik verwend ben met drie studenten die alle drie zoveel bruikbare resultaten hebben 
geproduceerd. Samen met Mike, Jeroen, Vladimir, Sander (v D.) en Melinda, de studenten die 
begeleid zijn door Frank of Danny, wil ik jullie heel erg bedanken voor al jullie hulp aan het 3A werk. 
Ook wil ik graag mijn collega’s van de parasitologie en urologie bedanken voor hun interesse en de 
gezelligheid. Als ik de pauze met de virologie gemist had, was ik altijd welkom om te “integreren”. 
Ik ga de vrijdagmiddag borrels in de Aesculaaf of andere kroegen zeker missen. Ook wil ik de 
leden van de PhD commissie bedanken voor alles wat ik van hun heb geleerd. Ik vond het heel 
leuk en leerzaam om lid te zijn van deze commissie. Verder wil ik alle mede junior onderzoekers 
van het NCMLS bedanken voor hun interesse in mijn onderzoek. Jullie vormden een makkelijk 
aanspreekpunt als ik weer eens in de toren ging “shoppen”. 
 Een dankwoord is ook een mooie plaats om de mensen met wie ik samengewerkt heb 
te bedanken. Peter en Sjenet, bedankt voor de hulp met het PLD werk. Peter, ook bedankt voor 
de interesse die je als mentor in mij en mijn onderzoek hebt  getoond. Henri, bedankt voor alle 
hulp bij de confocal microscoop. Frank (de L.), bedankt voor alle hulp bij het FRAPpen, FRETten, 
en FLIPpen. Het heeft heel wat uurtjes naar de microscoop turen gekost, maar ik heb het altijd 
heel gezellig gevonden en er zijn ook hele mooie resultaten uitgekomen. Jack en Huib, jullie ook 
bedankt voor de hulp met de microscoop. Richard, het model van 3A dat jij gemaakt hebt, heeft 
de basis gevormd voor al het werk dat beschreven is in hoofdstuk 3. Bedankt voor al je hulp en 
succes met je eigen promotieonderzoek. Maaike, Frederique en Gosse, bedankt voor de hulp bij 
de yeast two-hybrid screening. Deze methode heeft helaas geen bruikbaar resultaat opgeleverd, 
maar gelukkig hebben we de interactiepartner van 3A op een andere manier kunnen achterhalen. 
Viola en Judith, bedankt voor de EM plaatjes van 3A-expresserende cellen. Andreas and Steffi, 
thank you for performing the mouse study with the mutant coxsackievirus. Cathy, you have been 
an invaluable help in the achievement of this thesis. Thank you very much for your interest and 
enthusiasm, for sharing all reagents and preliminary results, for criticizing the manuscripts, for 
giving me the opportunity to work in your lab for two weeks and for all other help. Ting, thank you 
for performing the GGA pulldowns and for risking the fines for speeding to be able to meet me at the 
NIH. Ellie, thank you very much for your interest and for sharing your experience and preliminary 
results. I have enjoyed meeting you at several meetings and your hospitality during my visit at the 
NIH. I would like to thank Kurt Bienz for the kind gift of the EM picture that is shown in chapter 1. 
 Tot slot wil ik graag mijn vrienden en familie bedanken voor alle steun en interesse die ik 
van hen gekregen heb. Zonder andere mensen tekort te doen wil ik een aantal personen specifiek 
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noemen. Mijn vrienden die ik in Breda of Nijmegen heb ontmoet, bedankt voor jullie interesse en 
steun. My friends of the “Uppsala period”, tack så mycket för allting! Gijs, ik sluit me aan bij Cécilia: 
je bent een super supervisor. Marieke en Dennis, bedankt voor alle gezellige relax-weekendjes 
in Twente. Elly, Peter, Frank en Vivienne, bedankt dat ik al sinds kinds af aan altijd op jullie kan 
rekenen. Hans, bedankt voor het ontwerpen van de kaft van dit proefschrift. Beppie en Jan, bedankt 
dat jullie er altijd voor mij zijn. Tijdens de vele tennisavondjes heb ik alle promotiestress letterlijk van 
me af kunnen slaan. Oma, bedankt voor al Uw steun en interesse. Ik ben trots op het feit dat ik zo’n 
fantastische oma heb.
 En dit brengt me naar de meest belangrijke personen in mijn leven: papa, mama, en 
Petra. Pap, het verdient zeker een vermelding dat je elke (werk)dag een e-mail naar mij gestuurd 
hebt om me te steunen. De vele (verre) reizen die we met z’n vieren gemaakt hebben, waren een 
heerlijke ontspanning tijdens mijn studie of promotieonderzoek en ik geniet nog steeds na van elke 
reis. Ik weet dat jullie dag en nacht voor mij klaar staan en ik heb daar dan ook regelmatig gebruik 
van gemaakt. Bedankt voor al jullie liefdevolle steun! 
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Chapter 2, Fig. 1. CVB3 infection and expression of the 3A protein inhibit VSVG-GFP trafficking. BGM cells were transfected 
with a construct coding for the GFP-tagged ts045 temperature-sensitive mutant of the VSVG protein, either alone or together 
with 3A, and grown at 40ºC for 20 h. (A to C) Control cells. In control cells, VSVG was improperly folded at 40ºC, and as a 
consequence, was retained in the ER, as shown by its colocalization with calreticulin (merged picture on the right in panel A). 
Upon shifting to the permissive temperature (32ºC), the VSVG-GFP protein was correctly folded and transported out of the ER. 
VSVG could be observed in the Golgi complex after 45 min, as shown by its colocalization with GM130, a cis-Golgi marker (B), 
and at the plasma membrane after 120 min (C). (D to F) Cells infected with CVB3 (MOI of 50) for 5 h at 40ºC. At 40ºC, VSVG 
was retained in the ER (D). Upon shifting to 32ºC for 120 min, VSVG could be found in the ER (E) and a post-ER compartment 
that also contained the cis-Golgi marker (F). (G to I) 3A-expressing cells. VSVG was retained in the ER at 40ºC (G), whereas 
it was observed in the ER (H) and a post-ER compartment that also contained the cis-Golgi marker (I) when shifted to 32ºC for 
120 min.  Bar = 10 µm.
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Chapter 2, Fig. 7. Putative model of CVB3 3A protein. The structural model shows a homodimer of the N-terminal 60 aa of 
CVB3 3A. Molecular modeling (using WHAT_IF [Vriend, 1990] and YASARA NOVA [Krieger et al., 2002] software) was used 
to predict the CVB3 3A structure on the basis of the published nuclear magnetic resonance structure of the N-terminal 60 aa 
of PV 3A. Pro14,	Pro17, Pro18, Pro19, and Pro20 in the bottom of the 3A dimer and Ser31 in the loop connecting the two α-helices 
are indicated.
Chapter 3, Fig. 4. Identification of second-site suppressor mutations for mutation D24A. Ten transfections were performed 
with RNA transcribed from the cDNA clone containing mutation D24A. The 3A sequence of the obtained viruses is shown. 
The mutations D24A/K41N, D24A/K41Q, and D24A/K41E were introduced into the cDNA clone and the result of transfections 
with RNA transcribed from these clones is depicted. The nucleotide (nt) changes leading to the amino acid substitutions are 
indicated. The sequence plot of the virus mixture containing D24A/K27I and K27I is shown. The asterisk indicates the nt change 
resulting in the K27I substitution. The arrow indicates the nt that differs between the two populations of which the virus mixture 
is comprised (the major population contains an adenine residue resulting in Asp24, whereas the minor part contains a cytosine 
residue resulting in Ala24).
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Chapter 4, Fig. 2. Effects of 3A on the distribution of early secretory pathway components. (A) Cells transfected with VSVG-GFP and	
3A-myc were incubated at 40°C for 16 h to accumulate VSV-G in the ER and subsequently shifted to 32°C for 2 h. 3A was 
stained with an antibody against myc. (B-L) GFP-3A-expressing cells (16 h after transfection) stained with antibodies against 
Sec24 (B), ERGIC53 (C), GM130 (D), α/γ-COP (F), Arf1 (G), GBF1 (H), ArfGAP1 (I), TGN46 (J), BIG1 (K), and BIG2 (L). 
One or more control cells are shown in all figures. (E) Cells co-expressing GalT-GFP and 3A-myc (16 h after transfection).	
Bars represent 10 µm.
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Chapter 4, Fig. 3. Immuno-electron microscopy of control (A, C, D) and 3A-expressing (B, E) Hela cells (32 h after transfection). 
(A) In control cells, COP-II (Sec23, 15 nm gold) was found on ER budding profiles (arrow) and associated vesicles. The 
asterisk indicates COP-II negative VTC membranes. (B) 3A expression (10 nm gold) leads to an accumulation of ER-associated 
vesicles and tubules that are sometimes also positive for COP-II (15 nm gold, arrowhead). The asterisk marks the VTC area. 	
(C-D) ERGIC53 (15 nm gold) normally localizes to the cis-Golgi cisterna (arrowhead in [C]) and Golgi-associated VTC 
membranes (D). (E) In 3A (10 nm gold) expressing cells, ERGIC53 (15 nm gold) is found on a portion of the 3A-induced 
membrane clusters. The asterisk marks the VTC area. ER, endoplasmic reticulum; G, Golgi; M, mitochondrion; E, endosome; 
NE, nuclear envelope; N, nucleus. Bars, 200 nm.
Chapter 4, Fig. 4. Dynamics of Sec24-YFP and p58-ERGIC-YFP in 3A-expressing cells. (A-B) FRAP traces showing the relative 
fluorescence of cells stably expressing Sec24-YFP (A) or p58-ERGIC-YFP (B), either alone (control cells), co-expressing 	
CFP-3A or Arf1-T31N-CFP, or treated with BFA. The traces in all graphs show the average recovery and SEMs (n ≥ 9 cells, from 
at least two independent experiments). The fluorescence intensity before bleaching was normalized to 1 and the fluorescence 
intensity directly after the bleach to 0. The fluorescence intensity was corrected for bleaching of the cell during imaging and 
background fluorescence. Values for the halftime of fluorescence recovery are calculated from the traces depicted in panels 
A and B.
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Chapter 4, Fig. 5. 3A blocks Arf1 activation by interacting with GBF1 and Arf1-GDP. (A) Arf1-GTP pulldown assay. COS7 cells 
were transfected with pCMS-Arf1-GFP, pC-3A-myc-S-Arf1-GFP or pC-3A-ins16S-myc-S-Arf1-GFP. The upper panel shows 
the total amount of Arf1-GFP in cells, the lower panel shows the amount of GTP-bound Arf1-GFP. (B) In vitro Arf1 GEF assay. 
Recombinant myristoylated Arf1 and rat liver Golgi membranes were incubated in the presence of 35S-GTPγS. The amount of 
membrane-bound label in the absence of 3A (-3A) was normalized to 100% and represents the Arf GEF activity. Recombinant 
3A(1-60) proteins (+3A or +3A-ins16S) were added at a concentration of 1 µM. The average values of two independent 
experiments are shown. (C) Schematic representation of 3A and the high-molecular weight Arf GEFs. HD, hydrophobic domain 
(aa 61-82); N, N-terminal part of GEFs (BIG1, aa 1-708; BIG2, aa 1-653; GBF1, aa 1-709); Sec7, Sec7 domain of GEFs 	
(BIG1, aa 709-892; BIG2, aa 654-837; GBF1, aa 710-895); C, C-terminal part of GEFs (BIG1, aa 893-1850; BIG2, aa 838-1786; 
GBF1, aa 896-1856) (D) Yeast two-hybrid analysis shows that the N-terminal 60 aa of 3A specifically interact with the N-terminal 
part of GBF1. Left panel shows growth of yeast on leucine- and tryptophane-deficient medium; middle panel shows growth 
on histidine-deficient medium; right panel shows growth on adenine-deficient medium. Interactions between binding partners 
result in white colonies on the leu, trp-deficient medium and in growth on his- and ade-deficient media. (E) The N terminal 60 
aa of 3A pull down GBF1 and Arf1 from mouse brain lysates. (F) Co-IP experiments. 3A-myc is specifically coprecipitated from 
cells co-transfected with YFP-GBF1 or Arf1-GFP. (G) Co-IP experiments with the dominant negative (T31N) and dominant 
active (Q71L) mutants of Arf1 show that 3A preferentially interacts with Arf1 in its inactive, GDP-bound form (Arf1-T31N). 	
(H) 3A in CVB3-infected BGM cell lysates preferentially binds to columns containing GDP-saturated, recombinant Arf1-T31N. 
WB, western blot; IP, immunoprecipitation.
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Chapter 4, Fig. 6. Overexpression of GBF1 or Arf1 suppresses the effects of 3A. (A) BGM cells transiently co-transfected with 
3A-myc and GFP, Arf1-GFP, YFP-GBF1, or GM130-GFP for 16 h were stained with an antibody against COP-I. Bars represent 
10 µm. (B) Percentage of 3A-myc and GFP, Arf1-GFP, YFP-GBF1, or GM130-GFP co-expressing cells, in which COP-I is 
dissociated from membranes. Calculations were made from at least two independent experiments (of which a typical example 
is shown in panel A). In each experiment, at least 100 cells were analyzed. (C) Arf1-GTP pulldown assay. COS7 cells were 
transfected with pCMS-Arf1-GFP or pC-3A-myc-S-Arf1-GFP, either alone or in combination of with YFP-GBF1 or HA-BIG2. The 
upper panel shows the total amount of Arf1-GFP in cells, the lower panel shows the amount of GTP-bound Arf1-GFP.
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Chapter 4, Fig. 7. Dynamics of GBF1 and Arf1 in 3A-expressing cells. (A-B) FRAP traces of cells expressing YFP-GBF1 (A) or 
Arf1-YFP (B), either alone (control cells), or together with CFP-3A or CFP-3A-ins16S. The traces in the graphs show the average 
recovery and SEMs (n ≥ 10 cells, from at least two independent experiments). The fluorescence intensity was calculated as 
described in Fig. 4. (C) Inset of panel B, showing traces of the first 40 sec after bleach. (D) Halftime of fluorescence recovery 
values of Arf1-YFP alone, together with CFP-3A or CFP-3A-insS16, as calculated from the traces in panel B.
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Chapter 4, Fig. S1. Effects of BFA treatment (2h, 5 µg/ml) or Arf1-T31N expression (16 h after transfection) on the distribution 
of various early secretory pathway components; Sec24 (A), ERGIC53 (B), GM130 (C), Gal-T (D), α/γ-COP (E), Arf1 (F), GBF1 
(G), ArfGAP1 (H), TGN46 (I), BIG1 (J), BIG2 (K). Bars represent 10 µm. A 2h BFA treatment was used to mimic the long-lasting 
effects of 3A or Arf1-T31N expression.
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Chapter 4, Fig. S2. EM picture of a 3A-expressing cell. In 3A (10 nm gold) expressing cells, ERGIC53 (15 nm gold) is found on 
a portion (arrowheads) of the 3A-induced membrane clusters (asterisk). The arrow points to an elongated 3A-positive budding 
profile associated with the ER. Bar, 200 nm. ER, endoplasmic reticulum. 
Chapter 4, Fig. S3. Determination of the diffusion coefficient D of Arf1 in the cytosol of living cells using Fluorescence Correlation 
Spectroscopy (FCS). (A) In cells transfected with the plasmid pC-3A-myc-S-Arf1-GFP, 3A is localized in the ER and punctate 
structures, whereas both Arf1-GFP and COP-I are dissociated from membranes. Bars represent 10 µm. (B) FCS measurements 
on Arf1-GFP in BGM cells. Total Arf1 in control cells is comprised of two populations, a fast and a slow diffusing population. The 
fast population (high D) represents monomeric, cytosolic Arf1, whereas the slow population (low D, typically ~ 1 µm2	s-1 [Altan-
Bonnet et al., 2003]) is Arf1 bound in a large protein complex or membrane-bound Arf1 (Elsner et al., 2003). In 3A-expressing 
cells, the fraction of slowly diffusing Arf1 in the cytosol was not considerably altered compared to control cells. The D of the 
fast Arf1 population in 3A-expressing cells was not decreased relative to that in control cells, instead it was a little increased, 
indicating that Arf1 is not associated to small membrane structures (which could have remained after Golgi disassembly and 
are not resolvable by confocal microscopy, and which would have caused a decreased D). Similar effects were found in 	
Arf1-T31N-expressing cells and BFA-treated cells. These data support the idea that Arf1 is persistently inactive in 3A-expressing 
cells.
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Chapter 5, Fig. 1. Inhibition of COP-I recruitment to membranes by mutant 3A proteins. (A) Amino acid (aa) sequence of 
CVB3 3A. The C-terminal hydrophobic domain (aa 61 to 82) is depicted in the boxed area. Aa that are mutated are indicated 
by asterisks and the Ser insertion at position 16 is also indicated. (B-H) BGM cells expressing Myc-tagged 3A wt (B), 	
3A-REIKI (C), 3A-ins16S (D), 3A-PPP (E), 3A-LL (F), 3A-VDSE (G), and 3A-VREY (H) are stained for the Myc tag and COP-I. 
(I) Table summarizing the ability of 3A mutants to inhibit protein transport and COP-I recruitment. 1, Wessels et al., 2006a; 2, 
Wessels et al., 2006b; 3, Wessels et al., 2005. 3A-REIKI, 3A-R6A/E7A/I8A/K9A/I10A; 3A-PPP, 3A-P17A/P18A/P19A; 3A-LL, 	
3A-L25A/L26A; 3A-VDSE, 3A-V29A/D30A/S31A/E32A; 3A-VREY, 3A-V34A/R35A/E36A/Y37A. Bars represent 10 µm. 
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Chapter 5, Fig. 3. Interaction of 3A mutants with GBF1 and effect on GBF1 dynamics. (A) Interaction of 3A wt, 3A-REIKI, 	
3A-ins16S, 3A-PPP, 3A-LL and 3A-VREY with the N-terminal part of GBF1 in yeast two-hybrid. The upper, middle, or lower 
panel show growth of yeast on non-selective medium (leucine- and tryptophane-deficient medium), selective medium lacking 
histidine (-His), or selective medium lacking adenine (-Ade), respectively. (B) Interaction of 3A wt, 3A-REIKI, 3A-ins16S, 3A-PPP, 	
3A-LL and 3A-VREY with the N-terminal part of GBF1 in mammalian two-hybrid. The firefly luciferase activity measured at 48 h 
posttransfection is depicted. The activity measured with wild-type 3A and the GBF1 N terminus was set at 100%. (C) Dynamics 
of YFP-GBF1 when localized at dispersed membrane structures. FRAP traces of cells expressing YFP-GBF1 together 
with CFP-fusion proteins of 3A wt, 3A-ins16S, 3A-PPP, 3A-LL, or 3A-VDSE. (D) Dynamics of YFP-GBF1 when localized at 	
ER membranes. FRAP traces of cells expressing YFP-GBF1 either alone (no 3A), or together with CFP-fusion proteins of 
3A-REIKI or 3A-VDSE. The traces show the average recovery (n ≥ 10 cells) from at least two independent experiments. 	
The fluorescence intensity before bleaching was normalized to 1 and the fluorescence intensity directly after bleach to 0. The 
fluorescence intensity was corrected for bleaching of the cell during imaging and background fluorescence.
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Chapter 5, Fig. 4. Effect of 3A mutants 
on Arf1 dynamics. The upper panel 
shows FRAP traces of cells expressing 	
Arf1-YFP either alone (no 3A), or 
together with CFP-fusion proteins of 	
3A wt, 3A-REIKI, or 3A-VDSE. The 
FRAP traces of Arf1-YFP in cells 
expressing 3A-ins16S, 3A-PPP, or 
3A-LL are similar to that observed in 
cells expressing 3A-REIKI. The FRAP 
trace of Arf1-YFP in cells expressing 
3A-VREY is similar to that in cells 
expressing 3A-VDSE. The lower 
panel shows halftime of fluorescence 
recovery values of Arf1-YFP when 
expressed alone, or together with 3A 
wt, 3A-REIKI, 3A-ins16S, 3A-PPP, 
3A-LL, 3A-VDSE, or 3A-VREY. The 
traces show the average recovery (n ≥ 
10 cells) from at least two independent 
experiments. The fluorescence 
intensity was calculated as described 
in the legend to Fig. 2.
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Chapter 5, Fig. 6. A GBF1 mutant that lacks the extreme N terminus cannot rescue the effects of 3A. (A) Cells expressing 
YFP-GBF1 or YFP-GBF1∆N are stained for COP-I. (B) Images showing GBF1 (left) and 3A (right). Cells expressing YFP-GBF1 
and 3A-myc or YFP-GBF1∆N and 3A-myc are stained for the Myc tag. (C) Images showing GBF1 (left) and COP-I (right). Cells 
expressing YFP-GBF1 and 3A-myc or YFP-GBF1∆N and 3A-myc are stained for COP-I. GBF1∆N, GBF1 lacking aa 1-37. Bars 
represent 10 µm.
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Chapter 6, Fig. 2. The HRV 3A proteins have a reduced ability to bind GBF1 and inhibit its function. (A) Alignment of enterovirus 
and HRV 3A proteins. Gray boxes indicate the hydrophobic regions of the 3A proteins, as predicted using the Kyte and Doolittle 
method. (B) FRAP traces of cells expressing YFP-GBF1 either alone (no 3A), or together with CFP-fusion proteins of the 
3A proteins of CVB3, PV, HRV14, or HRV2. The traces in the graphs show the average recovery (n > 10 cells), from at 
least two independent experiments. The fluorescence intensity before bleaching was normalized to 1 and the fluorescence 
intensity directly after bleaching to 0. The fluorescence intensity was corrected for bleaching of the cell during imaging and for 
background fluorescence. (C) Interaction of the 3A proteins of CVB3, PV1, HRV14 and HRV2 with the N-terminal part of GBF1 
as assayed by yeast two-hybrid analysis. Upper, middle, and lower panels show growth of yeast on non-selective medium 
(leucine- and tryptophane-deficient medium), selective medium lacking histidine (-His) and selective medium lacking adenine 
(-Ade), respectively. CVB3, coxsackievirus B3; PV1, poliovirus 1; HRV14, human rhinovirus 14; HRV2, human rhinovirus 2.
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Chapter 6, Fig. 3. The N terminus of 3A is very important for its transport inhibiting function. (A) Graph showing the percentage 
of cells in which the VSVG protein was localized at the plasma membrane. The percentages were calculated as described in the 
legend to Fig. 1. (B) Graph showing the COP-I localization in cells expressing HRV14 3A-E8K, C3H14 3A, C3H2 3A, or C3PV 
3A. The percentages were calculated as described in the legend to Fig. 1. (C) BGM cells expressing Myc-tagged mutant or 
chimeric 3A proteins (HRV14 3A-E8K, C3H14 and C3H2) are stained for the Myc tag to show their localization. (D) Interaction 
of the mutant or chimeric 3A proteins (HRV14 3A-E8K, C3H14 and C3H2) with the N-terminal part of GBF1 as assayed by 
yeast two-hybrid analysis. The results are depicted as described in the legend to Fig. 2. (E) FRAP traces of cells co-expressing 
YFP-GBF1 and CFP-fusion proteins of HRV14 3A (wild-type or E8K). Traces were calculated as described in the legends to 
Fig. 2. HRV14, human rhinovirus 14; HRV2, human rhinovirus 2; C3H14, CVB3/HRV14 3A chimeric protein; C3H2, CVB3/
HRV2 3A chimeric protein; C3PV, CVB3/PV1 3A chimeric protein. a, significantly different from HRV14 3A wt expressing cells; 	
b, significantly different from HRV2 3A wt expressing cells; c, significantly different from PV1 3A wt expressing cells (calculated 
by Student t-test, P < 0.05).
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